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Neurodegenerative diseases, like Multiple Sclerosis and Parkinson’s disease, lead to 
disability that worsens with time.  Being able to predict prognosis in these diseases is 
important for both patients and clinicians when making medication choices and planning for 
the future.   My aim was to look at drug effectiveness over a ten-year period in Multiple 
Sclerosis, in the absence of a long-term clinical trial, and to look at prognosis in Parkinson’s 
disease by deriving subtypes. 
 
I developed a longitudinal model for the untreated natural history of patients with Multiple 
Sclerosis using multilevel models.  This model was used to predict the untreated trajectories 
of treated MS patients over a ten year period.  A comparison between the observed treated 
trajectories and the predicted untreated trajectories gave an estimate of long-term drug 
effectiveness. I carried out intention-to-treat and per-protocol approaches along with imputed 
analyses to adjust for missing data. The medications were found to be effective in the long-
term. 
 
I used a k-means cluster analysis on the baseline phenotype of a large cohort of recently 
diagnosed Parkinson’s patients to attempt to derive subtypes.  These subtypes were 
subsequently found to be associated with medication response.  This approach was extended 
in another large inception cohort using a development and validation approach. Before 
combining the two cohorts in an analysis I had to harmonise the data from the cohorts as 
olfaction was measured using two different tests. I used Item Response Theory to convert the 
two tests onto the same scale. The harmonised baseline phenotypic data from both cohorts 
was used to estimate subtypes.  This approach was relatively stable when comparing the 
actual and predicted subtypes in the smaller cohort. These subtypes were associated with 
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“Parkinson’s is a slow but inevitable process. It’s hard living with it on a daily basis.  The 
difficulty facing people with it is that they never quite know ‘Can I or can’t I do this today?’” 
- Helen Mirren 
 
1.1. Neurodegenerative disease 
 
Neurodegenerative diseases, such as Multiple Sclerosis and Parkinson’s disease, are chronic 
diseases that lead to disability that generally gets progressively worse with time.  
 
Prognostic research in these diseases is important for many reasons.  It can help to counsel 
patients and family at diagnosis as to what they can expect from the years ahead.  It can help 
with risk stratification for treatment options - for instance, if someone had a poor prognosis 
they might consider medications with a worse side effects profile. It can also help in 




The objectives for the presented work were as follows: 
1.  To develop a multilevel model for the natural history of untreated MS and validate 
this on an independent cohort. 
2. Use this model as a comparator in a large cohort of treated patients followed up for 10 
years to determine drug effectiveness in the long-term. 
3. Derive subtypes of Parkinson’s disease using cluster analysis in a large inception 
cohort of Parkinson’s patients. 
4. Harmonise the data across two large inception cohorts of Parkinson’s patients 
5. Use the harmonized data to derive subtypes of Parkinson’s disease in both cohorts 




6. Examine how these validated subtypes relate to disease prognosis and response to 
medication. 
 
1.3. Structure of the thesis 
 
In chapter 2 I will introduce the disease Multiple Sclerosis and describe its basic 
epidemiology and some treatment options. The following chapter will describe the work I 
have done looking at prognosis in Multiple Sclerosis.  In chapter 4 I will introduce 
Parkinson’s disease and describe its basic epidemiology and the reason why clinicians believe 
there are subtypes of the disease.  The following chapter will describe the work I have done 
looking at prognosis in Parkinson’s disease by deriving subtypes.  The sixth chapter is a 
discussion of the work in this thesis which includes sections on the significance of the 
publications, strengths and limitations of the work, any ongoing and future research, 
recommendations for future research, and ends with a conclusion.  In the seventh chapter I 
will detail exactly what contribution I made to the published works.  Following that, will be a 
list of my references and then finally all the published papers that will be referred to as P1 to 
P6, (see above).  Along with each published paper will be any supplementary materials that 




2. Background to Multiple Sclerosis 
“I realized this is what God has dealt me, and I should be thankful considering all that’s 
happened to me in my life, but MS caused the movies to stop - stop dead - and I miss it” 
- Richard Pryor 
 
Multiple Sclerosis (MS) is a chronic neurodegenerative disease which is caused by damage to 
the nerve coating (myelin) and to the nerves themselves.  This can bring about a range of 
symptoms which are mostly dysfunction in motor and autonomic function.  The symptoms 
will generally worsen with time and eventually patients might need ambulatory assistance 
such as a walking stick or a wheelchair. In some cases the disease can cause death. 
 
It has been estimated in the UK (2010) the prevalence of MS was 203 per 100,000 of the 
population and the incidence in one year was 9.64 per 100,000 1. Tragically it is a disease that 
affects people when relatively young with an average age at onset of 30 years 2.  However life 
expectancy is only reduced by 6-7 years 3 so people live for a long time with the disease. The 
presentation of disease is highly heterogenous including different clinical features and rates 
of accumulation of neurological disability.   
 
It is widely accepted that there are different subtypes to the disease. The majority of patients 
(~85%) present with relapses (“attacks”) where symptoms appear and then disappear (either 
partially or completely) 4.  This is called relapsing-remitting MS (RRMS).  Some of these 
RRMS patients will convert to secondary-progressive MS (SPMS) where the frequency of 
relapses decreases and the accumulation of disability increases steadily 5.  Some patients 
(~15%) will present with a primary-progressive MS (PPMS) that gets progressively worse 
over time without relapses 4. In a group of RRMS/SPMS patients the estimated median time 
to requiring assistance to walk was 18 years and to being bedridden was 28 years 6. The 
prognosis tends to be worse in PPMS patients with an estimated median time to requiring 





2.1. Treatment for Multiple Sclerosis 
 
Currently there is no cure for the disease.  In 2002 there were a range of disease modifying 
therapies (DMTs) that were licensed for treating RRMS or SPMS.  They were shown to 
reduce relapse rates and also the seriousness of relapses 8-11. The four DMTs available at that 
time were: two forms of interferon beta-1a, interferon beta-1b and glatiramer acetate 12. 
 
The UK’s National Institute for Care Excellence decided these DMTs were not cost-effective 
in the long-term over a 10 or 15 year period 13.  However these conclusions were based on 
clinical trials that typically lasted no longer than three years and hence there was no 
information about the long-term effectiveness of these DMTs reducing disability 
accumulation.  Since these drugs were already licensed to reduce relapse rates it was felt 
unethical to carry out a long-term placebo controlled trial, however not everyone agreed with 
this position 14. To determine the long-term effectiveness of DMTs the UK MS risk-sharing 
scheme (MS-RSS) was established by the UK’s Department of Health.  The plan was to 
follow-up a large cohort of treated patients for a ten year period.  A model for disability 
accumulation could then be built from historical data on untreated MS patients. This model 
could be applied to the MS-RSS to predict an individual’s progression if they had remained 
untreated and compared to each individuals’ observed progression on treatment thus giving 
an estimate of the long-term effectiveness of the DMTs. 
 
2.2. Scales for measurement of severity of disease in Multiple Sclerosis 
 
The most common outcome measure for measuring the severity of MS is the Expanded 
Disability Status Scale (EDSS) 15, 16. It is an ordinal 20 unit scale based on a neurologist’s 
examination.  It ranges from 0 (normal) to 10 (death due to MS) in half unit increments (apart 
from no score of 0.5), a description of each score is in table 1.  The EDSS has been used in 
many cohort studies and also clinical trials.  An alternative scale is the MS Functional 
Composite 17 which is a metric scale and includes a measure of cognitive impairment which 





A measure of quality of life, related to the EDSS, was a utility measure derived from data that 
reported EQ5D scores at different EDSS states, see table 1 below, where a score of 1 is 
perfect health and 0 death.  These utility scores are reported in the appendices of papers P2 
and P3.  It could be argued that utility scores are more appropriate outcome measure for 
patients because the data are created using a patient reported outcome rather than an arbitrary 
scale created by clinicians to rate severity of disease. 
 
Table 1.  A description of the Expanded Disability Status Scale (EDSS) scores along with the 





0 No disability 0.9248 
1 No disability, minimal signs in one functional system (FS) 0.7614 
1.5 No disability, minimal signs in more than one FS 0.7614 
2 Minimal disability in one FS 0.6741 
2.5 Mild disability in one FS or minimal disability in two FS 0.6741 
3 Moderate disability in one FS, or mild disability in three or 
four FS. No impairment to walking 
0.5643 
3.5 Moderate disability in one FS and more than minimal 
disability in several others. No impairment to walking 
0.5643 
4 Significant disability but self-sufficient and up and about 
some 12 hours a day. Able to walk without aid or rest for 
500m 
0.5643 
4.5 Significant disability but up and about much of the day, able 
to work a full day, may otherwise have some limitation of 
full activity or require minimal assistance. Able to walk 
without aid or rest for 300m 
0.5643 
5 Disability severe enough to impair full daily activities and 
ability to work a full day without special provisions. Able to 
walk without aid or rest for 200m 
0.4906 
5.5 Disability severe enough to preclude full daily activities. 





6 Requires a walking aid - cane, crutch, etc - to walk about 
100m with or without resting 
0.4453 
6.5 Requires two walking aids - pair of canes, crutches, etc - to 
walk about 20m without resting 
0.4453 
7 Unable to walk beyond approximately 5m even with aid. 
Essentially restricted to wheelchair; though wheels self in 
standard wheelchair and transfers alone. Up and about in 
wheelchair some 12 hours a day 
0.2686 
7.5 Unable to take more than a few steps. Restricted to 
wheelchair and may need aid in transfering. Can wheel self 
but can not carry on in standard wheelchair for a full day 
and may require a motorised wheelchair 
0.2686 
8 Essentially restricted to bed or chair or pushed in 
wheelchair. May be out of bed itself much of the day. 
Retains many self-care functions. Generally has effective 
use of arms 
0.0076 
8.5 Essentially restricted to bed much of day. Has some 
effective use of arms retains some self care functions 
0.0076 
9 Confined to bed. Can still communicate and eat -0.2304 
9.5 Confined to bed and totally dependent. Unable to 
communicate effectively or eat/swallow 
-0.2304 












3. Prognosis in Multiple Sclerosis 
“my left side is asking for directions from a broken GPS.” 
Selma Blair 
3.1. Multiple Sclerosis cohorts 
 
We had access to three cohorts of individuals with Multiple Sclerosis which are detailed 
below.  In the UK the Association of British Neurologist (ABN) criteria are used to determine 
whether an individual with MS can be treated with DMTs.  The ABN criteria was defined as 
age ≥ 18 years, EDSS ≤ 6.5 and had ≥ 2 relapses during the previous two years 18.  A relapse 
was defined as worsening neurologic symptoms lasting > 24 hours, in the absence of fever or 
infection and the starting date of each relapse was recorded by an MS specialist neurologist. 
 
3.1.1. University of Wales MS cohort 
 
The University of Wales MS cohort (UoWMS) is based at the University Hospital of Wales 
which is the major tertiary referral center for neurology in Wales, United Kingdom.  It serves 
a local population of 1.2 million and provides a network of MS clinics across South East 
Wales.   Data were initially collected in a cross-sectional study and were updated periodically 
until 2002 when data were essentially collected prospectively. Sociodemographic and clinical 
features at disease onset are recorded in a standardized fashion, including degree of recovery 
and initial inter-relapse interval. Approximately 1,000 patient contacts are documented 
annually, and clinical data, including EDSS scores, are collected routinely at presentation and 
at each visit.  At the time of extraction there were roughly 2,000 registered MS patients with 
1,283 and 809 patients having at least 2 or 4 or more EDSS scores over time, respectively. 
 
The UoWMS data came in four spreadsheets which identified different patient variables: one 
with all the EDSS data, another with all the treatment data, another with all the relapse data 
and the fourth with other phenotypic data. This data required time to manipulate and merge 
together into one dataset in a format appropriate for statistical analysis.  Our aim was to 
create a model for the untreated disease accumulation for individuals who would have been 
eligible for treatment under the MS-RSS (using the ABN criteria).  To select our patient 





1. Removed any EDSS at an age of less than 18 years 
2. Looked at any EDSS observations ≤ 6.5 and checked whether there were two or more 
relapses during the previous two years.  Took the earliest of these observations for 
any patients and used that as the ABN eligibility start date and removed any 
observations made before this date. 
3. Truncated the data when patients initiated any DMTs. 
 
After data cleaning and restricting to those who were eligible for treatment under the ABN 
criteria we were left with 404 patients for the analysis. 
 
3.1.2. British Columbia MS cohort 
 
The British Columbia MS (BCMS) cohort was established in 1980 and is population based, 
capturing around 80% of the population of British Columbia which is a province on the 
western side of Canada.  As of 2009, the database contained records for over 5,900 MS 
patients spanning 28 years of prospective follow-up from four clinics across British 
Columbia.  The BCMS cohort has been the subject of many papers looking at the natural 
history of MS 19-22.  
 
All the data cleaning and the majority of data preparation was done by the BCMS site 
statistician rather than by myself.  Due to the original ethics approval the data could only be 
analysed on site in the Brain Research Centre, University of British Columbia, Vancouver, 
Canada. After data cleaning and restricting to those who were eligible for treatment under the 
ABN criteria we were left with 978 patients for the analysis. 
 
3.1.3. United Kingdom MS risk-sharing scheme 
 
The UK MS risk-sharing scheme (MS RSS) recruited 5,583 patients between 2002 and 2005 
across 70 neurology centres in the UK23.  These were patients who met the ABN criteria for 
treatment and represented about 80% of patients with MS starting treatment in the UK over 
this period.  The high uptake of patients starting treatment in that period reduces the potential 
for selection bias. However, drug selection across the four DMTs was led by clinician choice 





3.2. Developing a longitudinal model for untreated Multiple Sclerosis 
 
Most previous studies that have modelled EDSS have used survival analysis 24-26, considering 
the time to specific milestones - for instance an EDSS of 6, which is equivalent to needing an 
aid to walk.  However, this ignores data both before and after reaching the milestone. Also, 
individuals with very different disease accumulation might reach the milestone at the same 
time, for instance two people with annual EDSS scores of 4, 5, 6 and 0, 1, 6 would contribute 
the same information.  Also, if an individual had reached the milestone when we started 
modelling they would have to be ignored. 
 
Percentiles of EDSS scores derived at yearly intervals with data-smoothing techniques have 
also been used to create disability curves over time 27, 28.  However, these do not model how 
any given individual changes, or the relationship between patient characteristics and the 
centiles. 
 
Another potential method is to use discrete Markov models which models the probability of 
transitioning between EDSS states as time progresses.  Markov models have been used 
previously to relate progression in MS to baseline covariates 29, 30.   This model type was also 
the original model planned to be used in the MS-RSS analysis and was the only model used 
in the 2 year analysis of this dataset 23.  After the 2 year analysis it was decided to carry out 
an independent analysis using multilevel repeated measure models.  This would allow the 
MS-RSS to test the robustness of results by using two different modelling strategies. 
 
Multilevel repeated measures models 31 are easily able to model unbalanced data, such as we 
have from our observational cohorts, where individuals have different numbers of 
observations and the time between observations is not constant.  Such models can account for 
both within and between patient variability.  To our knowledge multilevel models had only 
previously been used once to model the accumulation of disability in MS 32 using a 
transformation of the EDSS and assuming a quadratic relationship between EDSS and time 





In my first paper, P1, we have improved upon this method by testing for different non-linear 
relationships (instead of the standard assumption of adding a quadratic term) using fractional 
polynomials, testing/adjusting for observation level variation, checking and adjusting for 
autocorrelation, and removing the effect of relapse so that we are modelling only the 
accumulation of underlying disability and not relapse related disability.  As we were 
censoring our data when a patient started medication we also tested for indication/selection 
bias.  We also show how we can use the baseline measurement to predict all future data, since 
that is how our analysis in the MS-RSS will work. 
 
We found that a model using log and linear time terms for time since onset was optimal.  
Adding an additional time term to the observational level variation improved the model fit, 
presumably because the upper end of the EDSS scale has lower measurement error than the 
lower end since it is more subjective at the lower end.  We adjusted for autocorrelation by 
grouping together observations made within a short time frame.  We tested for the effect of 
relapse by dropping observations made within certain time frames of start of a relapse.  
Testing for selection bias by including ever started DMTs as a covariate provided some 
evidence that selection bias was not present.  Although the EDSS scale is not technically 
continuous we felt that the QQ-plots from the residuals in our model were acceptable given 
our sample size. 
 
3.3. Long-term effectiveness of Disease Modifying Therapies 
 
The MS-RSS was to be a 10 year study, with interim analyses every two years though 
because of the delay in getting these data prepared by the time the 2 year data were published 
it was decided to work on the 6 year data as this was almost complete. Hence there were only 
2 interim analyses prior to the final 10 year results, at year 2 and 6. The 2 year analysis used a 
longitudinal cohort from London Ontario to develop the untreated natural history model 23.   
This cohort had a rule that EDSS scores could not improve from one visit to the next. In the 
year 2 analysis carrying out a sensitivity analysis when they used unadjusted EDSS scores at 
baseline gave remarkably different results, changing from treatment having a large 
detrimental effect in the primary analysis to treatment having a large beneficial effect in this 
sensitivity analysis 23. Also it was felt this “no improvement” rule was not a reflection of 




patients not due to relapse which could mean that EDSS might improve at the next visit.  Due 
to these problems after the 2 year analysis it was felt this cohort was inappropriate for 
modelling the untreated natural history of MS.  To better reflect the reality of the EDSS the 
MS-RSS decided to change the natural history dataset for the year 6 and 10 analyses and the 
BCMS cohort was used as the historical cohort instead. Not it only was it larger, it was more 
contemporaneous hence reducing any bias due to secular changes in the natural history of 
MS. Although there were multiple drugs within the MS-RSS the plan was not to analyse any 
drug-specific data due to commercial confidentiality.   
 
Using the models we developed, we were able to calculate the predicted EDSS if the patients 
had remained off treatment conditional on the patients baseline EDSS.  Importantly for the 
economic analysis we also derived a predicted EDSS on treatment.  To estimate predicted 
EDSS on treatment the pharmaceutical companies had estimated a hazard ratio, derived from 
their short-term clinical trials, and this hazard ratio was used to adjust the accumulation of 
disability in our natural history multilevel models. We used two approaches for the expected 
values on treatment, an intention-to-treat approach where the whole trajectory used the 
hazard adjusted multilevel model and a per-protocol approach where the trajectory reverted to 
the natural history multilevel model at the time treatment was stopped (if treatment was 
stopped). 
 
At the outset of the project a deviation measure was created to inform the economic analysis 
as shown below  
 
 (!) =  
 #(!) −   %
∗(!)




 #(!)  is the actual value of the outcome measure at year t with treatment 
 %
∗(!)  is the expected value of the outcome measure at year t with treatment estimated from 




 %(!)  is the expected value of the outcome measure at year t without treatment estimated 
from our natural history model 
 
A value of 0% would mean the drugs worked exactly as predicted, lower than 0% implies 
that the drugs work better than predicted and higher than 0% worse than predicted. 
 
Although in our model development paper (P1) we used time since onset of MS as the time 
axis we resorted to using time since ABN eligibility as our time axis for the main analyses as 
requested by the scientific advisory group.  This would allow us to make more robust 
comparisons between the multilevel model and the Markov model as they would use the 
same time axis. We also added age at onset as a covariate in our model 30 as this was found to 
be important for the Markov model.  This covariate was used to adjust our intercept and also 
our two time terms. Table 2 below shows the validation of this new model in the UoWMS 
cohort where we used the first available EDSS to predict all future values.  The figure below 
shows this same validation graphically. This validation shows good characteristics with 








Table 2 Observed EDSS for the UoWMS dataset, and EDSS predicted by the BCMS model 
relating EDSS to time since ABN eligibility and including age at onset as a binary covariate. 
N is the number of observations in each time frame and N* is the number of individuals 




EDSS observed EDSS predicted EDSS predicted – observed 
N (N*) Mean SD Mean SD Mean SD 
0-0.5 88 (72) 3.76 1.71 3.77 1.63 0.01 0.99 
0.5-1.5 292 (153) 4.18 2.02 4.26 1.81 0.08 1.14 
1.5-2.5 265 (118) 4.82 1.78 4.87 1.59 0.05 1.14 
2.5-3.5 202 (101) 5.27 1.61 5.19 1.62 -0.08 1.32 
3.5-4.5 182 (92) 5.61 1.77 5.58 1.67 -0.03 1.53 
4.5-5.5 142 (72) 5.74 1.73 5.86 1.42 0.12 1.46 
5.5-6.5 138 (54) 6.07 1.77 5.85 1.35 -0.22 1.57 
6.5-7.5 75 (39) 6.09 1.79 5.98 1.38 -0.11 1.68 
7.5-8.5 52 (30) 6.10 1.92 6.27 1.38 0.17 1.69 
8.5-9.5 29 (14) 7.33 1.22 7.22 1.67 -0.10 1.48 
9.5-10.5 30 (10) 7.48 1.16 7.45 1.80 -0.03 1.49 
Total 1495 (253) 5.20 1.97 5.20 1.80 -0.001 1.35 
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EDSS was our primary outcome however we also carried out sensitivity analyses where we 
converted EDSS scores to utility scores. Although EDSS was treated as continuous in our 
models we rounded to the nearest EDSS score for all our predictions.  In the Markov model, 
due to sparsity of some of the transition data, the Markov model was derived using only the 
integer values, similar to the table above.  To ensure comparability between the two 
approaches we carried out analyses using the normal EDSS scale and another where we used 
only the integer values of the EDSS (called rounded EDSS in the papers). 
 
For our primary analyses we used the last available EDSS score. However, as with any long-
term study there is likely to be drop-out, so for some individuals the last available EDSS 
score might have been earlier, e.g. they could have dropped out after year 5.  To adjust for 
this drop-out we carried out a sensitivity analyses where we imputed on-treatment scores at 
the missing years. Imputation was carried out using multilevel model fitted to the MS-RSS 
population where this multilevel model had the same parameterization as our natural history 
model.  We used a single mean imputation taken from the patient specific fitted lines 
(accounting for individual level random effects) and also a multiple imputation where the 
observation level residuals were taken from the appropriate distribution to add uncertainty the 
mean imputed EDSS values.  Imputation was carried out using different approaches 
1.  Intention to treat 
2. Per-protocol where the trajectories were adjusted for being on or off treatment and 
individuals were assumed to stay on treatment for the missing years. 
3. As 2. but individuals were assumed to be off treatment for the missing years 
 
As we could not be certain that data is missing at random (missingness associated with 
observed data) we carried out an imputation where we added 0.5 to the EDSS scores in an 
attempt to account for data that is not missing at random (missingness associated with 
unobserved data).  This would imply that the individuals missed their later visits because 





The 95% confidence intervals for the deviation measure and relative rate of progression were 
derived using bootstrapping since they involved dividing multiple estimates making it hard to 
derive a formula for the confidence interval.   
 
To account for the uncertainty in the BCMS model parameter that we used to derive the 
predicted untreated EDSS, we carried out a sensitivity analyses in the year 6 analysis where 
we sampled from the parameter distribution (which is a multivariate normal distribution).  
We did this 500 times predicting EDSS on and off treatment for each re-sampled model.  The 
mean and variance of these 500 predictions were then combined with the use of Rubin’s rules 
33.   
 
For our year 10 analysis, P3, as well as repeating the analyses from year 6 we also carried out 
pre-specified sub-group analyses.  These included stratifying by baseline EDSS (≤3.5, 4 to 
5.5 and ≥ 6), type of MS at baseline (RRMS or SPMS) and date of baseline assessment 
(on/before 31 August 2003 or after 31 August 2003). The last sub-group reflected some 
concern that the patients initially recruited into the RSS were a mixture of prevalent and 
incident cases and may therefore have better prognosis due to “length bias” whilst later 
patients recruited would only include patients who newly met the inclusion criteria.  Some of 
these subgroup analyses were combined for instance stratifying by both baseline EDSS and 
date of baseline assessment.  In the year 10 analysis we also explored the apparent changes in 
treatment effect over time by considering the difference between observed and predicted off 
treatment at 2, 4, 6, 8 and 10 years.   This seemed to show a “waning” effect where the effect 
of the medication (difference between observed and predicted off treatment) was more 
pronounced at earlier time points. 
 
Generally, all results show that the medications are effective in the long-term.  The analyses 
using EDSS as the outcome had different estimates of effect of drugs between the Markov 
and multilevel models although both are consistent with a positive effect of medication over 
the long-term.  However the analyses using the utility score as an outcome gave more similar 
results across the two modeling approaches.  Imputed analyses were similar to the main 




We can formalise the causal inference we are doing using the framework set out by Hernan 
and Robins 34.  Our conceptual question is whether treatments used within the RSS reduce 
progression rates in EDSS for those meeting the ABN criteria.  If A= 1 is on treatment and A 
= 0 is not on treatment, whilst Y is our outcome (EDSS progression) the two causal effects, in 
essence, that we are interested in deriving are: 
 
(i) E[Y|A= 1] - E[Y|A= 0] (what we called absolute treatment effect in paper P3) 
(ii) E[Y|A= 1] / E[Y|A= 0] (what we called relative treatment effect in paper P3) 
 
We have observed E[Y|A= 1] as all of the patients in the RSS are on treatment, although this 
is still just an estimate of the target population of interest (all MS patients fulfilling the ABN 
criteria). 
 
The counterfactual outcome E[Y|A= 0] is unknown for all the patients in the RSS, something 
that we are trying to predict using the untreated natural history model we have derived, along 
with the covariate age at onset and baseline EDSS.  For our predictions to be a valid 
exchangeable counterfactual then conditional on the baseline EDSS and age at onset all other 
risk factors for EDSS progression would need to be the same within the RSS population and 
the BCMS population used for the untreated model. This is often called the no unmeasured 
confounder assumption. 
 
In table 1 of paper P2 we can see that sex, time since symptom onset and number of 
confirmed relapses in the past 2 years are relatively similar within the BCMS and RSS.  We 
also know from, table 2 and figure 1, that conditional on the baseline EDSS and age at onset 
our model predicts EDSS progression in an external dataset without any bias. However we 
can never be certain that all risk factors for EDSS progression are the same within the RSS 





4. Background to Parkinson’s Disease 
“I don’t have a choice whether or not I have Parkinson’s but surrounding that non-choice is 
a million other choices that I can make” 
-Michael J. Fox 
Parkinson’s disease is a chronic neurodegenerative disease and was first described by Dr. 
James Parkinson in the early 1800’s in a paper called “An essay on the Shaking Palsy”. It is 
caused by a loss of dopamine in parts of the brain and is commonly categorized by its motor 
symptoms bradykinesia (slowness of movement), tremor, rigidity and postural instability.  
The level of dopamine will continue to decline over the years leading the disease to get 
progressively worse. 
 
Parkinson’s disease is the second most common neurodegenerative disorder, after 
Alzheimer’s disease 35, with an estimated crude incidence of 13.0 per 100,000 person-years 
36.  Parkinson’s currently has a prevalence of 210.1 per 100,000 of the population in the UK.  
This rises from a prevalence of 1.8 per 100,000 of those aged 20-29 to 1,696 per 100,000 in 
those aged 80-84 37.  The numbers with PD is expected to rise considerably over the next 30 
years due to an aging population 38.  A recent meta-analysis showed that mean disease 
duration at death in 10 studies ranged from 7 to 14 years 39.  
 
Diagnosing Parkinson’s disease comes with its own challenges.  There are other Parkinsonian 
syndromes such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and 
corticobasal degeneration that in the early stages of disease are often mistaken for PD.  In fact 
the only way to be certain is following autopsy where one study showed that 24/100 patients 
diagnosed with PD did not have PD following postmortem brain examination 40.  Another 
study showed that at least 15% of patients with a diagnosis of PD do not satisfy strict clinical 
criteria 41. 
 
As well as the classic motor symptoms it is now well recognized that there are many non-




problems, hyposmia (loss of sense of smell) and autonomic problems like constipation, 
urinary dysfunction and postural hypotension.  A recent systematic review showed the rate of 
PD dementia was 24.5% 42.  Whilst another publication showed the rate varying from 2% in 
early-onset cases to 81% in an unselected patient population 43.  Along with the motor 
symptoms, dementia will clearly have large implications with respect to loss of independence 
and the requirement for support or a caregiver. 
 
The motor and non-motor symptoms present at differing severities within each person with 
Parkinson’s and prognosis will also vary considerably.  This heterogeneity has led many 
clinicians to believe that there are subtypes of the disease 44, 45. Unlike MS which has well 
defined subtypes (RRMS, SPMS and PPMS) there is no consensus within PD about how to 





5. Prognosis in Parkinson’s Disease 
“It isn’t the mountains ahead to climb that wear you out: it’s the pebble in your shoe” 
- Muhammad Ali 
5.1. Parkinson’s Disease cohorts 
 
For the papers presented in this thesis I worked on two prospective cohorts of individuals 
with Parkinson’s disease.  The Oxford Parkinson’s Disease Centre Discovery cohort 
(hereafter referred to as the Discovery cohort) and the Tracking Parkinson’s cohort (hereafter 
referred to as the Tracking cohort).   
 
Within both cohorts, patients are recently diagnosed at recruitment, within 3.5 years of 
diagnosis, hence reducing the chance of any survival bias seen with prevalent cohorts.  They 
must also satisfy the Queen Square brain bank criteria for PD diagnosis 46.  In short this 
criteria requires a patient to have bradykinesia and at least one of the following: muscular 
rigidity, rest tremor or postural instability.  Demographic and phenotypic data were collected 
by questionnaires completed via a clinician, nurse or the patient themselves.  Patients are 
followed up every 18 months and ~90% of the questionnaires are collected in both cohorts.  
All patients gave informed consent and full ethical approval was granted to both studies.  The 
charity Parkinson’s UK funded both of these cohorts. 
 
The Discovery cohort 47 has roughly 1000 patients with PD that were recruited from 11 
hospitals in the Thames Valley Region. Patients were recruited between September 2010 and 
January 2016.  Exclusion criteria for participation were: non-idiopathic parkinsonism, 
dementia within one year of diagnosis suggestive of Dementia with Lewy bodies and 
cognitive impairment precluding informed consent.  People at-risk of developing PD (first 
degree relatives of PD patients and those with REM sleep behavior disorder) and some 
control subjects were also recruited as part of this cohort.  These at-risk and control 
individuals were not used for any analyses described within this thesis. 
 
The Tracking cohort 48 has roughly 2000 patients with PD that were recruited from 72 sites 
providing secondary care treatment for PD patients across the entire United Kingdom.  




severe comorbidities not allowing clinic visits, other forms of parkinsonism (like PSP and 
MSA), and patients with drug-induced parkinsonism.  A smaller dataset of ~250 individuals 
with early onset PD (age onset <50 years) and first degree relatives were also recruited. These 
early onset PD and relatives were not used for any analyses described within this thesis. 
  
The Discovery cohort data was stored in an Open Clinica online database and the Tracking 
cohort data was stored in a ClinBase online database.   This data required considerable time 
to download and manipulate into a format that would allow detailed statistical analysis.  I also 
spent time checking for any illogical or inconsistent data and contacting admin staff at each 
centre so this data could be checked against the original paper CRF’s. 
 
As mentioned in the previous chapter diagnosing PD can be difficult. So in an attempt to 
ensure that individuals with other similar diseases were not included within any of our 
analysis datasets we excluded any patients with a firm alternative diagnosis or who had a 
probability of PD <90% as rated by a research neurologist/movement disorder specialist at 
their latest available visit.  The numbers that were dropped in papers P4 and P6 can be seen 
from the flow-charts in the respective papers. 
 
5.2. Scales for measurement of disease severity 
 
One of the most common measures of disease severity comes from the Movement Disorder 
Society (MDS) Unified Parkinson’s Disease Rating Scale (UPDRS) 49 which is split into four 
parts.  We are most interested in part III which measures the severity of motor function from 
33 questions on a Likert scale of 0 to 4.  The MDS-UPDRS III is our main outcome measure 
when looking at motor prognosis with values from 0 to 132 where higher values are 
associated with worse motor function. 
 
The main cognitive outcome in both cohorts was the Montreal Cognitive Assessment 
(MoCA) 50 which is commonly adjusted for the education years to account for a patient’s 
intelligence whereby a more intelligent person might find the cognitive tasks easier.  The 





5.3. Parkinson’s Disease subtypes 
 
Our method to derive subtypes was first to carry out a factor analysis and then a k-means 
cluster analysis on the factor scores and any variables that were not loading into one of these 
factors.  The factor analysis is important because if many variables from a similar domain 
(that are highly correlated) were included in a k-means analysis then that domain would be 
given greater importance in the k-means algorithm.  We also used multiple imputation with 
chained equations to adjust for missing data which is more robust and less biased than 
excluding individuals with missing data (complete case analysis), although in some 
untestable situations a complete case analysis would be unbiased whilst an imputed analysis 
would be biased 51. 
 
In our analysis we had variables from the following phenotypic domains: 




d. Postural stability 
e. Speech 
2. Get up and go (getting up from a chair walking turning around and sitting back down) 
3. Flamingo (standing on one leg) 






10. Impulsive- compulsive behaviours 
11. Cognition 
a. MoCA 
b. Mini-mental state examination (MMSE) 




12. Orthostatic blood pressure (difference in blood pressure when going from a lying 
position to a standing position) 
13. Olfaction (sense of smell) 
14. REM sleep behavior disorder (RBD) 
15. Daytime sleepiness 
16. Hallucinations 
17. Constipation 
18. Urinary function 
19. Personality traits 
 
There have been many other attempts at deriving PD subtypes and a systematic review 45 
from 2010 reviewed all papers published on PD subtypes using cluster analysis and came up 
with the following recommendations for future studies on this topic: 
 
1. Select a sample of patients with a similar disease duration. 
2. Critically select a set of conceptually similar clinical variables that adequately 
represent the clinical spectrum of PD 
3. Take the limitations of K-means cluster analysis (CA) into account or apply another 
CA technique that does not have these limitations 
4. Critically evaluate the cluster results: Are they clinically meaningful and 
interpretable? Which variables discriminate best between the clusters?  How do the 
clusters differ with respect to variables not included in the CA? 
5. Validate the results in independent samples.  Studies that apply a similar design in 
different cohorts and take into account the aforementioned recommendations will 
likely increase our knowledge on subtypes in PD. 
 
To take into account these recommendations we did the following 
 
1. As mentioned in section 5.1 our cohorts were based on individuals who were recently 
diagnosis (within 3.5 years of diagnosis) and hence more similar disease duration than 
other cross-sectional studies. 
2. Our cohorts were well phenotyped across a wide range of important motor and non-





3. We took into account the limitations of k-means by: 
a. Using hierarchical cluster analysis prior to the analysis to help determine the 
number of clusters 
b. Standardizing all variables so that they have equal weighting within the CA 
c. Using 500 random starts to prevent the selection of local rather than global 
optima 
4. We looked at independent associations between our clusters and response to 
medication. 
5. In our first paper we did not validate our results in an independent sample, however 
we did use cross-validation techniques to look at the stability of our analysis 
approach. We had already established a collaboration with another cohort, Tracking, 
that would enable us to carry out a future cross-cohort validation. 
 
In the systematic review the largest CA was based on 346 patients. A recent follow-on paper 
written by the same author of the systematic review paper was based on 344 patients and 
validated in another 357 52. Two papers looking at cluster analyses in separate cohorts have 
since been written by Fereshtehnejad, the first based on only 113 patients 53 and the second 
based on 421 patients 54.  Our analysis was based on 769 patients making it the largest ever 
published at the time.  However in the same year another paper was published based on 1,510 
PD patients 55.  This paper was based on patients with much longer disease duration (64 
months on average) and was not as deeply phenotyped as our own cohort (they only had 
motor, cognition, depression, sleep quality and constipation variables). 
 
In paper P4 we found three factors: a psychological well-being factor, a non-tremor motor 
factor and a cognitive factor.  Using two different statistics on a hierarchical cluster analysis 
suggested that either the two or five cluster solution was optimal.  After looking at the 
different clusters and seeing that the two cluster solution only provided a good and poor 
group we decided that five groups solution was optimal.  The five subtypes from the k-means 
cluster analysis were arbitrarily called: (1) mild motor and non-motor disease, (2) poor 
posture and cognition, (3) severe tremor, (4) poor psychological well-being, RBD and sleep, 
(5) severe motor and non-motor disease with poor psychological well-being. Importantly 
these subtypes were related to variables not included in the k-means algorithm like age and 




effectiveness when we used the crude Clinical Global Impression of Change Scale.  In a 




5.4. Harmonising scales for cross cohort collaborations 
 
One of the most common non-motor features in PD is dysfunction with olfaction (sense of 
smell).  However, the way that we measured olfaction was not carried out in the same way 
across and within the two cohorts.  The Tracking cohort measured olfaction using the 
University of Pennsylvania Smell Identification Test (UPSIT) but then changed to using 
Sniffin’ sticks when the UPSIT became difficult to source from the USA. The Discovery 
cohort measured olfaction only using Sniffin’ sticks. 
 
The UPSIT 56  is based on 40 scratch and sniff panels and each panel has a corresponding 
multiple choice question with one correct answer and three incorrect answers or “distractors”. 
This test has a forced choice paradigm so if an individual taking the test is unsure of an 
answer they were asked to guess the correct answer.  Hence the UPSIT is on a scale of 0 to 
40 where a higher score is better olfaction. 
 
The Sniffin’ sticks identification test 57 is based on 16 sticks that look similar to a marker pen.  
Again the test has multiple choice questions with one correct answer and three distractors and 
has a forced choice paradigm. So the Sniffin’ is on a scale of 0 to 16 where a higher score is 
better olfaction. 
 
Since olfaction was measured using different tests on different scales we need a way to put 
our olfaction data onto the same scale.  One crude method would be to standardize the data 
from each scale.  However this would be based on the assumption that the average olfaction 
and variability in olfaction is the same for people taking the UPSIT and the Sniffin’. We 
already had strong evidence that some motor and non-motor characteristics were different 
across the two cohorts so making that assumption could potentially be incorrect. Therefore 
we used scale equating methods such as equipercentile equating and Item Response Theory 





Equipercentile equating matches score based on their percentile ranks after first smoothing 
the centile distributions.  This method requires that the two groups are equivalent in terms of 
distribution usually because individuals have taken both tests or individuals are randomized 
to receive one test.  Equipercentile equating has been applied to cognitive scales in PD by 
other groups and ourselves 58-60.  IRT fits a series of latent variable models (where the latent 
variable is olfaction for our analysis) for each item on a test.  These models are then 
harmonized across the two tests using items that are common to the two tests.  This 
harmonization relies on the fact that the model parameters would be equal if the latent 
variable was identical in the populations taking each test.  These methods are described in 
detail elsewhere 61. 
 
As well as the data from the Discovery and Tracking cohorts the PI from the Tracking cohort 
was able to collect a small dataset of 61 PD and 67 control subjects who took both the UPSIT 
and Sniffin’ tests so that we could validate any method converting UPSIT to Sniffin’ scores. 
This group of individuals were recruited as a convenience sample from the regional West of 
Scotland Movement Disorder Clinic. Our main outcome when comparing converted and true 
scores was to be the concordance correlation coefficient 62 whilst also considering the 
mean/median of the difference.  Concordance is very similar to a correlation coefficient but is 
derived from deviation about the line of perfect agreement. When we compared our IRT 
converted Sniffin’ scores to true Sniffin’ scores within this datatset it had a high concordance 
of 0.80 and a mean and median difference of 0.14 and 0 respectively. Using the 
equipercentile equating method gave a concordance 0.79 of and a mean and median 
difference of 0.66 and 1 respectively, providing more evidence that the distribution of 
olfaction was different in those who took the UPSIT and Sniffin’ tests. However our IRT 
conversion method had acceptable characteristics with converted and true scores being 
similar. 
 
As well as allowing us to analyse olfaction in these two cohorts this conversion method will 
also assist future researchers doing cross-cohort collaborations or individual patient meta-
analyses.  For this aim we also equated scores from the UPSIT to the Brief-SIT (a smaller 12 






5.5. Parkinson’s Disease subtypes using a development validation approach 
 
Our first analysis to derive Parkinson’s subtypes was based on only the Discovery cohort but 
now that we were able to harmonise the olfaction data we could extend our approach to also 
include the Tracking cohort.  In this new analysis we used a development/validation approach 
where we developed the clusters in both cohorts and then created a model for the Tracking 
cohort clusters using a discriminant analysis.  We could then predict these Tracking cohort 
clusters in the Discovery cohort and compare to the k-means clusters to determine the 
stability of our approach using a kappa statistic.  This satisfies the criteria for point 5 in the 
systematic review’s recommendations.  To better satisfy point 4 we critically evaluated our 
clusters by looking at levodopa response and also motor (MDS-UPDRS III) and cognitive 
(MoCA) progression using multilevel random slope and intercept models.  We also carried 
out a sensitivity analysis adjusting for patient withdrawal from the study using pattern-
mixture models 63 as we were concerned that patients loss to follow-up might bias our 
progression estimates. 
 
To our knowledge at the time only the two papers written by Fereshtehnejad have used 
cluster analysis on baseline phenotype and then looked at whether they predict subsequent 
prognosis 53, 54.  However we have used all the follow-up data in a multilevel random slope 
and intercept model which is arguably better than the approach used by Fereshtehnejad using 
only the baseline measurement and the latest available follow-up measure. Using all available 
data will give us a more precise and less biased measure of the slope.  We also used pattern-
mixture models in an attempt to adjust for the potential loss-to-follow up bias whilst 
Fereshtehnejad excluded those individuals who dropped out after their baseline assessment. 
 
We looked at levodopa response using what is called a levodopa challenge. This involves a 
patient omitting their usual levodopa dose approximately 12 hours before the morning 
challenge test.  The patient is then given their usual dose of oral levodopa and the MDS-
UPDRS III performed at baseline and 1 hour later.  The percentage change from the pre and 
post dose MDS-UPDRS III then gives a more quantitative measure of drug effectiveness than 




There were some variables that were not collected in Tracking but were collected in the 
Discovery cohort and used in the P4 paper.  These were the get up and go, flamingo, and 
dexterity variables, one of the two depression measures, MMSE and the phonemic fluency.  
This only removed four variables from our non-tremor motor factor, one variable from the 
psychological well-being factor and prevented us from detecting a cognitive factor.  However 
since the MoCA had the highest loading on the cognitive factor losing these variables did not 
have a large impact on any of the domains in the cluster analysis.   
 
Using the same statistical approach as the previous paper again showed that either two or five 
clusters was optimal.  We then examined the proportions between the k-means clusters in 
Discovery and those predicted by the Tracking discriminant model looking at each solution in 
turn.  The five and four cluster solutions gave the same overall agreement of 67.9% and as 
the four cluster solution was more parsimonious we decided that was best. 
 
We called the four subtypes: (1) fast motor progression with symmetrical motor disease, poor 
olfaction, cognition and postural hypotension; (2) mild motor and non-motor disease with 
intermediate motor progression; (3) severe motor disease, poor psychological well-being and 
poor sleep with an intermediate motor progression; (4) slow motor progression with tremor 
dominant, unilateral disease. The third cluster from our P6 paper was essentially a merger of 
the fourth and fifth cluster from the P4 paper. 
 
Our approach was relatively stable with a kappa of 0.58 (95% confidence interval 0.54 to 
0.61) between the k-means clusters in Discovery and those predicted by the Tracking 
discriminant model. According to accepted guidelines which are used to determine the 
strength of agreement64 0.4-0.6 is moderate agreement and 0.6-0.8 is substantial agreement.  
Since our kappa is close to the border of these two groups and the 95% confidence interval 
includes both groups we interpreted this as being moderate to substantial agreement, although 
a more conservative view would be to just say moderate agreement.  Interesting we found 
67.9% of patients stable which compares to 73.8% stable using cross-validation in the P4 
analysis.  This might be due to the baseline differences between the two cohorts reported in 





The levodopa challenge showed that medication response differs significantly across the 
clusters.  We also found that MDS-UPDRS III progression rates differ significantly across the 
clusters with the difference between the fastest and slowest progressors in the Tracking 
cohort being 2.6 points per year.  Given that this is near equivalent to the primary endpoint in 
some clinical studies this has implications for future clinical trials in Parkinson’s. A clinical 
trial is more likely to have a false negative finding if we fail to take into account that some 
individuals will not respond to medication due to their disease subtype. 
 
When we compared our approach to a cruder but more recognised method for determining 
subtypes (tremor dominant, postural instability gait difficulty and mixed phenotype) we did 
not find significant difference in MDS-UPDRS III progression rates.  Although in the 
Tracking cohort only we did find a suggestion that the PIGD subtype has faster cognitive 
decline. Our validated clusters were not strongly associated with different rates of cognitive 
decline, however the patterns of cognitive decline for the clusters across the two cohorts were 
remarkably similar.  It may be that the MoCA, which was designed to be a screening test, 
lacks the sensitivity for us to detect differences across our four clusters or we need a longer 
follow-up for this to emerge.  
 
The olfaction conversion proved very important. If we had removed this variable due to not 
being able to harmonise the data, or we had used a crude method we may not have been able 
to pick out our first cluster robustly (which had poor olfaction).  This cluster turned out to 
have the fastest motor progression. 
 
In paper P6 not only have we taken into account all five recommendations for future research 
from the systematic review but also our analysis had much far greater numbers (>2500 in 
both cohorts) than any previous cluster analysis in PD.  Also our cohort was unselected whilst 
some other cohorts like the Parkinson’s Progression Markers Initiative cohort are based on 
recently diagnosed (within two years of diagnosis) patients and also must be drug-naïve.  By 




exclude those with the most severe disease and hence add an element of selection bias into 








“Sure, Parkinson’s may be one step forward and two steps back, but I’ve learned that what is 
important is making that step count.” 
- Michael J. Fox 
 
6.1 How our results compare with others 
 
A latent class growth analysis has been used to model EDSS in PPMS patients to consider 
heterogeneity in disease progression 65.  The authors applied similar methods to our own 
using fractional polynomials to determine the trajectories and also found that including time 
since disease onset was superior to using age.  However they found the best trajectory was 
modelled with three time terms: linear time, square root of time and square of time.  Square 
root of time is relatively similar to log of time in that the effect diminishes as time progresses. 
 
Other papers have used different methods to answer the same question about drug 
effectiveness in the long-term.  One previous paper 66 looked at the association between use 
of interferon Beta and disease progression in RRMS patients within the BCMS cohort and 
found a remarkably similar hazard ratio of 0.77 when compared to our relative rate of 
progression, 0.72, providing more evidence that the drug slows progression in the long-term.  
However it should be noted that when using a contemporary control cohort instead of a 
historical control cohort the hazard ratio was in the opposite direction with little overlap 
between the 95% confidence intervals.   Another paper has reviewed 10 long-term follow up 
studies, which were generally open-label studies continued after a short term RCT 67. One 
study found evidence that interferon beta-1b reduced mortality 68 and another study found 
that interferon beta-1a slowed progression, gave greater independence and improved quality 
of life at 15 years 69. This review concluded that early treatment gives persistent long-term 
benefits including conversion to clinically definite MS and time to and risk of relapse 67. 
Another recent paper showed that patients initially treated with DMTs had a lower risk of 
converting to SPMS over a median follow-up of 7.6 years 70.  A new study that used data 
from the BCMS cohort has shown that use of beta interferon for >3 years was associated with 
increased survival 71. Data from a new large registry cohort which examined the records of 




with a smaller increase in EDSS score 72. A systematic review published in 2016 looking at 
14 studies reporting on the long-term effectiveness of interferon or Glatiramer acetate showed 
a pooled hazard ratio of 0.49 (95% confidence interval 0.34-0.69) to reaching an EDSS of 6 
73. All providing more evidence that these drugs are effective in the long-term and backing up 
our findings, although the problem of publication bias whereby negative studies are not 
published should be considered. 
 
In the discussion of paper P6 we list qualitatively similar findings from previous cluster 
analysis papers in PD. In particular a previous paper that also looked at disease progression 
for their data derived subtypes discovered three clusters that were associated with different 
rates of motor progression 53.  Their diffuse/malignant cluster that progressed the fastest had 
higher rates of cognitive impairment and orthostatic hypotension.  Our fast motor progression 
cluster also had worse than average cognition and orthostatic hypotension.  Another recent 
paper found three clusters and their fastest progression cluster also had worse cognition and 
higher SCOPA-AUT scores 74. The SCOPA-AUT is a questionnaire about autonomic 
function which includes questions about cardiovascular disfunction and one about orthostatic 
hypotension. 
 
6.2 Significance of publications 
 
We used a novel methodology to model disease progression in MS. At the time only one 
other MS longitudinal analysis had used multilevel models and we improved on that 
approach by considering the best time axis and different trajectories with fractional 
polynomials whilst also thinking about complex measurement error and removing the effect 
of relapse and autocorrelation.  We have looked at drug effectiveness over a 10 year period 
using a large cohort of treated patients and a natural history model comparator which has 
never been done before.  Our work on paper P2 has been highly cited with 77 citations 
(Google Scholar, Aug 2019).  The 10 year results in paper P3 has helped inform the current 
NICE guidelines for treating Multiple Sclerosis with Beta interferons and glatiramer acetate 
75.  In particular it was noted that all treatments in the RSS slowed disease progression and 
that the effect will not stay constant over time, what was called the waning effect.  I was an 




Italy, November 2018 with a talk entitled “The use of multi-level modelling to produce 
virtual placebo groups for long term assessment of MS drug effectiveness: experience from 
the risk sharing scheme”.   
 
We have carried out a cluster analysis in PD using two cohorts in a development and 
validation framework and found clusters associated with different rates of motor progression 
and response to medication.  Ours is not only the largest cluster analysis ever in PD but is in 
early PD, hence more applicability for recently diagnosed patients, and it satisfies all five 
criteria for future research from a systematic review of cluster analyses in PD 45.  At the time 
it was one of only three papers that had looked at disease progression of their data derived 
subtypes 53, 54.  The other papers used a cruder method to consider disease progression by 
only using the baseline and most recent follow-up measure, whilst our method used all 
available follow-up measurements and also accounted for withdrawal from the study.  We 
used methods to convert UPSIT scores to Sniffin’ scores, as well as validating the 
conversion, which has never been attempted before.  These methods will enable individuals 
to harmonise data across cohorts for instance carrying out individual patient meta-analysis 
with cohorts who used different olfaction tests. 
 
Our work on cluster analysis has been presented at many conferences.  I created a poster 
about paper P4 and took this to the Young Statisticians Meeting in 2015.  Since then I have 
created two posters about paper P6.  One focused on the main results of the cluster analysis 
and the subsequent longitudinal analysis of motor disability.  The other was more 
methodological in nature and compared our standard longitudinal analysis to the pattern-
mixture model analysis (adjusting for drop-out).  I took both posters to a centre PD meeting 
(a collaboration between the Oxford Parkinson’s Disease Centre and two European PD 
Centres 76) in March 2018 and out of three poster prizes I won two awards. One got the award 
for most collaborative project (presumably because the analysis was based on two cohorts) 
and another the award for most innovative project (presumably because it focused on a novel 
method in PD to account for withdrawal). The main poster I also took to the University of 
Bristol Population Health Sciences annual symposium where I was awarded the prize for best 
poster.  In Sept 2018 I took my more methodological poster to the Royal Statistical Society 




Network Meeting in June 2019 with a talk entitled “Clinical subtypes in Parkinson’s: Results 
from the Discovery and Tracking Parkinson’s cohorts”.   
 
6.3 Strengths and limitations 
 
The strengths of our MS papers are that we have developed and validated our natural history 
model within two observational cohorts from different geographical regions. The RSS cohort 
is large and incorporates most individuals starting therapy within that window reducing the 
possibility of selection bias.  Our modelling approach, multilevel models, in the RSS was 
compared to an alternate modelling approach, Markov models, which gave similar answers 
that the drugs are effective in the long-term.  Using imputation and changing how we defined 
the patient population (for instance including or excluding observations where individuals 
had switched treatments) also gave us similar answers providing more robust evidence the 
drugs are effective in the long-term. 
 
A major limitation was the allocation of drugs used in the RSS was not randomized in any 
way, instead it was decided by clinician and patient choice.  If the drug had been randomized 
then we would now have robust evidence to decide whether any drugs within the scheme 
perform better.  The BCMS study had an average follow-up time of only 5.8 years with only 
159/978 (16.3%) of individuals contributing at least 10 years of follow-up.  A placebo 
controlled trial would clearly give better evidence than our approach although it would be 
difficult to run over 10 years with non-responders likely to drop out thinking they might be 
on placebo. It is also harder to justify with licensed drugs that are labelled as “disease 
modifying therapies”, though this was based on strong evidence of a reduction in relapse rate 
rather than disability. The assumption being made that relapses lead to gradual decline in 
physical ability and hence this should translate into reduced disability. However, a counter-
argument is that relapses reflect a response to primary neuronal degeneration and may be an 
epi-phenomenon so simply masking relapses may not result in reduced disability.  
 
An alternative approach to looking at the causal effect of a medication would be to carry out 
a large observational study using inverse probability weighting or propensity score methods 




biased than standard approaches in non-randomised observational studies although these also 
rely on many assumptions and requires untreated individuals who can be compared to treated 
individuals.  We changed to using time since ABN eligibility after developing our model 
using time since onset, however this new model had no bias when validated in an external 
dataset. 
 
There were many other problems and biases with the RSS that were outlined at the inception 
of the study 14.   One issue was that prevalent cases were included in the study which could 
bias estimates of drug effectiveness. We examined sensitivity of our conclusions to this by 
carrying out a sub-group analysis that stratified by recruitment date, thereby effectively 
removing those who were prevalent cases.  Interestingly it was felt that prevalent cases might 
bias in favour of treatment but this is not what was observed in this sub-group analysis with 
the drugs seemingly more effective when excluding the prevalent cases. Another concern was 
that patients might not be followed up once they stop treatment. However, in the year 10 
paper we had a mean follow-up of 8.7 years and 9 years or more data for nearly 80% of 
patients and we also used imputation to account for withdrawal.  Two potential biases that 
were not possible to examine were the lack of blinded assessment of the outcome and the 
issue of non-randomised comparisons.  It was also felt that the EDSS is not that sensitive to 
change but this is the most widely used measure of disability in MS research 80, 81 and was 
found to be differ both within and between patients. 
 
The strengths in our PD papers are we had two cohorts with almost identical 
inclusion/exclusion criteria and similar data collection instruments allowing validation of our 
modelling approach. These are the largest numbers ever used in a PD cluster analysis. Both 
cohorts are well phenotyped across a range of motor and non-motor symptoms and the data 
was harmonised where the questionnaires were different for olfaction.  The individuals within 
this study have more similar disease duration than some other cross-sectional studies.  The 
patients in both cohorts are followed-up every 18 months allowing for a longitudinal analysis.  
In our longitudinal analyses we used pattern-mixture models to adjust for withdrawals from 
the cohort which provided similar results.  However this method does rely on untestable 




is less relevant with the kind of sample size we were dealing with.   We were able to validate 
our olfaction test conversion method in an external dataset. 
 
One limitation relates to our clustering approach as alternative clustering methods can 
perform better than k-means in certain circumstances 82 for instance k-means tends to favour 
spherical clusters which could lead to misclassification if data was skewed within a cluster.  It 
is also very difficult to choose the number of clusters and other individuals with the same 
data might have decided that a different number of clusters was optimal.  We used multiple 
imputation to adjust for missing data in both cohorts. However there are particular situations, 
when the data is missing not at random, where an imputed analysis would be biased and a 
complete case analysis would be unbiased 51.  In the Discovery cohort we had a relatively 
small proportion completing the levodopa challenge and this test was not carried out at 
baseline in both cohorts so it was affected by withdrawal.  Hence our associations with the 
levodopa challenge could have selection bias whereby individuals with worse disease who 
need to drop-out of the study might respond less to levodopa 83.  Some of the questionnaires 
that we used were designed as screening questionnaires, like the MoCA and the RBD 
questionnaire84, whilst we were using them as severity questionnaires which might reduce the 
potential to identifying differences in these phenotypes across individuals.  Also if we had a 
perfect diagnostic method for picking up other parkinsonian syndromes, like MSA and PSP, 
and other diseases often mistaken for PD, like dystonic/essential tremor, it would give us the 
most accurate representation of PD subtypes without enrichment from other diseases.   
Although the duration of disease in our two cohorts was much more similar than other cross-
sectional PD cluster analyses the range of 3.5 years is still relatively large and duration of 
disease is a big confounding factor in terms of disease severity and could make patients 
phenotype seem more different than the true difference at a similar time-point. An ideal 
cohort would only recruit participants within 6-12 months of diagnosis.  Also we found 
statistically significant differences in duration of disease between our clusters which could 
have impacted on the robustness of our clusters.  However we felt this was not clinically 
significant as the largest difference in mean duration between clusters was only 3.5 months.  
An alternative approach to remove the confounding effect of disease duration would have 
been to carry out regressions of each cluster variable against time (with appropriate non-
linear time terms if required) and then to use the residuals from this regression in the cluster 




are continuous and not categorical which would have meant excluding some variables on 
constipation and urinary function from our analysis.   
 
Our kappa (0.58) between the actual and predicted clusters in the Discovery cohort is 
moderate rather than very high.  This may be due to the baseline differences between the two 
cohorts however one might expect this is due to different proportions in subtypes between the 
two cohorts which is what we observed.  It could also be due to inter-rater variability because 
the Discovery cohort has much fewer centres and fewer raters.  Then there is also the 
possibility that our subtyping approach does not function correctly or that subtypes do not 
actually exist and there are instead underlying continuous axes of phenotypic variation that 
contribute to the heterogeneity in PD. However reassuringly we do see very similar patterns 
of gender, age, motor and cognitive progression across the two cohorts post cluster analysis. 
 
6.4 Ongoing and future research 
 
A project has started looking at the genetics of MS progression in the UoWMS cohort. This 
project will use Genetic Wide Association Study (GWAS) approaches to discover single 
SNPs associated with progression, and also two sample Mendelian Randomisation 
approaches to look at causal effects of different exposures on disease progression.  The work 
I did on developing a model for disease progression will help inform the models of genetic 
variables on prognosis. 
 
Due to the interest in our work on paper P6, another British PD cohort, ICICLE 86, has asked 
if we could collaborate and derive our subtypes within their cohort.  We are currently 
harmonizing our data allowing us to derive these subtypes in ICICLE and we are drawing up 
a formal data sharing agreement.  This will allow us to look at the effect of some serum 
immune biomarkers 87, already assayed in this cohort, against our subtypes whilst further 
validating our subtypes in another cohort. 
 
We are continuing to look at our validated PD subtypes in relation to both genetics and blood 




the results of these biomarkers vs. subtypes has recently been accepted for publication by 
Movement Disorders.  We have found evidence that Apolipoprotein-A1 is significantly 
reduced and C-reactive protein significantly increased within our third severe motor, poor 
psychological well-being and poor sleep cluster.  This provides more evidence that our 
subtypes have a biological basis. The initial results of the genetic analyses look interesting 
and we are starting to write up a paper with these results. In this genetic analysis so far we 
have created a genetic risk score for developing PD using data from a large GWAS of PD vs. 
controls. When comparing our clusters against this genetic risk score, our third cluster seems 
to have a lower genetic risk of the disease than clusters 2 and 4.  This along with the 
biomarker associations could suggest that the third cluster has a different etiology than the 
other clusters. We have also started a project looking at Mendelian Randomisation of PD 
progression in both the Discovery and Tracking cohorts to try and find different exposures 
that are causally related to disease progression. 
 
There are plans for us to use a different methodology, growth mixture models 88, to define 
subtypes. Growth mixture models cluster individuals together who have similar trajectories in 
a longitudinal analysis. If our main aim is to find clusters associated with disease progression, 
then using growth mixture models and how these progression clusters relate to baseline 
characteristics is arguably better than clustering on baseline characteristics and subsequently 
looking at progression.  We are also considering testing our k-means cluster analysis against 
other cluster analysis methods such as latent profile analysis 89 which is a model-based 
clustering approach trying to cluster using statistical distributions rather than an algorithm 
that is used to distinguish clusters.  Another future plan is to look at whether we can reduce 
the number of variables to reliably predict our subtypes which would mean they could be 
used within clinical practice much faster. 
 
I have been invited, as one of two statisticians, to work on a Movement Disorders taskforce 
doing a systematic review of Parkinson’s disease subtypes due to my experience in this area.  
My job is to rate the quality of the statistical methods within each paper and to broadly 





We are currently writing a paper, using the Tracking Parkinson’s cohort data, that compares 
different methods for dichotomizing UPSIT scores and looking at the agreement between 
these methods. Our conversion allows us to combine the UPSIT and Sniffin’ data within that 
cohort for this analysis.   
 
6.5 Recommendations for future research 
 
How to define the time axis in neurodegenerative diseases is particularly difficult.  Age is 
often very inappropriate because if you start the time at the lowest age, for instance 18 years 
old, and someone does not get diagnosed until 40 years old then you have 22 years of “dead” 
space to model.  This is not so much an issue in a linear analysis ( at least when considering 
the slope), however if you are deriving non-linear trajectories with fractional polynomials this 
“dead” space can absorb a lot of the non-linearity, for instance the effect of log time 
diminishes with time.  Time since symptom onset is difficult to determine because it relies on 
the awareness and memory of the individual.  Also in PD motor symptom onset might be 
easier to remember for someone whose first motor symptom was tremor compared to 
someone whose first motor symptom was bradykinesia.  Time since diagnosis seems the best 
candidate, in my opinion, however there might also be heterogeneity in someone’s disease 
severity before seeking a diagnosis from a medical professional thus introducing bias in the 
true time scale of the disease.  An alternative is to add a latent variable to the time term in our 
multilevel models, allowing the heterogeneity in time to be modelled by a random effect, 
which has been applied to Parkinson’s previously 90 and this latent time term seemed to 
separate well healthy controls, prodromal and PD patients.   
 
Determining non-linearity in progression rates is important as linear models fitted to non-
linear trajectories might, for example, over predict at baseline but under predict at the other 
extremes of time.  Using fractional polynomials allows for a simpler and easier to interpret 
model than methods like cubic splines although at the cost of being less flexible 91. Our 
research suggests that simply adding a square time term to a model to deal with non-linearity, 
which is quite common, may not be the most suitable option and has also been shown before 
in other contexts 92.  Unfortunately in our PD cohorts we do not currently have the data to 




measurement error (heteroscedasticity in observation level variation) is also important for 
multilevel models and can improve model fit and change standard errors.  However many 
standard statistical programs like STATA do not allow for multilevel models that add time 
terms to observation level random effects. So if researchers find heteroscedasticity of 
observation level residuals across time they should consider modelling this using a package 
like MLwiN 93. Alternatively if researchers are modelling cohorts that have balanced data 
(time of measurements for each individual is the same) then observational level variation can 
be freely estimated at each time point using structural equation modelling approaches 94. 
 
The best evidence for subtypes would come from cohorts where all individuals are 
phenotyped at the same time point, for instance at diagnosis, or using residuals from a 
regression model including time as cited in the strength and limitations.  Better phenotyping 
of PD cohorts, especially with regards to cognition would assist in deriving subtypes through 
a cluster analysis, however to get more cognitive data in a very large cohort such as ours is 
costly and adds to participant burden.  If measurements of MDS-UPDRS III can be taken in 
the “off” state after overnight withdrawal of medication then this would give measurements 
unconfounded by medication response.  However this needs to be weighed up against the 
distress and discomfort this would give to patients.  Newer methods such as using 
smartphones to measure motor disability will eventually be cheaper and should have far 
smaller inter-rater variability than current methods.  However these smartphone apps are still 
in their infancy and require further validation until they can replace the current in-clinic 
questionnaires 95, 96.  Also to reduce the inter-rater variability to the current accuracy of 
smartphone sensors would require all patients using these apps to follow the protocol 
correctly which may be hard to achieve in practice. 
 
It is important to validate any statistical model 97-99. An external validation in an independent 
distinct cohort is clearly best, as we did with our MS natural history model, our olfaction 
scale harmonization method and our PD subtypes. If the sample size of a cohort was 
particularly high then a split-sample approach where part of the dataset is kept aside for 
validation would suffice. However, this kind of random split-sampling often means that the 
dataset for development and validation is more similar than an external dataset as the 




protocol. There are also other internal validation techniques available like bootstrapping and 
cross validation 100. 
 
Parkinson’s disease has many motor and non-motor features.  Most of these features rely on 
questionnaires completed by the patient or in a consultation with a nurse or clinician.  
However for each motor and non-motor feature there are often a number of questionnaires to 
choose from which are generally measured on a scale unique to that questionnaire with 
different numbers of questions often rated on a different Likert scale.  This means that most 
of the observational PD cohorts have their disease phenotyped on different scales.  Data 
harmonization of these scales will allow more cross cohort collaborations or large individual 
patient meta-analyses. These type of methods 61 have been applied before to cognitive scales 
in PD 58-60 allowing multicenter analyses 101, 102.  It will also allow cohorts to create large 
collaborations giving the kind of numbers required to have decent power in genetic analyses 
where the effect sizes tend to be small.   
 
One issue with determining causal effects in observational studies is the problem of 
confounding.  It is often difficult to know the confounders in advance of a study and to 
measure them accurately leading to unmeasured and residual confounding 103.  A relatively 
new method that overcomes the problem of confounding is to use Mendelian Randomisation 
(MR) 104, 105.  This method uses genes as an instrumental variable that according to Mendel’s 
Laws should be assigned randomly at birth.  Thus creating a natural randomized study where 
individuals are randomly assigned to have genes that might increase or decrease the risk of 
the exposure of interest allowing us to find the causal effect of an exposure on an outcome.  
Two sample MR 106  takes the gene-exposure associations from a genome wide association 
(GWAS) study and the gene-outcome associations from another study.  In the future two 
sample MR might allow us to determine exposures causally related to disease progression 
using these MS and PD cohorts. This could assist in finding new treatments that could be 
tested within an RCT or in counselling of patients.  However in practice this does not always 
work as in the MR study that showed high uric acid was beneficial 107 in PD but the phase 3 
clinical trial (SURE-PD3 NCT02642393) testing raising uric acid was ended early due to 
futility 108.  Using the two sample MR framework also means that as long as there is genetic 




biomarker then this biomarker can be tested against prognosis without the need to assay it in 
participants within the study which could prove costly. 
 
Another important question to consider is whether risk-sharing schemes should be used in the 
future for other neurodegenerative diseases.  For instance imagine the hypothetical situation 
where a drug is licensed as a symptomatic medication for one of the many non-motor features 
of PD but there is ambiguity as to whether it reduces motor disease progression and hence 
may or may not be cost effective.  The major argument for the MS-RSS was a question of 
ethics and whether there is clinical equipoise.  I think there are two ways of viewing this 
1.  There is clinical equipoise for the question “Is this medication effective in the long-
term for reducing disease progression”. 
2. There is not clinical equipoise for the question “Should this medication be prescribed 
for a person with this symptom” because it is already licensed for treating that 
disease. 
A long-term randomised controlled trial (RCT) is clearly going to be the best evidence but a 
risk-sharing scheme is a good alternative for a condition that lasts many years if these ethical 
issues exist along with the problems of retaining participants within the study who see 
themselves as non-responders. Whether an RCT would use a placebo or an active comparator 
would depend on currently available treatment options routinely used in clinical practice.  In 
a risk sharing scheme I think it makes logical sense to develop and validate any natural 
history model prior to the inception of such a scheme (unlike what happened in the MS-RSS) 
and to think carefully about how to reduce any of the biases that might be an issue in this 
scheme.  Developing this model is going to be far cheaper than any risk sharing scheme or 
RCT and if there was a situation where this model did not validate well then you may already 
have spent millions on the risk sharing scheme without having a decent comparator for your 
treated cohort.  New tools for assessing the risk of bias in non-randomised studies of 
interventions also exist (ROBINS-I) 109 which should be considered at the beginning of any 
such study.  A previous paper found they could not replicate the results from an RCT using a 





There would be considerable risks when developing an untreated natural history model for a 
risk sharing scheme.  It could be difficult to obtain the data and would most likely involve 
obtaining a cohort initiated before any of the drugs in question were available.  This would 
ultimately lead to a potentially biased comparison of historical untreated data with 
contemporary treated data.  Also a major assumption (the unmeasured confounding 
assumption) of such a study would be that any risk factors for progression are equally 
distributed within the risk sharing scheme and the historical cohort.  The alternative would be 
identifying all risk factors for progression in advance and including them as covariates within 
the untreated natural history model.  As within any long-term study there would be difficulty 
in dealing with drop-outs (in both the risk sharing scheme and the observational untreated 
cohort) which requires using methods that adjust for missing data and/or assuming that the 
missing data does not have a particular pattern, such as assuming the data isn’t missing not at 
random. Within a long-term placebo controlled trial of a licensed drug it might become 
difficult to maintain blinding if particular side-effect profiles are well known and 
documented.  An advantage of having an RCT with an active comparator is it would allow 
indirect comparisons within a network meta-analysis framework 111 provided that active 
comparator has also been compared with other treatments in RCT’s. 
 
Alternatives to a risk sharing scheme or a long-term RCT would include a long-term 
observational study following up both treated and untreated patients. Such a study could use 
methods for causal inference in observational studies such as inverse probability weighting 
that were mentioned in chapter 6.3, although such studies require knowing and being able to 
measure all confounders.  Another alternative would be to have an active comparator 
(depending on currently available treatment options) within an observational active 
comparator new user study design 112.   
 
We think that failure to account for PD subtypes in an RCT could bias results towards the 
null especially if some of the subtypes do not respond as well to a specific medication, which 
is what we observed with levodopa.  This raises important questions about how to design a 
clinical trial accounting for subtypes and can we find simpler methods to predict a patients 
subtype.  To have the power to detect a clinically important difference within each subtype 




needing four times the number of patients to account for each of the four subtypes.  An 
alternative might be to specifically target a medication to only one of the subtypes, however 
this then limits the generalizability of the RCT to all PD patients. There is clearly a trade-off 
between the cost of screening for the sub-types versus the greater efficiency and hence 
reduced cost of the subsequent RCT if limited to a sub-type. Future work needs to model 
these options to determine the trade-off point whilst new technologies may result in far 
reduced costs than currently required for sub-type identification. 
 
PD subtypes might eventually be useful for counselling of patients at diagnosis.  However 
this will require longer follow-up data and firm clinical end-points such as time to developing 
severe disability or dementia.  These kind of end-points would be more familiar to a patient 
than the annual change in an clinical score that a patient would not understand (such as the 




The work presented in this thesis considers prognosis in two neurodegenerative diseases, 
Multiple Sclerosis and Parkinson’s disease.  There were six objectives which we have met in 
the following ways: 
 
1. We developed a multilevel model for the natural history of MS and validated this in 
an independent cohort.  Our modelling approach considered the choice of time axis, 
the best fitting trajectory, complex observation level variation, and adjustments for 
relapses and autocorrelation.  We found that a model with time since onset as the time 
axis with both linear and log time terms best modelled the trajectories. Adding a 
linear time random effect to the observation level variation improved the model fit.  
Grouping together observations made within a ¼ year time frame removed most of 
the autocorrelation. We found that removing observations made within three months 
of start of relapse in the UoWMS cohort (although only one month in BCMS) reduced 
our observation level variation giving evidence it removed any effect of relapse on the 




dataset - future measurements predicted from the first measurement were very close to 
the observed measurements on average.  
2. This natural history model was used as a comparator in a large cohort of treated 
patients followed up for 10 years to determine drug effectiveness in the long-term.  
Our modelling approach used a complete case analysis along with imputed analyses 
for individuals who were lost to follow-up.  We looked at different outcomes, EDSS 
and utility scores, carried out sub-group analyses and considered whether the 
effectiveness changed over time.  Our analyses suggest that these disease modifying 
treatments are effective in the long-term. 
3. We derived subtypes of Parkinson’s disease using a k-means cluster analysis in a 
large cohort of individuals who were recently diagnosed with Parkinson’s.  Our 
cohort was well phenotyped across important motor and non-motor symptoms and all 
of these were included within our cluster analysis.  The modelling approach first 
carried out a factor analysis followed by a k-means cluster analysis where we took 
into account the limitations of the k-means method.  We found three factors, one a 
psychological well-being factor including depression and anxiety, another a non-
tremor motor factor including rigidity, bradykinesia and postural instability and a 
third including cognitive variables. Using clinical and statistical methods we decided 
that five clusters gave the optimal solution. We carried out an internal validation of 
our method using cross-validation which showed it was relatively stable.  These 
clusters were associated with response to medication. 
4. We harmonized the data across two cohorts of Parkinson’s patients to allow us to 
carry out a cluster analysis using the data from both cohorts. Our modelling approach 
involved using item-response theory to convert scores from one olfaction test, the 
UPSIT, to another, the Sniffin. This conversion method performed well when it was 
validated in an external dataset of PD patients and controls who took both olfaction 
tests. 
5. We used the harmonised data to derive subtypes of the disease using the same 
approach as before within both cohorts. The larger cohort (Tracking) was used as the 
development cohort and the smaller (Discovery) was used as the validation. In this 
analysis we decided that four clusters gave us the optimal solution. Following that we 
used a discriminant analysis model derived from the clusters in the larger cohort to 
predict the clusters in the smaller.  We then compared the predicted and derived 




6. We took our validated subtypes and used multilevel models to look at prognosis in 
motor and cognitive variables.  Our subtypes were different in terms of their motor 
prognosis, and this conclusion remained after adjusting for withdrawal from the 
cohort using pattern-mixture models.  Using data from a levodopa challenge we also 
found our subtypes were associated with response to levodopa. 
 
Modelling prognosis in neurodegenerative diseases is important due to the substantial 
heterogeneity in patient progression.   The work presented herein details some empirical and 
methodological results from looking at prognosis in two neurodegenerative diseases. This 
work adds to the existing literature in demonstrating how one can use more advanced 
statistical methods to inform the evaluation of observational data on effectiveness as well as 
how to determine prognostic sub-groups that may have implications for the design of future 





7. Statement of contribution to published work 
“Parkinson's is my toughest fight. No, it doesn't hurt. It's hard to explain. I'm being tested to 
see if I'll keep praying, to see if I'll keep my faith. All great people are tested by God.” 
- Muhammad Ali 
For paper P1 I cleaned and checked all of the UoWMS cohort data, as noted in chapter 3, and 
then manipulated both the UoWMS and BCMS data ready for analysis.  I helped write the 
analysis plan and performed all of the statistical analysis myself.  I was the first author for 
this paper and contributed to writing the majority of this paper.  For papers P2 and P3 I 
helped write the analysis plan and performed all of the statistical analysis that was relevant to 
the multilevel modelling approach.  Although I was not the lead author I wrote the methods 
section relevant to the multilevel modelling approach, helped design the results tables and 
reviewed the paper.  As my work on the MS-RSS was funded by the National Institute for 
Health Research Health Technology Assessment (NIHR-HTA) there is also a HTA report 12 
that I did all the statistical analysis for and designed all the tables and figures.  This report 
was not included as a paper within this thesis because of the duplication of most of the work. 
 
For papers P4 to P6 I cleaned and checked all of the Discovery cohort and Tracking cohort 
data, as noted in chapter 5.  For paper P4 I helped to write the analysis plan and performed all 
of the statistical analysis.  I was the lead author of this paper but required some help from my 
clinical colleagues to write the discussion section.  For P5 I helped to write the analysis plan 
and carried out all of the statistical analysis. I was also the lead author on this paper.  
Additionally these harmonization methods were not familiar to any of our collaborators or 
anyone within my department.  Hence all the statistical analysis and programming I did was 
completely self-taught from reading published papers and books.   For P6 I wrote the analysis 
plan and performed all the statistical analysis. I was the lead author of this paper but again 
required some clinical input to write the discussion section.   
 




Table 3.  Summary of my contributions to the published papers 
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Abstract
Objectives: To develop a model of disease progression using multiple sclerosis (MS) as an exemplar.
Study Design and Settings: Two observational cohorts, the University of Wales MS (UoWMS), UK (1976), and British
Columbia MS (BCMS) database, Canada (1980), with longitudinal disability data [the Expanded Disability Status Scale (EDSS)]
were used; individuals potentially eligible for MS disease-modifying drugs treatments, but who were unexposed, were selected.
Multilevel modeling was used to estimate the EDSS trajectory over time in one data set and validated in the other; challenges ad-
dressed included the choice and function of time axis, complex observation-level variation, adjustments for MS relapses, and
autocorrelation.
Results: The best-fitting model for the UoWMS cohort (404 individuals, and 2,290 EDSS observations) included a nonlinear function
of time since onset. Measurement error decreased over time and ad hoc methods reduced autocorrelation and the effect of relapse. Repli-
cation within the BCMS cohort (978 individuals and 7,335 EDSS observations) led to a model with similar time (years) coefficients, time
[0.22 (95% confidence interval {CI}: 0.19, 0.26), 0.16 (95% CI: 0.10, 0.22)] and log time [!0.13 (95% CI: !0.39, 0.14), !0.15 (95% CI:
!0.70, 0.40)] for BCMS and UoWMS, respectively.
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1. Introduction
Prognostic models for chronic diseases [1] are needed to
guide management decisions and counseling of patients and
their families. Such models can consider outcomes ranging
from treatment response to changes in disability [2e4] and
may model individual disease trajectories. This poses tech-
nical challenges because progression may be nonlinear, the
outcome measure(s) may not be continuous or normally
distributed, and individuals may have been observed a
different number of times and at irregular intervals.
One example in which modeling long-term trajectories
poses challenges is multiple sclerosis (MS). MS is a chronic
inflammatory neurodegenerative disorder, with considerable
interindividual variation in the disease course. Most patients
presentwith relapsing-remittingMS (RRMS), inwhich symp-
toms appear for a varying amount of time and then disappear
(either partially or completely). However, over time individ-
uals with RRMS can progress to secondary progressive MS
(SPMS), where the frequency of relapses decreases and the
accumulation of disability increases steadily [5].
Disability in individuals with MS is commonly
measured using the Expanded Disability Status Scale
(EDSS) [6]. EDSS is an ordinal scale, based on a neurolo-
gist’s examination, ranging from 0 (normal neurologic ex-
amination) to 10 (death due to MS) in half unit
increments (but there is no score of 0.5). Previous studies
of EDSS progression have used survival analysis [7e9],
considering the time to specific milestones, for example,
an EDSS score of 6, which is equivalent to needing an
aid to walk. This ignores available data both before and af-
ter reaching the milestone and therefore fails to differen-
tiate two individuals reaching a milestone at the same
time but with different trajectories.
Empirical percentiles derived at yearly intervals and
data-smoothing techniques have been used to create
disability curves over time at different percentiles [10,11].
These methods do not model how a given individual
changes over time or the relationship between the centiles
and patient characteristics.
Markov models have been used to relate progression in
MS to age and disease duration as well as other baseline co-
variates [12,13]. However, such models assume that further
progression essentially depends only on the previous mea-
surement and may be less able to cope with issues such as
missing data and the need for imputation.
An alternative approach is using multilevel repeated
measure models where observations are clustered within
individuals [14]. We have used multilevel models to model
disability after stroke [4,15], and prostate-specific antigen
changes in men with localized prostate cancer [16,17].
Such models could account for both within and between pa-
tient variability of the EDSS measurements in MS. These
multilevel models are ideal to analyze unbalanced data, that
is, where observations are unequally spaced in time and
differ in number between individuals. Multilevel models
have been used to model the accumulation of disability in
MS using a transformation of EDSS [18], assuming a
quadratic curve for each individual and ignoring
observation-level (within individual) variation over time.
Our aim was to develop a generalizable model for the nat-
ural history of patients with relapsing-onset MS in two in-
dependent data sets who were not treated with any specific
disease modifying therapy (DMT) for MS but who would
have been eligible for a DMT. This was to facilitate future
comparisons with long-term cohorts of DMT-treated pa-
tients, such as the UK MS risk sharing scheme [13,19].
Here, we report how we have approached a variety of
analytical challenges and our proposed solutions for the
development of our natural history (untreated) model of
MS disease progression.
2. Methods
2.1. Study design and settings
We used data from the University of Wales MS
(UoWMS) cohort, United Kingdom, and the British
Columbia MS (BCMS) database, Canada, to develop and
validate the model.
2.1.1. UoWMS cohort
The University Hospital of Wales is the major tertiary
referral center for neurology in Wales, United Kingdom,
serving a local population of 1.2 million and provides a
network of MS clinics across South East Wales. Data were
initially collected in a cross-sectional study in 1985 [20]
and were updated periodically [21,22], until 2002 when
data were essentially collected prospectively [23]. Sociode-
mographic and clinical features at disease onset are re-
corded in a standardized fashion, including degree of
recovery and initial interrelapse interval. Approximately
1,000 patient contacts are documented annually, and clin-
ical data, including EDSS scores, are collected routinely
at presentation and at each visit. The database, at the time
of extraction, had around 2,000 registered MS patients with
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What is new?
# Considering different functions of time to find the
best-fitting trajectory of the Expanded Disability
Status Scale (EDSS).
# Accounting for nonconstant measurement error in
the multilevel model of EDSS.
# Adjusting data to avoid including the potential
confounding effects of short-term disease fluctua-
tions (i.e., multiple sclerosis relapses) on an indi-
vidual’s background longer-term disability
outcomes.
# Investigating autocorrelation and suitable ap-
proaches to minimize this.
# Replicating and cross-validating the model in an
independent cohort.
1,283 and 809 patients having at least 2 or 4 or more EDSS
scores over time, respectively.
2.1.2. BCMS cohort
BCMSdatabase [8,24e30], established in 1980, is popula-
tion based, estimating to capture 80% of the BCMS popula-
tion. Strengths of the BCMS database include longitudinal
follow-up of both DMT-treated and untreated patients, and
consistent care provided by the same four core neurologists
who have examined over 85% of the patients considered for
this study. EDSS scores are recorded after a face-to-face
consultation with an MS specialist neurologist. As of 2009,
the database contained records for over 5,900 MS patients
spanning 28 years (O25,000 cumulative years) of prospective
follow-up, from four MS clinics in British Columbia.
2.1.3. Eligibility criteria
We included patients in either cohort (UoWMS and
BCMS) if they ever became eligible for DMTs. This eligi-
bility was according to the 2001 Association of British
Neurologists (ABN) criteria for interferon beta and glatir-
amer acetate (IFN-b/GA) use (adapted from online supple-
mentary appendix IV Health Service Circular 2002/2004),
defined as: aged $18 years, EDSS %6.5, and had $2
relapses during the previous 2 years. Similar criteria are
broadly adopted in other legislative areas as well as the
United Kingdom and British Columbia, Canada. All EDSS
observations before a patient reaching the ABN eligibility
criteria were excluded.
A relapse was defined as worsening neurologic symp-
toms lasting O24 hours, in the absence of fever or infec-
tion. The starting date of each relapse was recorded by an
MS specialist neurologist.
As we wished to model the natural history of MS, we
truncated the patient profiles once a DMT was initiated.
In addition, in the BCMS cohort, the data were truncated
to 1995, the last year in which the DMTs were not widely
available in British Columbia. This was to avoid ‘‘indica-
tion bias’’ whereby a patient’s trajectory may influence
the decision as to whether they started a DMT [27].
2.2. General multilevel model
We modeled the EDSS scores of individuals with MS us-
ing multilevel models [14]. Our model had two levels: ob-
servations (level 1) within individuals (level 2). A simple
multilevel repeated measure model is a linear random inter-
cept and random slope model. This type of model estimates
a linear population mean along with a specific line for each
individual. A graphical representation of the model shown
below is given in Fig. 1.
yij5b0 þ u0i þ ðb1 þ u1iÞ$tij þ eij; ð1Þ
where yij and tij are the EDSS score and the time variable
for the ith individual at the jth time point. Hence,
b0 þ u0i is the ith individual’s baseline EDSS, whereas b0
is the mean baseline EDSS, and b1 þ u1i is the ith individ-
ual’s slope over time, whereas b1 is the mean slope over
time.
The uki (k 5 0, 1) is often referred to as the individual-
level random effects and the eij as the observation-level
Fig. 1. Graphical representation of the simple multilevel model with
linear random intercept and random slope model as shown within
Equation (1). Squares are subject 1, circles subject 2, and triangles
subjects 3.
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random effects, whereas the bk (k 5 0, 1) are the fixed ef-
fects. Conceptually, the individual-level random-effects
measure the deviation of the individual-specific line from
the population mean line, and the observation-level
random-effects measure the deviation of observations about
the individual-specific line.
The eij is assumed normally distributed with mean zero
and variance s2, and u0i and u1i are assumed normally
distributed with mean zero and an unstructured covariance
matrix Du.
Removing u1i from the equation would give us a linear
random intercept model, and removing both u0i and u1i
would give us a linear fixed effects only model.
2.3. Developing the model
We initially developed our model using the UoWMS
data set and then used the BCMS data set for replication.
The model was originally developed in UoWMS (the
smaller of the two cohorts) because access to the BCMS
data set was only possible at the University of British
Columbia, Canada. We cross-validated each model using
the other data set.
2.3.1. Choice of time axis
We considered modeling EDSS as a function of either
the age of an individual or the time since onset of MS at
each observation [8,24]. It is important to center the time
axis at a meaningful time point such as the minimum age
of the onset (18 years) or zero for the time since onset.
Models with different types of time are nonnested but use
the same data, so the Akaike information criterion (AIC)
was used to compare the models, selecting the model with
the lower AIC. In addition, we considered the root mean
square error (RMSE) for the difference between the
individual-specific predicted EDSS and observed EDSS,
and the proportion of these differences that were less than
0.5 or more than or equal to 2 EDSS points.
2.3.2. Choice of function of time
The next model choice was the best-fitting trajectory of
EDSS. A simple multilevel model (see Equation 1) allows a
random intercept and slope for each individual. Options for
more complex models include fractional polynomials to
choose the best-fitting curve [4,31], fitting cubic (or linear)
splines, finding a transformation of the outcome or time
axis (or both) which have a linear relationship, or
smoothing. We used fractional polynomials [4] to find the
best-fitting trajectory because these require all data to be
positive we added one to time. This procedure, see Web
Appendix A at www.jclinepi.com, tests what functions of
time best represent the individual trajectories of EDSS over
time. Fractional polynomials have the advantage that the
model has a simple algebraic form. Linear splines also have
a simple form but assume biologically implausible piece-
wise linear growth [32]. Cubic (or other complex) splines,
although more flexible, are more difficult for prediction
purposes than fractional polynomials as they require esti-
mation of the curves between each knot point rather than
one single global curve. Also, all splines involve the selec-
tion of knot points, which would further complicate the
multilevel model. Having selected the best-fitting fractional
polynomial for each time axis, we then compared these two
models using the same criteria as above.
As sensitivity analyses, we repeated the fractional poly-
nomial procedure on a restricted data set, only including
observations made within 30 and then 15 years from MS
symptom onset to check to what extent outliers were influ-
encing the choice of trajectory.
The model with both the best-fitting time axis and func-
tion of that time-axis is referred to hereafter as the ‘‘best-
fitting’’ simple model.
2.3.3. Observation-level variation
Observation-level variation is the extent to which EDSS
observations on a given individual at any one time are
likely to differ and can be considered as a mixture of mea-
surement error and within-person fluctuation, which will
change over time, because there is greater interrater and in-
trarater variability for lower EDSS values [33,34]. To
examine complex measurement error empirically, we
plotted the observation-level residuals against time for the
best-fitting simple model. Fractional polynomials were then
used to obtain the best-fitting function of time for the
observation-level variance, in the same way as described
in the previous section, see Web Appendix B at www.
jclinepi.com. The best-fitting simple model, with the addi-
tion of the selected best-fitting observation-level variance
function, is referred to as the ‘‘complex’’ model.
2.3.4. Autocorrelation
Autocorrelation occurs when measures on the same indi-
vidual are correlated more than would be implied by the
overall within-individual correlation. We investigated auto-
correlation by examining the association in lagged differ-
ences between observations and the individual-specific
predictions. A large correlation coefficient for these lagged
differences can indicate autocorrelation.
As an ad hoc method to reduce autocorrelation, we
divided each individual’s time axis into quarter year inter-
vals. If there was more than one observation within that in-
terval, a new observation was created by taking the median
time and the median EDSS score of all the observations
within that interval.
Other possible methods to take into account autocorrela-
tion would be autoregressive-moving average models. We
could also have created a more complex model with an
autocorrelation parameter that is a function of the time
between observations within an individual [35]. Other
methods to account for autocorrelation usually require data
to be balanced, and more research is necessary to
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incorporate methods for measuring autocorrelation in un-
balanced repeated measure models.
2.3.5. Relapses
Our focus was to model the true accumulation of
disability over time and avoid short-term disability second-
ary to an acute relapse. Consequently, all EDSS observa-
tions recorded within 1 month postrelapse were removed
from both data sets. However, some patients may continue
to improve in physical disability beyond the 1-month post-
relapse window [36]. Therefore, we carried out sensitivity
analyses using the complex model taking account of auto-
correlation, by also removing all observations within 3
and then 6 months after a documented relapse.
2.3.6. Assessing model assumptions and fit
We assessed the normality of the residuals by using QQ
plots and the fit of the model by comparing the actual and
predicted EDSS values. All analyses were carried out using
Stata software (Texas, USA) [37], and all multilevel models
were estimated by the runmlwin command [38].
2.3.7. Indication bias
We could bias our results by censoring individual obser-
vations after they started treatment because individuals who
start treatment might differ to those who never started treat-
ment. We avoided ‘‘indication bias’’ in the BCMS cohort
by truncating the data at 1995. However, because of the
smaller size of the UoWMS cohort, we instead tested for
indication bias by including ‘‘starting a DMT’’ as a covar-
iate within the multilevel model.
2.3.8. Conditional predictions for cross-validation
We carried out external validation using the model from
one cohort to predict the data from the other cohort, by pre-
dicting future trajectory based on the first observed EDSS
score for each individual [4,39]. We used the BCMS model
to predict theUoWMSdata and theUoWMSmodel to predict
the BCMS data. The EDSS scores were predicted using the
complex model accounting for autocorrelation and relapses.
3. Results
Table 1 shows the characteristics of the MS patients
included in the two cohorts, that is, those reaching eligi-
bility for drug treatment. The BCMS data set included more
than twice as many individuals as the UoWMS and had a
larger number of EDSS observations per person. However,
the patient characteristics were similar for sex and propor-
tion ever starting a DMT. For age and disease duration at
ABN eligibility and the proportion of patients with SPMS
at ABN eligibility, there was some moderate evidence of
a difference between data sets (P-values between 0.018
and 0.052) although these differences were small. BCMS
patients were on average 2 years younger at the onset than
UoWMS patients, although the longer disease duration at
ABN eligibility meant that they were only 1.3 years
younger on average at ABN eligibility. A higher proportion
of the BCMS cohort reached secondary progressive disease
Table 1. Patient demographics of all those eligiblea for disease-modifying drug treatment within the two multiple sclerosis cohorts from British
Columbia, Canada, and the University of Wales, United Kingdom, with all observations made within 1 month postrelapse removed








Number of EDSS observations; mean per person(range) 7,335; 7.5 (1e73) 2,290; 5.7 (1e72)
Females 728 (74.4%) 306 (75.7%) 0.611b
Age at the onset, yr 29.1 (8.6; 3.4e61.1) 31.1 (8.7; 13.4e60.0) !0.001c
Age at eligibility, yr 37.3 (9.3; 18.1e7.0) 38.6 (9.1; 18.8e80.1) 0.018c
Disease duration at eligibility, yr 8.2 (6.9; 0.2e38.9) 7.4 (7.1; 0.5e43.8) 0.052c
SPMS reached by eligibility date 150 (15.3%) 83 (20.5%) 0.019b
Ever reached SPMSd 563 (57.6%) 139 (34.4%) !0.001b
Relapses in 2 years before eligibility: median(quartiles; range) 2.9 (1.2; 2e9) 3.5 (0.9; 2e9)
EDSS at eligibility: median(quartiles; range) 2 (1,3.5; 0e6.5) 3.5 (2,4.5; 0e6.5)
Year of EDSS at eligibility: range 1980e1995 1976e2011
Year of last EDSS included in the present study: range 1981e1995 1984e2011
Prospective follow-up timed, yr (first eligible EDSS to last DMT-free EDSS) 5.8 (3.8, 0e15) 2.98 (3.9, 0e29.3) !0.001c
Prospectively followedd, $5 years 560 (57.3%) 92 (22.8%) !0.001b
Prospectively followedd, $10 years 159 (16.3%) 16 (4.0%) !0.001b
Time between observations, yr 0.9 (1.0; 0.0, 11.3) 0.6 (1.2; 0.0, 21.3) !0.001c
Ever prescribed a DMTe 232 (23.7%) 109 (27.0%) 0.201b
Abbreviations: SD, standard deviation; EDSS, Expanded Disability Status Scale; SPMS, secondary progressive MS; DMT, disease modifying
therapy; BCMS, British Columbia MS.




d For the BCMS cohort only includes observations made within the dates of the truncated data set, that is, 1980e1995.
e Includes DMT exposure up until 2011 in the BCMS cohort, that is, beyond the 1980e1995 window.
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during follow-up, possibly due to the longer length of
follow-up. There were a slightly greater number of relapses
in the 2 years before ABN eligibility and a moderately
higher EDSS at baseline in the UoWMS compared with
the BCMS cohort. The BCMS cohort had a higher average
time between observations.
3.1. Choice of time axis
For the UoWMS cohort, Table 2 compares the linear
fixed effects, linear random intercept, and linear random
slope and intercept models with age and time since onset
as the time axes. The models with time since onset as the
time axis had a substantially lower AIC, a lower RMSE,
higher proportions of observations within 0.5 EDSS (apart
from the fixed effects only model), and a similar proportion
of observations out by two or more EDSS. The random
intercept and slope models had better fit by all the criteria
than the random intercept and fixed effects only models.
When comparing the best-fitting models with degree 2 frac-
tional polynomials for the individual trajectories (i.e., for
fixed effects and individual-level random effects) for age
vs. time since onset (Supplementary Table 1), the latter
consistently had lower AICs, implying that time since onset
should be chosen as the time axis.
3.2. Choice of powers of time
There was strong evidence of an improvement in model
fit when comparing degree 2 fractional polynomials to de-
gree 1 [P ! 0.001, degrees of freedom (d.f.) 5 5].
Supplementary Table 2 shows that models including linear
and log time, or square root and log time, are consistently
the models with the two smallest AICs. The exception
was for the data set restricted to 0e15 years since onset;
however, the AIC in this case was close to that of the best
model (a difference of only 5). Comparing the RMSE of
these two models, Table 2, however, shows that the model
with linear and log time tends to fit the observed data better.
Thus, the final simple model included time since onset and
log of time since onset for the individual trajectories (i.e.,
for the fixed and individual-level random effects).
3.3. Observation-level variation
The observation-level residuals from the best-fitting sim-
ple model appear to decrease over time (Fig. 2).
Fractional polynomials of degree 2 for the observation-
level random effects tended not to converge, so we only
considered fractional polynomials of degree 1. Adding a
linear time term to the observation-level random effects
showed a clear improvement in the model fit (P ! 0.001,
d.f. 5 3) compared with the model where observation-
level random effects had constant variance. The best-
fitting model included the square root of time in the
Table 2. Akaike information criterion (AIC), root mean square error (RMSE), and percentage of observations within 0.5 EDSS and 2 or more EDSS of




% (N ) within ±0.5 EDSS
individual-level predictions
% (N ) ‡2 EDSS difference
individual-level predictions
Linear fixed effects only (age) 9496.11 1.92 17.6 (404/2,290) 32.3 (739/2,290)
Linear random intercept (age) 6549.66 0.71 61.8 (1,416/2,290) 1.9 (43/2,290)
Linear random slope and intercept (age) 6256.66 0.59 69.7 (1,595/2,290) 0.7 (15/2,290)
Linear fixed effects only (time since onset) 9385.02 1.88 15.6 (357/2,290) 31.9 (731/2,290)
Linear random intercept (time since onset) 6525.80 0.71 62.1 (1,421/2,290) 1.7 (38/2,290)
Linear random slope and intercept (time
since onset)




log t (time since onset) 6063.25 0.55 71.2% (1,630/2,290) 0.5 (11/2,290)
t, log t (time since onset) 6066.72 0.54 72.5 (1,660/2,290) 0.5 (11/2,290)
t, log t (time since onset), adding t to
observation-level variance
6013.40 0.55 71.2 (1,630/2,290) 0.5 (11/2,290)
t, log t (time since onset) adding t to
observation-level variance with restriction
Var(t) 5 0
6018.23 0.55 72.1 (1,651/2,290) 0.5 (11/2,290)
Abbreviation: EDSS, Expanded Disability Status Scale.


















0 10 20 30 40 50
time since onset (years) plus one
Fig. 2. Observation-level (level 1) residuals plotted over time since
onset for the UoWMS best-fitting simple model with linear and log
time since onset (n 5 2,290).
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observation-level random effects. The difference between
the models with linear time and square root of time as
observation-level random effects was small (difference in
AIC 5 1.1), so the model with linear time in the
observation-level random effects was included for ease of
interpretation.
We constrained the observation-level time variance term
to be equal to zero because its 95% confidence interval (CI)
included zero. Hence, we only allowed the covariance term
between the constant and observation-level time term to be
freely estimated, which amounts to the assumption that
observation-level variance decreases linearly over time.
This constraint had minimal impact on the model fit
(Table 2). Hence, the complex model is of the form
yij5b0 þ u0i þ e1ij þ
"
b1 þ u1i þ e2ij
#
tij







As described in the methods, we have added one to time
since onset, to ensure strict positivity of log time. Unstruc-
tured covariance matrices,De andDu, were used for the indi-
vidual and observation-level random effects with a slight
modification to the observation-level variance as discussed
above, see Web Appendix C at www.jclinepi.com.
3.4. Autocorrelation
Supplementary Table 3 shows that in our model, we
have some autocorrelation, with a correlation coefficient
between consecutive observation-level residuals of 0.17
with some evidence that this increases with an individual’s
number of observations presumably due to a greater
chance of having an observation close together. Using
quarter year intervals (see methods) reduced the UoWMS
data set from 2,290 to 1,876 observations with a maximum
number of observations for a single individual being
reduced from 72 to 26. Supplementary Table 3 shows that
the correlations between lagged residuals were lower in
this reduced data set.
3.5. Relapses
There was little difference in the fixed-effect estimates
and individual-level random effects between the three
models when EDSS scores were removed at 1, 3, or
6 months postrelapse, with all the 95% CIs overlapping
(based on Equation (2), see Supplementary Table 4). How-
ever, when we consider the observation-level random ef-
fects, there is some evidence that the variance of the
constant term is lower in the 6 month model compared with
the 1 month model. For our final model, we choose the
3 month model, which seemed to have similar variance in
the constant term when compared with the 6 month model.
3.6. Assessing model assumptions and fit
The QQ plots from the complex model (Equation (2))
with observations up to 3 months postrelapse removed
and accounting for autocorrelation are shown in
Supplementary Figure 1 and are close to normal.
Supplementary Figure 2 shows the observed vs.
predicted values from the complex model adjusted for
autocorrelation and relapses, which are all relatively close
to the reference line of perfect predictions. The difference
between observed and predicted values has an average of
!0.003, a 95% central range (2.5th to 97.5th percentiles)
of !1.13 to 0.97 and an RMSE of 0.48. Supplementary
Figure 3 shows the observations and fitted patient-specific
lines for six randomly chosen individuals with at least three
observations.
3.7. Indication bias
When including a binary variable ‘‘ever used DMT’’ as a
fixed effect, we found little evidence that those who started
treatment have a different intercept (P 5 0.88) or different
progression (P 5 0.83 for interaction with time and
P 5 0.86 for interaction with log time). This provides some
evidence that ‘‘indication bias’’ was not a major issue in the
UoWMS cohort.
3.8. Model development with the BCMS data
Developing the model on the BCMS data gave very
similar results. Time since MS symptom onset was found
to be a better time axis than age. Linear and log time for
the individual trajectories gave very good fit to the data,
although linear and square root time did give slightly better
fit. Adding a linear time term to the observation-level
random effects gave a model with better fit, and fractional
polynomials of degree 2 showed little improvement.
In contrast to the UoWMS results, the model fitted to the
data with all observations 1 month postrelapse removed
gave similar results as those with all observations 3 and
6 months postonset of relapse removed (data not shown).
Hence, our final BCMS model was based on the model with
observations 1 month postrelapse removed.
3.9. Comparison of UoWMS and BCMS models and
model validation
The UoWMS model had a higher fixed effect, higher
individual-level random effect, and lower observation-
level random effect for the constant term than the BCMS
model (Table 3).
This indicates that the UoWMS patient population had a
higher average EDSS at the presumed onset of disease,
greater variation between individuals in EDSS at the onset,
and slightly lower variation within individuals in EDSS at
the onset (Table 1). The coefficients for the trajectory of
EDSS over time and log time, and the other variances
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and covariances of the individual-level and observation-
level random effects are remarkably similar between the
two cohorts. The fixed effects would correspond to an
average increase over 10 years from the onset of 1.9 EDSS
and 1.3 EDSS points within the BCMS and UoWMS
models, respectively.
We used the coefficients from the final BCMS model to
predict EDSS in the UoWMS data set (with the EDSS
scores removed 3 months postrelapse) conditional on the
baseline EDSS, rounding the continuous prediction to the
nearest true EDSS score. We observed a reasonable model
fit with a mean difference between prediction and observed
being !0.44 [standard deviation (SD): 1.36] and an RMSE
of 1.46; 49.2% of predictions were within 0.5 units of the
observed EDSS, whereas 22.5% of predictions were out
by 2 or more EDSS units. These conditional predictions
from the BCMS model are shown along with the observed
EDSS in the UoWMS cohort, averaged within yearly
bands, in Fig. 3A and Supplementary Table 5.
We also used the coefficients from the final UoWMS
model to predict EDSS in the BCMS data set conditional
on the baseline EDSS. The mean difference between pre-
diction and observed was !0.61 (SD: 1.83), with some ev-
idence of underprediction over time and RMSE of 1.93.
Only 35.9% of predictions were within 0.5 units of the
observed EDSS, whereas 35.8% of predictions were out
by 2 or more EDSS. These conditional predictions from
the UoWMS model are shown along with the observed
EDSS in the BCMS cohort, averaged within yearly bands,
in Fig. 3B and Supplementary Table 6.
4. Discussion
We used two large independent cohorts of MS patients
from Canada and the United Kingdom to build a complex
multilevel model for EDSS trajectory. Using the samemodel
building strategy resulted in the models for both cohorts hav-
ing the same time axis, powers of time that were consistent
with each other and the same parameterization of
observation-level variation. The average levels of disability
in the two cohorts were different, but the average patterns
of change were similar. This provided evidence that our
model is transportable to other populations. When two co-
horts are not available, it may be necessary to use other vali-
dation techniques such as randomly splitting the data set or
using bootstrap or jackknife techniques.
Two key choices made here related to the functional
form of the time axis. When both ‘‘time since onset’’ and
‘‘age’’ were considered, the best-fitting time axis was the
former. The pattern of EDSS progression was not linear
and fractional polynomials allowed us to identify the
best-fitting trajectory. This approach has been developed
and used for identification of nonlinear relationships in
nonrepeated measures regression [40,41]. However, their
use in multilevel models has been less widespread
[4,42,43]. This may be because of increasing complexity
of the models and also because of the additional need to
parameterize the individual-level and observation-level
random effects.
We found that observation-level variation (comprising
measurement error and short term fluctuations in the EDSS)
reduced as time progressed [i.e., as disability (EDSS)
increased]. Previous work has shown that measurement error
is lower for higher EDSS values [33,34] and that short-term
improvements in disability are more likely earlier in the dis-
ease course [29]. Identification of complex observation-level
variation highlights the importance of model checking when
fitting multilevel longitudinal models.
Our ad hoc approach to adjust for the autocorrelation pre-
sent was successful in reducing it further. A more robust
approach might be to adjust the interval for mergingmultiple
observations into one and then estimate the lagged residual
correlation for each different interval. However, this would
need to be balanced by the effect of concatenating too many
observations and reducing any real fluctuations in EDSS due
to using averaged data points. There is some evidence [44]
that moderate misspecification of the observation-level vari-
ation has little impact on the fixed-effects estimates. The
Table 3. Parameter estimates, mean (95% CI), of the final UoWMS and BCMS models
Variable BCMS (n [ 6,447) UoWMS (n [ 1,589)
Fixed effects
Intercept 1.05 (0.79, 1.31) 2.63 (2.00, 3.27)
Time since onset 0.22 (0.19, 0.26) 0.16 (0.10, 0.22)
Log time since onset !0.13 (!0.39, 0.14) !0.15 (!0.70, 0.40)
Individual-level (level 2) random effects
Var(intercept) 2.80 (1.87, 3.73) 8.67 (5.05, 12.29)
Cov(intercept, time) 0.09 (!0.05, 0.24) 0.09 (!0.23, 0.40)
Var(time) 0.10 (0.08, 0.12) 0.08 (0.05, 0.12)
Cov(intercept, log time) !2.73 (!3.82, !1.63) !5.38 (!8.57, !2.19)
Cov(time, log time) !0.65 (!0.81, !0.48) !0.60 (!0.92, !0.28)
Var(log time) 6.14 (4.78, 7.49) 7.13 (4.01, 10.27)
Observation-level (level 1) random effects
Var(intercept) 0.76 (0.70, 0.82) 0.40 (0.35, 0.45)
Cov(intercept, time) !0.004 (!0.005, !0.002) !0.003 (!0.005, !0.002)
Var(time) Set equal to zero Set equal to zero
Abbreviations: CI, confidence interval; UoWMS, the University of Wales MS; BCMS, British Columbia MS.
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moderate amount of autocorrelation present here had little
influence on our estimates of average EDSS progression
(the fixed-effect estimates were very similar in the models
with and without concatenated observations).
Removal of observation (EDSS) scores within 1 month
postrelapse appeared adequate for the BCMS cohort, but
in the UoWMS cohort, the optimal window was 3 months
postrelapse. This is consistent with the general approach
to data collection within the BCMS database (EDSS scores
were intended to be collected outside the influence of an
acute relapse [8]), as well as with previous findings from
the BCMS study [29]. Others have also shown that most
improvement in physical disability occurs within 2 months
postrelapse [36]. This underscores the importance of
exploring local effects within cohorts.
We treated the ordinal EDSS score as a continuous mea-
sure, which facilitates the interpretation of the model
parameters but does not imply that the meaning of a point
change in EDSS is equivalent in terms of disability progres-
sion across the range of scores. All the models showed
good fit to the observed data with normally distributed re-
siduals. Researchers seeking to model repeated measures
of ordinal scores should assess the normality of the resid-
uals as a key model check, but our results show that this
assumption may be satisfied even if the outcome measure
itself is ordinal and/or not normally distributed.
Modeling the trajectory of EDSS against the time since
MS symptom onset showed a good fit in both cohorts.
Cross-validating our models by predicting the future EDSS
trajectory conditional on the first observation in one data set
using the model derived on the other data set showed
reasonably good fit, with about half of all predicted EDSS
scores within 0.5 EDSS of the observed when validating the
BCMS model in the UoWMS data. However, the UoWMS
model performed less well in the BCMS data, with evi-
dence of underprediction at almost all time points. This is
not surprising given the relative sizes of the two data set.
The higher within-individual variation within the BCMS
data set means that predictions within the BCMS data are
likely to show greater variation than predictions made on
the UoWMS data. Our ability to examine model fit in
two different populations is important in validating any
prognostic model. Using a repeated measures model to pre-
dict individual trajectories based on one or more observa-
tions has been done before [4,15,45], but further research
needs to examine whether additional covariates can explain
why the trajectory of some subjects was not well predicted
in our current model. Bayesian methods could also be used,
such that the previous model estimates form priors for pa-
rameters to be estimated using a small number of observa-
tions from an individual [46].
Truncating data once a DMTwas started (UoWMS) or to
1995 (BCMS data) resulted in an average follow-up time
for individuals of 3 and 5.8 years, respectively. We had
limited data with 10 years of follow-up or greater (16%
and 4% of individuals, respectively). However, because in-
dividuals enter the study at different times since onset, we
are able to model this without extrapolation. Examining
Fig. 3 shows little evidence that the fit to our data is worse
at the upper end of 20e30 years since time of the onset.
Although the models are generally similar for most
parameters, it seems there is higher between-individual
variation in the UoWMS model and higher within-
individual variation in the BCMSmodel. One reason for this
could be an inherent difference between individuals from
Canada and Wales or a difference in when and how
individuals accessed the health systems in each area. Also,
the BCMS cohort wasmainly seen by the same four core neu-
rologists, which would reduce any between-rater variation.
The corresponding Markov model that was fitted to the
BCMS cohort [13] showed about a 2.2 EDSS increase over
a 10-year period since ABN eligibility. Looking at our fixed
effects over the same period (approx. 8e18 years since
Fig. 3. (A) and (B) The upper graph shows the observed EDSS within
the UoWMS cohort and the conditional predictions using the BCMS
model. The lower graph shows the observed EDSS within the BCMS
cohort and the conditional predictions using the UoWMS model.
The plotted data, over a 30-year period, are the annual means at each
year since time of the onset where data was grouped into yearly bins
that is 0e0.5, 0.5e1.5, and so forth. EDSS, Expanded Disability Sta-
tus Scale; UoWMS, the University of Wales MS; BCMS, British
Columbia MS; CI, confidence interval.
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onset) would correspond to a similar average increase of
2.1 and 1.5 EDSS within the BCMS and UoWMS models,
respectively. Using the fixed effects, we would expect the
average time from the onset to reaching an EDSS of 6 to
be 23.1 and 23.4 years using the UoWMS and BCMS
models, respectively. Scalfari [7] reported a mean time
from the onset of 21.2 years (95% CI: 19.8, 22.6) to reach-
ing EDSS 6, and Tremlett [8], who looked at six studies,
reported the median times ranging from 15 to 32 years,
consistent with our estimates. Comparing our study to
one previous multilevel model for MS [18] is difficult given
their transformation of EDSS into weighted change of
EDSS. However, they did include a quadratic term whose
estimate was positive, which creates a similar shape to a
negative log term with rate of change increasing over time.
Our results have implications for the design and analysis
of MS intervention trials, leading to more sensitive assess-
ment of treatment effects over time than cross-sectional an-
alyses of EDSS at fixed time points. Average EDSS could
be similar in an intervention and control arm after a fixed
follow-up period, but if the trajectory was different, the
intervention might still be considered an effective treatment
in the short and medium terms.
The development of this multilevel model is an impor-
tant methodological achievement that will enable predic-
tion of the expected long-term disease trajectory in other
populations. This is especially necessary for extrapolating
the findings from randomized controlled trials (which are
often short term, lasting no more than 2e3 years) or for in-
terpreting findings from DMT exposed cohorts of patients
with no specific unexposed control cohort. In particular,
these models facilitate natural history predictions within
the UK MS risk sharing scheme to determine the efficacy
of DMTs. It is only by modeling longer term follow-up
of such studies that one can advise patients about the poten-
tial therapeutic benefits that accrue in the long term.
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A fractional polynomial of degree m contains m different powers of the time variable.  The 
power zero denotes the logarithmic transformation and a combination of two identical powers 
is interpreted as the product of the power and the logarithmic transformation.  Hence a 
fractional polynomial in t of degree 2 with powers = (1, 1) would include t and t . In 
order to fit fractional polynomials, the time variable must be strictly positive (as the 
 
logarithm of zero or a negative number is undefined). We therefore added one year to time 




Models with different degrees of fractional polynomials of time were compared using the 
deviance [1]. Fractional polynomials of degree m and (m-1) are usually compared with 2 
degrees of freedom (one for the coefficient and one for the power) and we used a p-value of 
0.05 for our significance level, [1]. In our case we must also include extra degrees of freedom 
for estimation of the variance and covariance parameters within the random effects. The 
powers of time we considered for inclusion in the fractional polynomials were -2, -1, -0.5, 0, 
0.5, 1, 2 and 3.  In our model, for ease of interpretation, the same powers of time were used 
for the fixed effects and the individual-level random effects.  Hence the following multilevel 
model was considered: 
                                                                                   (1) 
where  m is the degree of fractional polynomial. 
 
,   and  have the same meaning as 




normally distributed with mean zero and unstructured covariance matrix 
 
. The rk are the 
powers of the fractional polynomials for the fixed effects and individual-level random effects. 





Powers of time used for the observation level random effects were allowed to differ from 
those used for the fixed and individual level random effects, i.e. we considered the following 
model: 










are normally distributed with unstructured covariance matrix .  The sl are 
the powers of the fractional polynomials for the observation-level random effects. 
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Supplementary Figure 1. The Q-Q plots for all the residuals within the UoWMS complex 
model accounting for autocorrelation and relapse with the functional form as described within 
equation (2). Level 1 are observation-level random effects and level 2 individual-level 















































































Supplementary Figure 2. Observed vs. predicted values the UoWMS model with the 


















































































Supplementary Figure 3. EDSS observations plotted against time since onset along with the 
fitted patient specific lines from the UoWMS complex model accounting for autocorrelation 
and relapse for six randomly chosen individuals. 
 
 
Supplementary Table 1.  Using different time axes the five best models for the UoWMS ABN 
eligible cohort, their fixed and individual-level random effects of time, and within the 
brackets their AIC.  
Powers of time for fixed and individual 
level random effects  with  age as time axis 
(AIC) (n=2290) 
Powers of time for fixed and individual 
level random effects with time since onset 
as time axis (AIC) (n=2290) 
                                          (6177.79) ,                    (6063.25) 
,                                         (6238.95) t,                       (6066.72) 
  ,                        (6252.38)                            (6073.26) 
 ,                (6254.55) t,                               (6073.89) 




Supplementary Table 2. Powers of time since onset for fixed and individual-level random 
effects (AIC) for UoWMS data subsets including observations made within different time 
frames 
 
Entire dataset (n=2290) 
 
Time from 0-30 years 
since onset (n=2244) 
Time from 0-15 years since 
onset (n=1713) 
,              (6063.25) ,                (5954.79)  (4695.39) 
t,  (6066.72) t,                  (5959.78) ,                  (4696.63) 
                  (6073.26)                   (5963.89)                            (4697.93) 
t,                       (6073.89) t,                       (5964.08) 
 
(4698.92) 





Supplementary Table 3.  
patient specific lines with a lag of one when considering individuals with different numbers 
of observations for the UoWMS complex model.  Individuals are grouped in this table by the 
number of observations they had before adjusting for autocorrelation so we compare the same 
individuals within each column. However since some individuals have only one observation 








correlation for the 
complete dataset  
(number of individuals 
: %) 
Lagged  
correlation for the dataset 
where observations within 
quarter year intervals are 
merged   
(number of individuals : %) 
Entire dataset  0.169 
(303/404 : 75%) 
-0.011 
(297/404 : 73.5%) 
3 or more  
 
0.197 
(233/404 : 57.7%) 
0.021 
(232/404 : 57.4%) 
4 or more 
 
0.222 
(187/404: 46.3 %) 
0.049 
(186/404: 46.0 %) 












   
 
 


















10 or more 
 
0.248 






Supplementary Table 4.  Parameter estimates, mean (95% CI), for models based on datasets 
with observations removed at different durations post onset of a relapse for the UoWMS 
complex model adjusted for autocorrelation 
 
Variable 1 month post 
relapse (n=1876) 
3 months post 
relapse (chosen 
model) (n=1589) 
6 months post 
relapse (n=1303) 
Fixed Effects 
Intercept  2.63 (2.09, 3.17) 2.63 (2.00, 3.27) 2.53 (1.85, 3.21) 
Time since onset  0.16 (0.10, 0.21) 0.16  (0.10, 0.22) 0.14 (0.08, 0.20) 
Log time since onset  -0.15 (-0.63, 0.34) -0.15  (-0.70, 0.40) 0.03  (-0.51, 0.57) 
Individual Level (level 2) random effects 
Var(intercept) 6.81 (3.97, 9.65) 8.67  (5.05, 12.29) 7.11  (3.48, 10.75) 
Cov(intercept, time) 0.04 (-0.26, 0.34) 0.09  (-0.23, 0.40) -0.17 (-0.38, 0.03) 
Var(time) 0.07 (0.04, 0.11) 0.08  (0.05, 0.12) 0.05 (0.03, 0.08) 
Cov(intercept, log time) -4.05 (-6.71, -1.39) -5.38  (-8.57, -2.19) -3.04 (-5.69, -0.39) 
Cov(time, log time) -0.51 (-0.81, -0.22) -0.60 (-0.92, -0.28) -0.31 (-0.53, -0.09) 
Var(log time) 5.86 (3.14, 8.58) 7.13  (4.01, 10.27) 4.41 (2.04, 6.79) 
Observation level (Level 1) random effects 
Var(intercept) 0.51 (0.46, 0.56) 0.40  (0.35, 0.45) 0.38 (0.33, 0.43) 
Cov(intercept, time) -0.004 (-0.006, -
0.003) 









Supplementary table 5. A table showing the observed EDSS data over time since onset for the 
UoWMS dataset as well as the predicted EDSS and the EDSS difference (predicted-





















0.5-1.5 13 (10) 3.42 (1.51) 2.38 (0.98) -1.04 (0.69) 3.04 (1.35) -0.38 (0.55) 
1.5-2.5 59 (35) 3.72 (1.93) 2.81 (1.10) -0.92 (1.12) 3.33 (1.33) -0.39 (0.96) 
2.5-3.5 93 (47) 3.99 (2.01) 3.43 (1.49) -0.56 (1.15) 3.75 (1.57) -0.24 (1.10) 
3.5-4.5 101 (51) 3.93 (2.03) 3.89 (1.43) -0.04 (1.30) 3.91 (1.34) -0.02 (1.30) 
4.5-5.5 86 (53) 3.99 (1.87) 3.83 (1.56) -0.16 (1.44) 3.76 (1.39) -0.23 (1.35) 
5.5-6.5 98 (53) 4.32 (1.86) 3.98 (1.64) -0.34 (1.65) 3.88 (1.47) -0.43 (1.50) 
6.5-7.5 105 (50) 4.82 (1.54) 4.46 (1.75) -0.36 (1.37) 4.35 (1.69) -0.47 (1.30) 
7.5-8.5 95 (47) 5.03 (1.56) 4.96 (1.48) -0.07 (1.25) 4.74 (1.34) -0.29 (1.18) 
8.5-9.5 70 (49) 4.98 (1.72) 4.86 (1.48) -0.11 (1.31) 4.66 (1.25) -0.32 (1.19) 
9.5-10.5 65 (42) 4.68 (1.78) 4.78 (1.43) 0.11 (1.15) 4.64 (1.37) -0.04 (1.15) 
10.5-11.5 78 (43) 5.04 (1.77) 4.66 (1.31) -0.38 (1.28) 4.58 (1.28) -0.46 (1.25) 
11.5-12.5 64 (27) 5.63 (1.80) 4.91 (1.36) -0.73 (1.35) 4.66 (1.16) -0.98 (1.35) 
12.5-13.5 64 (23) 6.38 (1.50) 5.52 (1.21) -0.85 (1.28) 5.17 (1.11) -1.20 (1.41) 
13.5-14.5 77 (28) 6.36 (1.47) 5.27 (1.07) -1.08 (1.38) 4.94 (1.03) -1.42 (1.52) 
14.5-15.5 92 (31) 6.77 (1.49) 5.45 (1.01) -1.32 (1.38) 5.13 (0.90) -1.65 (1.40) 
15.5-16.5 69 (23) 6.66 (1.65) 6.01 (1.41) -0.65 (1.22) 5.66 (1.29) -1.00 (1.25) 
16.5-17.5 39 (22) 6.65 (1.37) 5.94 (1.28) -0.72 (0.97) 5.72 (1.20) -0.94 (1.08) 
17.5-18.5 46 (20) 6.30 (1.48) 6.03 (1.48) -0.27 (0.97) 5.82 (1.38) -0.49 (0.91) 
18.5-19.5 26 (15) 6.31 (1.70) 6.02 (2.15) -0.29 (1.44) 5.75 (2.08) -0.56 (1.48) 
19.5-20.5 23 (17) 5.74 (1.44) 5.65 (1.91) -0.09 (1.29) 5.35 (1.78) -0.39 (1.26) 
20.5-21.5 39 (17) 5.94 (1.49) 5.49 (2.03) -0.45 (1.26) 5.19 (1.82) -0.74 (1.16) 
21.5-22.5 34 (18) 6.68 (1.54) 5.66 (1.97) -1.01 (1.47) 5.31 (1.87) -1.37 (1.48) 
22.5-23.5 17 (9) 6.26 (0.69) 5.59 (1.44) -0.68 (1.12) 5.62 (1.45) -0.65 (1.22) 
23.5-24.5 18 (10) 5.83 (1.60) 5.97 (1.61) 0.14 (0.97) 5.58 (1.49) -0.25 (0.97) 
24.5-25.5 14 (9) 6.18 (1.37) 6.29 (1.27) 0.11 (1.00) 5.93 (1.07) -0.25 (1.03) 
25.5-26.5 12 (5) 6.83 (1.15) 7.38 (1.28) 0.54 (0.50) 6.96 (1.01) 0.13 (0.38) 
26.5-27.5 18 (7) 6.69 (2.09) 6.61 (2.58) -0.08 (1.10) 6.25 (2.17) -0.44 (0.76) 
27.5-28.5 13 (3) 7.81 (1.16) 6.23 (1.73) -1.58 (1.46) 6.31 (1.11) -1.50 (0.79) 
28.5-29.5 12 (7) 6.83 (1.75) 6.88 (1.82) 0.04 (1.16) 6.46 (1.62) -0.38 (0.91) 
29.5-30.5 10 (3) 8.05 (0.50) 8.95 (1.23) 0.90 (0.81) 8.05 (0.72) 0.00 (0.75) 
 
 
Supplementary table 6. A table showing the observed EDSS data over time since onset for the 
BCMS dataset as well as the predicted EDSS and the EDSS difference (predicted-observed) 





















0.5-1.5 44 (37) 1.99 (1.46) 1.75 (0.74) -0.24 (1.03) 2.03 (1.24) 0.05 (0.99) 
1.5-2.5 178 (126) 2.36 (1.81) 2.07 (0.95) -0.29 (1.26) 2.53 (1.20) 0.17 (1.17) 
2.5-3.5 233 (152) 2.51 (1.80) 2.04 (0.97) -0.47 (1.37) 2.42 (0.99) -0.09 (1.38) 
3.5-4.5 311 (185) 2.71 (1.87) 2.24 (1.05) -0.46 (1.48) 2.57 (1.06) -0.14 (1.53) 
4.5-5.5 329 (200) 3.34 (2.15) 2.53 (1.21) -0.81 (1.74) 2.81 (1.13) -0.53 (1.81) 
5.5-6.5 361 (227) 3.47 (2.38) 2.63 (1.18) -0.84 (1.87) 2.89 (1.15) -0.58 (1.95) 
6.5-7.5 381 (241) 3.56 (2.35) 2.78 (1.17) -0.78 (1.86) 2.97 (1.16) -0.59 (1.97) 
7.5-8.5 385 (258) 3.51 (2.36) 2.89 (1.30) -0.62 (1.81) 3.04 (1.27) -0.48 (1.94) 
8.5-9.5 391 (263) 3.77 (2.37) 3.12 (1.37) -0.64 (1.84) 3.25 (1.31) -0.52 (1.89) 
9.5-10.5 382 (233) 3.98 (2.23) 3.20 (1.40) -0.78 (1.72) 3.27 (1.35) -0.71 (1.83) 
10.5-11.5 379 (230) 4.01 (2.32) 3.25 (1.35) -0.77 (1.91) 3.30 (1.32) -0.72 (2.00) 
11.5-12.5 307 (211) 3.94 (2.46) 3.40 (1.50) -0.54 (1.85) 3.39 (1.49) -0.55 (1.90) 
12.5-13.5 295 (192) 4.32 (2.25) 3.46 (1.34) -0.86 (1.95) 3.42 (1.31) -0.90 (1.99) 
13.5-14.5 300 (194) 4.27 (2.32) 3.59 (1.48) -0.68 (1.89) 3.50 (1.41) -0.77 (1.93) 
14.5-15.5 259 (156) 4.24 (2.32) 3.71 (1.46) -0.53 (1.85) 3.61 (1.38) -0.63 (1.86) 
15.5-16.5 232 (135) 4.18 (2.05) 3.77 (1.42) -0.41 (1.72) 3.64 (1.30) -0.54 (1.74) 
16.5-17.5 213 (117) 4.58 (1.98) 3.94 (1.49) -0.64 (1.83) 3.82 (1.38) -0.76 (1.81) 
17.5-18.5 196 (114) 4.52 (2.07) 3.91 (1.50) -0.60 (1.84) 3.77 (1.39) -0.75 (1.78) 
18.5-19.5 178 (107) 4.53 (2.02) 4.12 (1.56) -0.41 (1.76) 3.97 (1.37) -0.56 (1.72) 
19.5-20.5 165 (103) 4.82 (2.03) 4.07 (1.52) -0.75 (1.79) 3.92 (1.39) -0.90 (1.77) 
20.5-21.5 153 (89) 4.99 (1.73) 4.29 (1.57) -0.70 (1.67) 4.09 (1.46) -0.89 (1.56) 
21.5-22.5 129 (76) 4.81 (1.80) 4.42 (1.53) -0.39 (1.66) 4.22 (1.38) -0.59 (1.61) 
22.5-23.5 89 (67) 4.88 (1.72) 4.49 (1.61) -0.39 (1.66) 4.24 (1.51) -0.63 (1.58) 
23.5-24.5 79 (62) 4.67 (1.96) 4.43 (1.91) -0.24 (1.51) 4.15 (1.81) -0.52 (1.45) 
24.5-25.5 79 (49) 4.57 (1.96) 4.13 (1.83) -0.44 (1.76) 3.91 (1.70) -0.66 (1.71) 
25.5-26.5 51 (39) 5.28 (2.17) 4.48 (2.32) -0.80 (1.91) 4.17 (2.18) -1.12 (1.83) 
26.5-27.5 57 (35) 4.81 (1.87) 3.47 (1.82) -1.33 (2.11) 3.27 (1.72) -1.54 (2.02) 
27.5-28.5 39 (25) 5.36 (1.93) 4.23 (2.02) -1.13 (1.67) 3.90 (1.83) -1.46 (1.57) 
28.5-29.5 21 (14) 4.74 (1.81) 4.02 (1.30) -0.71 (1.66) 3.74 (1.24) -1.00 (1.80) 




Supplementary table 7. A table showing the notation used in the main paper and the web-only 
appendix equations. 
Notation Meaning 
yij EDSS score for the ith individual at the jth time point 
tij Time of observation yij 
0 Average intercept (constant fixed effect) 
k Fixed effect for the kth power of time 
u0i Individual-level random effect of the constant term for ith 
individual  
uki Individual-level random effect of the kth power of time for 
ith individual 
eij Constant observation-level random effect for observation yij  
elij Observation-level random effect of lth power of time for 
observation yij 
Du 
Unstructured covariance matrix unless otherwise stated. 
cov(u0i,u1i) 
Covariance between individual-level random effect uoi 
individual-level random effect u1i  
Var(u0i) 





www.thelancet.com/neurology   Vol 14   May 2015 497
Articles
Eff ectiveness and cost-eff ectiveness of interferon beta and 
glatiramer acetate in the UK Multiple Sclerosis Risk Sharing 
Scheme at 6 years: a clinical cohort study with natural 
history comparator
Jacqueline Palace, Martin Duddy, Thomas Bregenzer, Michael Lawton, Feng Zhu, Mike Boggild, Benjamin Piske, Neil P Robertson, Joel Oger, 
Helen Tremlett, Kate Tilling, Yoav Ben-Shlomo, Charles Dobson
Summary
Background In 2002, the UK’s National Institute for Clinical Excellence (NICE) concluded that interferon beta and 
glatiramer acetate would be cost eff ective as disease-modifying therapies (DMTs) for multiple sclerosis only if the 
short-term disability benefi ts reported in clinical trials were maintained. The UK Multiple Sclerosis Risk Sharing 
Scheme (RSS) was established to assess whether disability progression was consistent with a cost-eff ectiveness target 
of £36 000 per quality-adjusted life-year projected over 20 years. We aimed to evaluate the long-term eff ectiveness and 
cost-eff ectiveness of these DMTs by comparing a cohort of patients with relapsing-remitting multiple sclerosis 
enrolled in the UK RSS with a natural history cohort from British Columbia, Canada.
Methods In our clinical cohort we included patients starting a DMT who were enrolled in the UK RSS who had 
relapsing multiple sclerosis at baseline and had at least one further clinical assessment. In our control cohort we 
included patients in the British Columbia multiple sclerosis database (BCMS; data collection 1980–96) who met the 
same eligibility criteria as for the RSS cohort. We compared disability progression at 6 years for RSS patients with 
untreated progression modelled from BCMS patients using continuous Markov and multilevel models. The primary 
outcomes were the progression ratio (treated vs untreated) measured both in Expanded Disability Status Scale (EDSS) 
score and utility. A ratio of less than 100% for EDSS implied slower than expected progression on treatment compared 
with off  treatment; a utility ratio of 62% or less implied that the DMTs were cost eff ective.
Findings 5610 patients starting a DMT were enrolled in the UK RSS between Jan 14, 2002, and July 13, 2005 (72 sites), 
of whom 4137 were included in our clinical cohort. We included 898 BCMS patients in the control cohort who met the 
RSS inclusion criteria and had at least one EDSS score after baseline. RSS patients had a mean follow-up of 5·1 years 
(SD 1·4). Both models showed slower EDSS progression than predicted for untreated controls (Markov model, 75·8% 
[95% CI 71·4–80·2]; multilevel model, 60·0% [56·6–63·4]). Utility ratios were consistent with cost-eff ectiveness 
(Markov model, 58·5% [95% CI 54·2–62·8]; multilevel model, 57·1% [53·0–61·2]).
Interpretation Findings from this large observational study of treatment with interferon beta or glatiramer acetate 
provide evidence that their eff ects on disability in patients with relapsing-remitting multiple sclerosis are maintained 
and cost eff ective over 6 years. Similar modelling approaches could be applied to other chronic diseases for which 
long-term controlled trials are not feasible.
Funding Health Departments of England, Wales, Scotland, and Northern Ireland, Biogen Idec, Merck Serono, 
Bayer Schering Pharmaceuticals, Teva Pharmaceuticals Industries, UK National Institute of Health Research’s 
Health Technology Assessment Programme.
 Introduction
Multiple sclerosis presents substantial health economic 
challenges. The disease course extends over decades and 
the bulk of direct and indirect health costs related to 
disability are not apparent until many years after 
diagnosis. The 1990s saw the fi rst wave of published 
randomised controlled trials1–4 of disease-modifying 
therapies (DMTs) in relapsing-remitting multiple 
sclerosis, with the subsequent use in clinical practice of 
interferon beta-1b (Betaferon or Betaseron, Bayer Schering 
Pharmaceuticals, Berlin, Germany), two formulations of 
interferon beta-1a (Avonex, Biogen Idec, Cambridge, MA, 
USA; and Rebif, Merck Serono, Darmstadt, Germany), 
and glatiramer acetate (Copaxone, Teva Pharmaceuticals 
Industries, Petah Tikva, Israel) for relapsing-remitting 
multiple sclerosis. Betaferon and Rebif were also later 
licensed for the treatment of relapsing secondary 
progressive multiple sclerosis.5–7 Findings from the 
randomised controlled trials in relapsing-remitting 
multiple sclerosis showed a robust eff ect of all these 
drugs in reduction of relapse rates (about 30%) and MRI 
brain lesion activity. However, the eff ects on acquisition 
of disability were less certain, which has led to extensive 
debate8–10 about whether the disability eff ects reported in 
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randomised controlled trials are sustained or simply 
relapse related, and thus whether these short-term eff ects 
can be reasonably extrapolated over much longer periods.
These DMTs were appraised by the UK National 
Institute for Clinical Excellence (NICE; now known as 
the National Institute for Health and Care Excellence),11 
which concluded in 2002 that these drugs could not be 
classifi ed as cost-eff ective unless the estimated eff ects on 
disability reported in the short term persisted at much 
the same magnitude over a period of at least 20 years. In 
February, 2002, the UK’s Risk Sharing Scheme (RSS) for 
multiple sclerosis DMTs was launched,12 representing a 
managed-entry agreement between the UK health 
departments and the manu facturers, with the MS Trust 
as the data custodian. Drug costs were reduced when 
necessary to achieve a cost-eff ectiveness of £36 000 (at 
current exchange rates roughly €50 000 or US$54 000) 
per quality-adjusted life-year (QALY) projected over 
20 years. Projections were made with a discrete Markov 
model originally developed for NICE’s appraisal,13 using 
natural history data from London, ON, Canada, and 
hazard ratios (HRs) for attenuated disability progression 
derived from the individual randomised controlled trials 
of each drug. Actual disability progression was monitored 
in a cohort of 5600 patients, with the intention of making 
price adjustments to maintain cost-eff ectiveness should 
their progress diff er substantially from the pro jections. 
The fi rst interim analysis at 2 years14 highlighted 
various methodological issues and provided ambiguous 
evidence, making interpretation diffi  cult.
On the basis of lessons from the 2 year analysis, we 
identifi ed a more suitable natural history cohort and 
adopted a more fl exible continuous Markov model.15 
Additionally, we ran a parallel analysis using multilevel 
models. Here, we present RSS results for disability 
progression and cost-eff ectiveness at 6 years, to test two 
hypotheses: that patients on DMTs would have slower 
disability progression than untreated controls modelled 
from a natural history dataset; and that the treatment 
eff ect would be consistent with that predicted from the 
shorter-term trials so that the drugs remain cost eff ective 
when projected over 20 years according to NICE criteria.
 Methods
Study design and participants
We included patients enrolled in the UK RSS in our 
clinical cohort. Patients had to fulfi l the Association of 
British Neurologists (ABN) 2001 guidelines12 for 
prescribing multiple sclerosis drugs: for relapsing-
remitting multiple sclerosis (all drugs), age 18 years or older, 
two clinically signifi cant relapses in the previous 2 years, 
and Expanded Disability Status Scale (EDSS) score 
5·5 or lower; and for secondary progressive multiple 
sclerosis (interferon beta only), ambulant and with relapses 
as the main driver of advancing disability. In consultation 
with their physicians, patients could commence one of 
three formulations of interferon beta or glatiramer acetate. 
Patients were not randomly assigned, and the use of 
individual drugs represents patient and physician 
preferences at the time of prescribing. Patients were 
scheduled for annual review and assessment of EDSS 
score (except when the patient was in relapse),16 irrespective 
of whether they stopped or switched treatment.14 
We excluded patients with secondary progressive multiple 
sclerosis at baseline for the primary analyses, but we did 
not censor patients if they progressed to secondary progres-
 Research in context
Evidence before this study
The effi  cacy of the fi rst-line disease-modifying therapies 
(DMTs) for multiple sclerosis—interferon beta and glatiramer 
acetate—has been demonstrated in short-term randomised 
controlled trials from 1993, although these benefi ts were not 
shown to be cost eff ective. Whether these DMTs have longer-
term benefi ts for disability remains unclear in the absence of 
long-term randomised controlled trials. Several postmarketing 
studies have been done to assess the longer-term eff ectiveness 
of interferon beta or glatiramer acetate, with mixed fi ndings. 
Methodological concerns have been raised about immortal 
time bias and the most appropriate control group; one study 
had diff ering results when it used a historical instead of 
contemporary comparison population. Up to 2014, no large-
scale long-term prospective clinical cohort study with regular 
assessments has compared the rate of disability progression in 
a treated cohort of patients with that predicted from a 
natural-history untreated comparator with the aim of 
measuring eff ectiveness and cost-eff ectiveness of these 
treatments in multiple sclerosis over the long term.
Added value of this study
This study’s fi ndings show that interferon beta and glatiramer 
acetate result in a 24–40% reduction in disability progression in 
relapsing-remitting multiple sclerosis and are cost eff ective 
(using UK prices and a target of £36 000 per quality-adjusted 
life-year) over a 6 year follow-up period when modelled over a 
20 year trajectory.
Implications of all the available evidence
Our fi ndings suggest that these drugs represent value for 
money for the treatment of relapsing-remitting multiple 
sclerosis, and support the continued commissioning of these 
DMTs by health-care providers, albeit on the basis of 
observational data. The results are also useful in providing an 
evidence base to assess new DMTs by weighing their additional 
benefi ts and costs relative to these fi rst-generation treatments. 
The fi nal 10 year analysis will confi rm whether these benefi ts 
are maintained. Our approach could be applicable to therapies 
for other chronic diseases for which long-term randomised 
controlled trials are unavailable or not deemed suitable.
For the MS Trust see 
http://www.mstrust.org.uk
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sive multiple sclerosis because we wanted to capture 
information about long-term disability progression.
We used the British Columbia multiple sclerosis 
database (BCMS)17,18 as our control cohort. Established in 
the 1980s as a population-based database capturing about 
80% of the multiple sclerosis population in British 
Columbia, Canada,18 EDSS scores are recorded after a 
face-to-face consultation with a multiple sclerosis 
neurologist, with the same four core neurologists 
examining more than 85% of the patients during the 
period of our study. We used the same eligibility criteria 
as for the RSS to identify a subset of patients from the 
BCMS for the natural history cohort
All patient data for the BCMS were censored at the end 
of 1995 (after which DMTs became generally available in 
British Columbia) irrespective of whether patients 
commenced treatment, thereby avoiding confounding by 
indication. In our previously reported 2 year analysis we 
used the London, Ontario, dataset.14 The main reasons 
for changing to the BCMS dataset were that it contained 
complete, con temporaneously recorded longitudinal 
EDSS scores (unlike the London, Ontario, dataset in 
which observations were retrospectively smoothed to 
ensure that EDSS values could only remain the same or 
increase), was a larger cohort (thus reducing sampling 
variability), covered a more recent time period (so would 
be less confounded by any potential secular changes), 
and allowed us direct access to the data to enable RSS 
analysts to validate diff erent models.15
Ethical approval for the RSS was given by the South 
East Medical Research Ethics Committee (MREC 
2/01/78) and all patients gave written consent. BCMS 
patients gave consent to be enrolled in the BCMS database 
and the University of British Columbia’s Clinical 
Research Ethics Board approved the study. 
 Outcomes
Our primary outcome was accumulation of disability, 
measured both as EDSS progression and as loss of utility. 
Utility is a measure of society’s perception of the quality of 
life of a patient in a given state of health. A utility of 1 
represents perfect health; a utility of 0·5 implies that on 
average people would regard 12 months of life in that 
health state as equally preferable to 6 months of life in 
perfect health. We derived this measure from EDSS scores 
using previous data that reported EQ5D scores for diff erent 
EDSS states (appendix; Nicola Russell, MS Trust, personal 
communication).19 The EDSS progression ratio is the ratio 
of observed change in mean EDSS from baseline to the 
change predicted by the natural history model. We used 
this ratio to assess whether treatment had any eff ect on the 
rate of EDSS progression. A ratio of less than 100% means 
that EDSS progression on therapy is better than expected 
progression without therapy. Similarly we defi ned the 
utility progression ratio as the ratio of observed change in 
mean patient utility to the change predicted by the natural 
history model. We used this ratio to test whether the eff ect 
of the DMTs on utility progression was in line with that 
expected on the basis of fi ndings from short-term 
randomised controlled trials; a utility progression ratio of 
62% or lower means that utility progression for the drugs 
in aggregate is in line with, or slower than, the NICE 
target. The utility progression ratio can also be converted 
into a deviation score, which measures the diff erence 
between the required cost-eff ective benefi t from treatment 
(derived from the randomised controlled trial HRs) and 
the observed benefi t. Additionally, we compared the mean 
diff erences in EDSS with and without treatment at year 2 to 
compare our results with the fi ndings from the shorter-
term trials.
 Statistical analysis
We used two independent modelling approaches (a 
continuous-time Markov model and a multilevel model) 
each to calculate expected disease progression, both on 
and off  treatment, using data for both years 4 and 6; this 
report focuses on the year 6 results because of their 
longer follow-up period. Additional technical details are 
available in the appendix and have been previously 
reported.15
Markov modelling uses a set of transition probabilities 
(of moving between disease states, derived from the 
natural history data) which are applied to the RSS 
baseline EDSS distribution to predict mean EDSS and 
utility at year 6. Confi dence intervals are derived by 
bootstrapping. We developed a continuous-time Markov 
model20 from the BCMS data in place of the discrete 
Markov model used for the 2 year analysis, meaning that 
out-of-window EDSS assessments could be included. To 
permit a workable model, we rounded EDSS levels down 
to the nearest integer (eg, EDSS levels of 5 and 5·5 were 
grouped as a single state). We tested a set of candidate 
covariates in the development phase using the BCMS 
data alone. Age at onset, dichotomised at the median, 
resulted in the most parsimonious model. Internal 
validation within the BCMS was better than that with the 
original discrete Markov model.15
We derived a multilevel model from the BCMS cohort, 
treating EDSS as a continuous variable, allowing for 
variability between and within patients. The parameters 
of this multilevel model were then applied to the RSS 
baseline EDSS distribution to predict EDSS at year 6 for 
each individual. For the primary analysis with the 
multilevel model, we predicted the exact (half-integral) 
EDSS score for each patient, although for comparison 
with the Markov model we also present results after 
rounding down to the nearest integer EDSS. For 
consistency with the Markov model, we included binary 
age at onset as a covariate. Validation of the model was 
undertaken on the BCMS cohort (internal validation) and 
also with use of a natural history dataset from the 
University Hospital of Wales, UK (external validation).21
We used bootstrapping from the RSS cohort (with 
replacement) to derive 95% CIs. To allow for the 
See Online for appendix
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uncertainty in the BCMS model parameters, we sampled 
from the parameter distribution of our natural history 
model 500 times, predicted EDSS at 6 years for each 
individual, and used bootstrapping to estimate the 
variance of the predicted EDSS on and off  treatment. The 
mean and variance of these 500 predictions were then 
combined with use of Rubin’s rules.22
We used all EDSS points from patients who were on a 
scheme drug or who had ceased treatment during the 
study for the primary analysis. In modelling the group’s 
predicted progression on treatment, the HR for drug 
eff ect was applied only to the time an individual was on 
the active therapy, and we assumed that patients would 
revert to the natural history progression rate after all 
treatment had been discontinued. If a patient switched to 
a non-scheme drug, they were censored at that point.
We used a wide range of prespecifi ed supplementary 
analyses (appendix) to assess the sensitivity of con-
clusions to assumptions about stopping therapy, loss to 
follow-up, and inclusion of patients with secondary 
progressive multiple sclerosis at baseline. We did 
similar analyses using data to year 4 to identify any 
evidence of a trend. We undertook the equivalent of an 
intention-to-treat analysis, as might be done in a 
randomised controlled trial, in which we assumed that 
all patients continued on treatment throughout the 
6 years of follow-up. Finally, we assessed whether the 
results were sensitive to the choice of natural history 
comparator by comparing EDSS progression with the 
transition matrices derived from the London, Ontario, 
and BCMS datasets.
Role of the funding source
The administration costs of the RSS are split equally 
among the funding parties (the Health Departments for 
England, Wales, Scotland, and Northern Ireland and the 
four manufacturers of the DMTs [Biogen Idec, Merck 
Serono, Bayer Schering Pharmaceuticals, and Teva 
Pharmaceuticals Industries]). The pharmaceutical 
representatives were observers at the independent 
scientifi c advisory group meetings and had no role in the 
study design, in collection, analysis, or interpretation of 
data, or in writing of the report. The statistical analysis 
plan was developed by the scientifi c advisory group and 
the analyses were undertaken by authors who had access 
to patient-level data (BCMS data, FZ, HT; RSS data, TB, 
ML, BP, KT, and CD). All members of the scientifi c 
advisory group and the other authors of this paper had 
access to all the results and were free to request further 
analyses. The corresponding author had fi nal 
responsibility for the decision to submit for publication.
Results
Between Jan 14, 2002, and July 13, 2005, 5610 patients 
from 72 UK sites were enrolled into the RSS, most of 
whom were initiated onto DMTs (about 80% of all 
patients starting DMTs in the UK in this period).14 Of 
5610 patients identified
4304 patients with RRMS 
eligible and treated 
at baseline
4137 patients with valid 
EDSS data at least 
for year 1 or later 
after baseline
3533 had valid data for
year 4
2639 had valid data for 
year 6
819 not RRMS (770 SPMS, 49 unknown)
220 ineligible
2 did not meet ABN criteria
5 younger than 18 years
106 already on treatment
7 entered after close of 
recruitment
100 for other reasons*
246 eligible but not treated
5 had no baseline EDSS
16 with age at symptom onset unknown
100 missing EDSS after baseline
8 emigrated
83 had no year 1 or follow-up EDSS
4 lost to follow-up or withdrew 
from study
5 had non-multiple-sclerosis death
67 had no valid EDSS after baseline 
(switch to non-RSS DMT before year 1 
or before first available EDSS 
assessment)






Men 232 (26%) 1071 (25%) 1013 (24%)
Women 666 (74%) 3233 (75%) 3124 (76%)
Age at onset (years)
Mean 29·2 (8·7) 30·5 (8·4) 30·5 (8·4)
Median 28 (23–35) 30 (24–36) 30 (24–36)
EDSS at baseline
Mean 2·44 (1·70) 3·08 (1·52) 3·06 (1·52)
Median† 2 (1–3·5) 3 (2–4) 3 (2–4)
Time since symptom onset (years)
Mean 7·9 (6·9) 7·7 (6·6) 7·7 (6·6)
Median 5·9 (2·5–11·5) 5·7 (2·6–11·0) 5·7 (2·6–11·1)
Number of confi rmed relapses in past 2 years
Mean 2·9 (1·2) 3·0 (1·3) 3·0 (1·3)
Median 2 (2–3) 3 (2–3) 3 (2–3)
Data are n (%), mean (SD), or median (IQR). BCMS=British Columbia multiple sclerosis database. RSS=Risk Sharing 
Scheme. *All eligible and treated patients with relapsing-remitting multiple sclerosis at baseline. †EDSS scores as 
half-integers.
Table 1: Baseline characteristics of patients in the British Columbia multiple sclerosis database and Risk 
Sharing Scheme cohorts
Figure: Study profi le for the UK Risk Sharing Scheme
Data was taken from the year 8 locked dataset; follow-up data after year 6 were 
used only in secondary analyses to impute missing year 6 values. RSS=Risk 
Sharing Scheme. RRMS=relapsing-remitting multiple sclerosis. SPMS=secondary 
progressive multiple sclerosis. EDSS=Expanded Disability Status Scale. 
DMT=disease-modifying therapy. ABN=Association of British Neurologists. 
*Other eligibility criteria not met or “not eligible” ticked on withdrawal form.
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these individuals, 4304 were eligible, treated patients 
with relapsing-remitting multiple sclerosis (fi gure); 167 
had no subsequent valid EDSS follow-up data, leaving 
4137 patients for the primary analysis. 2639 patients 
had valid data collected at the year 6 visit (64%) and a 
further 894 patients had valid data for year 4 or year 5 
(3533 [85%] had data for at least 4 years). The mean 
follow-up was 5·1 years (SD 1·4) and median follow-up 
was 6 years (IQR 5–6), equivalent to 21 260 person-years 
at risk. Additionally, 582 patients with missing year 6 
data had data at year 7 or year 8 available at the time of 
analysis for use in imputation, thereby reducing the 
eff ect of participants missing at year 6 (appendix). 
978 patients in the BCMS cohort met the inclusion 
criteria of our study, of whom 898 had at least one 
EDSS score after baseline; BCMS patients had a mean 
follow-up of 6·4 years (SD 3·5).
Table 1 compares the baseline characteristics of the 
BCMS and RSS cohorts. The sex distribution, time since 
symptom onset, and number of relapses in the 2 years 
before entry in the BCMS cohort were similar to those in 
the RSS cohort. Participants in the RSS cohort were older 
at symptom onset and had a higher EDSS at baseline. 
The modelling approaches were designed to adjust for 
these diff erences.
Table 2 shows the main outcomes for year 6. For both 
outcomes and with use of both methods, patients in the 
RSS progressed more slowly than predicted from natural 
history models, because all ratios were less than 100%. 
The Markov model resulted in a 75·8% EDSS progression 
ratio (95% CI 71·4–80·2) and the multilevel model 
resulted in a 60·0% ratio (95% CI 56·6–63·4), equivalent 
to a 24·2% and 40·0% relative reduction in EDSS 
progression, respectively. Adding in the additional 
uncertainty for the BCMS parameters resulted in slightly 
wider 95% CIs (53·8–67·5) for the multilevel model. For 
cost-eff ective ness we noted that the central estimate of 
the utility progression ratio was better than the expected 
62% target (Markov 58·5%, 95% CI 54·2–62·8; multilevel 
model 57·1%, 95% CI 53·0–61·2). In absolute terms, 
patients in the RSS had a mean EDSS score that was 0·28 
(95% CI 0·23–0·34; Markov model) or 0·59 (95% CI 
0·54–0·64; multilevel model) units less than would have 
been predicted off  therapy. 
Table 3 shows the most important supplementary 
analyses; a wider range of results are available in the 
appendix. Generally, use of intention-to-treat and 
imputation analyses made little diff erence, except when 
we assumed a missing-not-at-random pattern and added 
0·5 of an EDSS point on top of the imputation prediction, 
resulting in weaker evidence of benefi t. Similarly, 
inclusion of patients with secondary progressive multiple 
sclerosis at baseline also decreased the treatment eff ect, 
although in all analyses the observed progression 
remained slower than the natural history predictions. 
The appendix shows characteristics of patients in the 
BCMS cohort according to the relative frequency of 
EDSS scores available and length of follow-up. In both 
the RSS and BCMS, patients with a worse prognosis 























Diff erence (actual absolute 





Markov 0.057 (0·053 to 
0·061)
0·098 (0·097 to 
0·099)
0·061 (0·060 to 
0·062)
0·041 (0·037 to 
0·045)
0·037 (0·037 to 0·038) 58·5% (54·2 to 
62·8)
0·004 (0·000 to 0·008) –10% (–21 to 1)
MLM 0·057 (0·053 to 
0·061)
0·100 (0·098 to 
0·103)
0·063 (0·061 to 
0·064)
0·043 (0·039 to 
0·047)
0·038 (0·036 to 0·040) 57·1% (53·0 to 
61·2)
0·005 (0·001 to 0·009) –14% (–25 to –2)
Rounded EDSS†
Markov 0·888 (0·836 to 
0·940)
1·172 (1·157 to 
1·188)
0·762 (0·748 to 
0·776)
0·284 (0·232 to 
0·336)
0·410 (0·405 to 0·415) 75·8% (71·4 to 
80·2)
–0·126 (–0·178 to –0·075) 31% (18 to 43)
MLM 0·888 (0·837 to 
0·940)
1·448 (1·430 to 
1·466)
0·861 (0·846 to 
0·875)
0·560 (0·507 to 
0·613)
0·588 (0·573 to 0·603) 61·3% (58·0 to 
64·7)
–0·028 (–0·079 to 0·024) 5% (–3 to 12)
EDSS
MLM 0·881 (0·830 to 
0·932)
1·468 (1·454 to 
1·482)
0·894 (0·883 to 
0·906)
0·587 (0·535 to 
0·639)
0·573 (0·565 to 0·582) 60·0% (56·6 to 
63·4)
0·013 (–0·038 to 0·064) –2% (–10 to 5)
Data for the primary analysis cohort (n=4137), with a mean follow-up of 5·1 years (SD 1·4). Utility is a ratio varying from 0 to 1; EDSS is an ordinal scale varying from 0 to 10. BCMS=British Columbia multiple 
sclerosis database. RSS=Risk Sharing Scheme. EDSS=Expanded Disability Status Scale. MLM=multilevel model. *Deviation measure refers to actual treatment eff ect minus predicted treatment eff ect, divided by 
predicted treatment eff ect. †For the Markov model, half-integer EDSS states are combined with the next lower integer EDSS state. For the MLM, predicted EDSS values are rounded to the nearest point on the 
EDSS scale and then rounded down to the next lower integer EDSS value.
Table 2: Accumulation of disability from the primary analysis
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of follow-up (appendix), suggesting that the less frequent 
availability of EDSS scores for these patients might not 
bias the relative comparison. By contrast, we did note 
diff erences in the quantity of data available at shorter 
periods of follow-up; in the BCMS dataset (but not in the 
RSS), patients with more severe disease tended to 
contribute more frequent data than did those with less 
severe disease. This fi nding could infl ate the apparent 
treatment eff ect, but our calculations suggested that any 
such eff ect was small (appendix). 
The results based on the year 4 data (appendix) showed 
slightly more benefi t of treatment than did the year 6 
analyses. At 2 years of follow-up we noted an absolute 
mean reduction of 0·22 units (95% CI 0·19–0·25) in 
EDSS change in the RSS by comparison with the natural 
history prediction. This estimate could be biased toward 
overly positive results because 574 (14%) of 4030 patients 
with data for years 1 or 2 lacked year 2 data and patients 
with missing data might be more likely to have worse 
EDSS scores.
Finally, when we applied transition probabilities from 
both the BCMS and the London, Ontario, datasets to the 
baseline EDSS distribution from the RSS, we predicted 
slightly more rapid progression over 10 years using the 
data from London, Ontario (appendix), suggesting that 
the switch in databases reduced the estimated treatment 
eff ect.
 Discussion
We believe our results provide the best available 
observational data about whether DMTs change the natural 
history of multiple sclerosis and are cost eff ective, at least 
within the setting of the UK RSS for multiple sclerosis. 
The RSS provides the fi rst example of a managed-entry 
agreement that incorporates long-term monitoring of out-
comes to allow analysis of cost-eff ectiveness. Patients with 
active relapsing-remitting multiple sclerosis meeting the 
2001 ABN prescribing guidelines, treated with either 
interferon beta or glatiramer acetate, seemed to progress 
more slowly over the fi rst 6 years of therapy than would be 
predicted from a natural history cohort. If this benefi t 
were sustained over 20 years, it would meet a cost-
eff ectiveness target of £36 000 per QALY, although 
cost-eff ectiveness would not necessarily be achieved for 
countries where drug costs are substantially higher.23 We 
cannot comment on the benefi ts of specifi c DMTs, because 
our analyses included DMTs only in aggregate.
The prespecifi ed primary analyses showed similar 
results across two independent analytical approaches. 
Generally, the multilevel model showed that the observed 
progression was consistent with the predicted treatment 
eff ect for utility and EDSS progression. The Markov model 
showed slightly worse progression than did the multilevel 
model, and the 95% CIs for the utility measure just 
overlapped the target for cost-eff ectiveness, although 
actual EDSS progression was still better (24·2%) than 
predicted from natural history. This fi nding might result 
from diff erences in how the models dealt with 
measurement error, and the slower progression under the 
natural history model predicted by the Markov model than 
predicted by the multilevel model. The greater similarity 
between the two models for utility than for EDSS probably 
results from the fact that diff erent EDSS scores can have 






Absolute treatment eff ect (EDSS) Deviation scores (utility)
Markov model Multilevel model Markov model Multilevel model
Mean 95% CI Mean 95% CI
Primary analysis 4137 5·1 (1·4) 0·284 0·587 0·535 to 0·639 –10% –14% –25 to –2
Intention-to-treat analysis* 4137 5·4 (1·2) 0·273 0·590 0·537 to 0·642 ·· ·· ··
Imputation—Markov model
Last value carried forward 4209 6·0 (0·2) 0·378 ·· ·· –32% ·· ··
Linear interpolation-
extrapolation
4209 6·0 (0·3) 0·226 ·· ·· 34% ·· ··
Imputation—multilevel model†
Single imputation 4137 6·0 (0·2) ·· 0·644 0·593 to 0·694 ·· –7% –17 to 4
Multiple imputation 4137 6·0 (0·2) ·· 0·643 0·590 to 0·697 ·· –2% –13 to 10
Single imputation plus 0·5 
EDSS (points for each imputed 
value)
4137 6·0 (0·2) ·· 0·464 0·411 to 0·516 ·· 38% 26 to 49
Including patients with SPMS at 
baseline
4780 5·1 (1·5) 0·173 0·521 0·473 to 0·568 3% 11% 2 to 20
EDSS=Expanded Disability Status Scale. SPMS=secondary progressive multiple sclerosis. *Because the intention-to-treat analysis is essentially a comparison of actual disease 
progression with predicted progression off  treatment (rather than predicted progression on treatment), the deviation measure cannot meaningfully be calculated for these 
variants. †In this analysis we assumed that patients went off  treatment when they were lost to follow-up.
Table 3: Sensitivity analyses
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An extensive range of supplementary analyses showed 
consistently positive, although variable, treatment eff ects, 
including when missing data were imputed under various 
assumptions. The addition of patients with relapsing 
secondary progressive multiple sclerosis at baseline 
weakened the observed benefi t. We did not examine 
conversion of relapsing-remitting multiple sclerosis to 
secondary progressive multiple sclerosis as an outcome, 
because clinicians in the RSS tended to delay the diagnosis 
of secondary progressive multiple sclerosis (because it 
could result in treatment withdrawal) whereas clinicians 
in British Columbia would not have (because treatment 
was not available). This diff erence would have exaggerated 
the treatment eff ect.
Findings from our 2 year analysis14 showed that the 
outcome was extremely sensitive to the use of a no-
improvement smoothing rule to the RSS dataset so that 
it could be compared with the London, Ontario, dataset. 
The use of the BCMS database removed the need for 
smoothing rules to be applied to the RSS dataset. 
Modelling the two sets of transition probabilities to the 
baseline EDSS of the RSS cohort over 10 years produced 
similar mean EDSS trajectories.
We cannot directly compare our models with the 
published randomised controlled trials, partly because 
of diff erences in measured outcomes (eg, many trials 
used point increases in the EDSS confi rmed at 3 or 
6 months). Reassuringly, however, the diff erence in the 
mean EDSS change after 2 years between the treated 
RSS patients and predicted pr ogression off  treatment 
was 0·22, consistent with a mean EDSS diff erence of 
0·25 (95% CI 0·05–0·46) reported in a meta-analysis of 
studies of interferon beta in relapsing-remitting 
multiple sclerosis.8
Several post-marketing studies have been done, aimed 
at assessment of the longer-term eff ectiveness of 
beta interferon or glatiramer acetate, with mixed 
fi ndings.24–28 Positive treatment eff ects were reported by 
investigators of an Italian study,26 but a reanalysis29 
suggested that the benefi t could have been due to 
immortal time bias. Immortal time bias arises because 
patients treated with a drug start their follow-up at fi rst 
exposure, whereas those not treated start their follow-up 
earlier, when entering the study; because outcomes 
(eg, disability milestones) cannot occur in this gap for 
the treated individuals, they experience immortal time.29 
A previous analysis of the BCMS database used historical 
and contemporary control groups to determine the 
association between DMT exposure and disability 
progressions,27,28 with use of time to EDSS 6 as the 
outcome. The HR when comparing their contemporary 
treated patients with a historical control group (0·77, 
95% CI 0·58–1·02) was consistent with our results; we 
noted the EDSS progression ratio for most of our 
analyses to be about 70%. However, the results calculated 
with use of a contemporary control group did not show 
evidence of any benefi t for DMTs, which the investigators 
attributed to possible residual indication bias despite 
using sophisticated analytical methods.27,28
Our results, like those from other studies, suggest that 
these treatments only slow down and do not completely 
halt the progress of disability. However, our fi ndings 
would support the notion that treatment of the infl am-
matory processes of multiple sclerosis in the relapsing-
remitting stage leads to a downstream eff ect on 
neurodegeneration and reduced long-term disability.
Do these results represent a treatment eff ect? There are 
several potential non-causal explanations. First are 
 geographical diff erences. We would have noted an 
apparent treatment eff ect if the natural history of 
Canadian patients with multiple sclerosis were more 
aggressive than that of our UK patients. Although British 
Columbia has an ethnically diverse population, most 
patients were of European ancestry during the study 
period.30 We validated the BCMS multilevel model in an 
independent cohort of untreated patients and found that 
the model fi tted the Welsh data well (appendix).
Second are temporal diff erences. The BCMS data come 
from an earlier period than the RSS, and relapse rates in 
the placebo groups of clinical trials in multiple sclerosis 
have been reducing since the 1980s,31 suggesting that the 
natural history of multiple sclerosis might be improving. 
However, recent randomised controlled trials might be 
enrolling milder cases of multiple sclerosis as patients 
with more severe disease are treated in clinical practice 
with available drugs (and could be unwilling to receive a 
placebo). There have been other changes such as the use 
of early rescue protocols and stricter defi nitions for 
relapses.31 Population-based cohorts are less likely to be 
biased by selection and neither the BCMS dataset32 nor 
recent data from south Wales (Robertson NP, 
unpublished) have shown evidence for milder prognosis 
in more recent cohorts.
The third explanation is confounding by indication. A 
well recognised problem in pharmacoepidemiology, 
variables such as disease severity and comorbidity 
confound treatment decisions and clinical outcomes. 
This issue did not arise in our analysis because all the 
BCMS patients were untreated and the sample was 
selected on the basis of explicit inclusion criteria that 
applied to both cohorts. Both models took account of 
diff erences in the baseline EDSS distribution and age at 
entry; other covariates added little to the prediction of 
progression (appendix).15
 The fourth non-causal explanation is selection bias. 
The RSS cohort probably would have excluded some 
patients with rapid disease progression who would have 
been eligible for treatment according to the ABN criteria 
in the past but were no longer eligible in 2002. This bias 
would favour a treatment eff ect. Working in the opposite 
direction, patients with mild disease who were no longer 
actively relapsing at the time of recruitment would have 
been excluded. Similarly, the presence of prevalent as 
well as incident ABN-eligible patients would have led to 
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patients with later disease being treated, and DMTs 
might be less eff ective later on in the disease course. 
Reassuringly, time from symptom onset to cohort entry 
was almost identical for both datasets (table 1).
The fi fth potential explanation is loss-to-follow-up bias. 
The pattern of loss to follow-up could diff er between the 
cohorts. The available evidence (appendix) suggests that, 
although there are some diff erences as well as some 
similarities in the patterns of follow-up between the two 
datasets, the diff erences are unlikely to account for more 
than a small proportion of the apparent treatment eff ect.
The strengths of our study are the large number of 
patients followed up prospectively with regular EDSS 
assessments, an acceptable follow-up rate, and a high-
quality, historical, natural history comparator. To some 
researchers, no observational study—no matter how 
rigorous—will ever provide as convincing evidence for 
treatment eff ects as a large, well conducted randomised 
controlled trial. However, long-term randomised controlled 
trials are diffi  cult to imple ment after drugs have been 
shown to have short-term benefi ts, and cannot generally 
assess the eff ective ness of treatments in routine clinical 
practice. Careful assess ment of observational data can then 
provide important supportive evidence about long-term 
benefi ts.33,34 NICE allows only direct costs to be incorporated 
into its cost-eff ectiveness analysis, so cost-eff ective ness 
might be even greater if indirect costs such as loss of work 
for the patient or their carers is included.
This is an exciting time in multiple sclerosis therapy, 
with new drugs becoming available. Ensuring the cost-
eff ectiveness of increasingly expensive drugs is becoming 
imperative. Managed-entry and risk-sharing agreements 
between commissioners and manufacturers are in-
creasingly used to deliver value for money of new and 
expensive therapies. The application of prognostic 
models supports the use of this type of scheme for other 
chronic diseases for which long-term trials are not 
thought appropriate. This 6 year analysis supports a 
predicted long-term eff ect of multiple sclerosis DMTs in 
patients with relapsing-onset disease, consistent with 
their UK cost-eff ectiveness at an aggregate level. The 
fi nal 10 year analysis will confi rm whether these benefi ts 
are maintained.
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Appendices to Assessing the long-term effectiveness and cost-effectiveness of 
interferon-beta and glatiramer acetate in the UK multiple sclerosis risk sharing 
scheme at six years: a clinical cohort study with natural history comparator 
 
 
Appendix 1:  Background to the UK MS Risk Sharing Scheme 
 
1.1  The MS disease modifying therapies (DMTs) are licensed for relapsing MS ie for early stage 
disease, whereas the major disability is incurred in the later progressive phase. However none of the 
DMTs have been shown to be effective in reducing progressive disability when instituted during the 
later stages of disease when relapse-free or independent free progressive disability occurs. Thus the 
main debate in extrapolating short-term effects of MS treatments to the longer-term is around whether 
the later progressive disability phase is attributable to downstream events of remote acute inflammation 
(which are affected by DMTs) or to ongoing compartmentalised chronic CNS inflammation and/or 
neurodegeneration (which appear not to be directly affected by interferon beta or glatiramer acetate).  
 
1.2  In order for the DMTs to be cost-effective they must demonstrate that they do more than only 
prevent early relapses in RRMS. They must delay an individual reaching higher levels of disability 
particularly because this is where the major costs are incurred. For example, transient clinical relapses 
have only a modest impact on cost (in the UK , mean £1500/attack). Fixed disability related to MS has 
however a substantial cost, for example in 2001 the NICE model
1
 estimated £5,678/yr for an individual 
with an EDSS of 6 (requiring a stick to walk 100m) and £17,327 at EDSS 7.0. The NICE models have 
only allowed direct costs to be taken into consideration, adding in indirect costs would make these 
values even greater.   
 
1.3  The EDSS used to calculate MS disability is a 20 point scale
2
 (0 and then 1 to 10 in 0.5 steps) 
incorporating clinical signs on examination and observed and reported impairments and disability. 
Population studies have ascribed a utility (quality of life) value to each integral point of the EDSS  
scale
3,4
, where 1 is the maximum and represents a year of normal health,  0.5 would represent the 
general populations view that 2 years at this health state would be worth 1 in full health and 0 is 
equivalent to death. By converting different outcomes into a common measure of benefit ie quality 
adjusted life years (QALYs) it is possible to compare cost-effectiveness of different treatments even 
across different diseases.   
 
1.4  The UK MS risk sharing scheme (RSS)
5
 has two components.  Firstly, the then current UK prices 
for the four main DMTs were reduced, where necessary, in order to achieve a cost effectiveness target 
of £36,000 per QALY, using the model of disability progression developed for NICEs 2001 
technology appraisal and target treatment effects (relative rates of disability progression) derived from 
the pivotal RCTs.  Secondly, the parties to the scheme agreed to track a prospectively observed MS 
cohort on DMTs against the trajectory required to offer cost effectiveness. The plan was to assess the 
data every two years, adjusting the price if necessary after each analysis to maintain the 20 year cost-
effectiveness target should the observed results differ significantly from the required trajectory.   
 
1.5  Considering the practicalities of running such a scheme, the decision was made to follow the 
cohort for the first 10 years of the twenty year model. Over 5,500 patients were enrolled in 2002/2003. 
EDSS scores were collected pragmatically, ie as part of normal clinical practice. Although the EDSS 
was not assessed  under trial standard protocols, it was performed by MS neurologists who were 
experienced in this scoring with the same neurologist being encouraged to continue scoring an 
individual patient throughout if possible.   
 
1.6   Since 2005, the parties to the scheme have been advised by a Scientific Advisory Group (SAG) 
chaired by Professor Richard Lilford. The groups main function is to advise on the analysis plan for 
the interim and final analyses and on the interpretation of the results.  In addition, the group advise the 
MS Trust (as the custodian of the data) on applications from other researchers to access the data on the 
RSS cohort. 
  
1.7  As published previously, the first interim analysis at two years
6
 revealed shortcomings in the 
original modelling and highlighted difficulties in interpretation of the results because the Ontario 
dataset did not record any EDSS improvements due to smoothing of collected data. Applying a no 
improvement rule to the treated RSS patients was felt to  bias against a treatment effect and indeed 
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removing this rule changed the results from a negative treatment effect (disability progression for 
treated patients worse than for untreated patients) to a marked over target effectiveness. This led the 
scientific advisory group to advise that the results were too unreliable to recommend price adjustment 
at the 2 year stage and to produce a new scientific analysis plan agreed by all parties. 
 
1.8  The cost-effective target for the four drugs is presented in aggregate, and this has been calculated 
to be equivalent to a relative rate of disability progression (on treatment versus off treatment, with 
disability measured using the EDSS scale) of 62% (ie at least a 38% treatment effect). This cost-
effectiveness target is set for the utility outcome. Despite the utility score being obtained from the 
EDSS, because these scores have a non-linear relationship the results on these outcomes will not 
always be the same.  The ratios for individual DMTs were agreed between the companies concerned 
and the Department of Health and remain commercially confidential.  
 
 
Appendix 2: Definition of the deviation measure 
 
2.1  According to the fundamental principles of the UK risk sharing scheme (RSS), adjustments to the 
prices paid by the NHS to the companies for DMTs are calculated on the basis of any deviation 
between the actual outcomes for patients in the RSS cohort and the target outcomes predicted on the 
basis of the Markov model.  In assessing these outcomes (benefits of treatment), a comparison is made 
between the disability progression of treated patients and the expected progression of a similar cohort 
of untreated patients, modelled using the same Markov model (a virtual placebo group). 
 
2.2  The basic calculation is set out in paragraphs 19 and 20 of the Health Circular
3
.  The circular refers 
to the deviation as a shortfall, but the term deviation is now preferred since it does not imply an 
expectation that the actual outcomes will be worse than their targets.   
2.3  Denoting the deviation measure at year t by )(tS , this is defined as the difference between actual 














)(tBe  is the expected benefit from treatment in terms of slowing disease progression for the 
cohort, and 
)(tBa  is the corresponding actual benefit. 
 
These quantities are defined further as: 
 ),()()(    ),()()( ** tDtDtBtDtDtB aeaeee  (2) 
where 
 
)(* tDe  is the expected value of disease progression at year t with treatment, 
)(* tDa  is the actual value of the disease progression at year t with treatment, 
)(tDe  is the expected value of the disease progression at year t without treatment. 
2.4  Disease progression can be defined in either utility terms (the primary outcome measure) or in 
terms of EDSS progression (secondary outcome).  In utility terms, disease progression at t years after 
recruitment to the scheme is defined as: 
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i
iii utPtPtD )1))(()(()( 0  (3) 
where 
 
)(tPi  is the proportion of patients in EDSS i at year t (t0: baseline), 
iu  is the utility for patients in EDSS i. 
 
The summation in equation (3) is over all possible EDSS scores from 0 to 10.  To calculate the 




Appendix 3:  Changes to the model after the year 2 analysis 
 
3.1  As noted in Appendix 1, the problems with the year 2 analysis
6
 led the schemes Scientific 
Advisory Group (SAG) to advise that the results should not be used as the basis of price adjustment.  In 
addition, the group advised that the parties to the scheme should seek an alternative natural history 
comparator. 
 
3.2  For the purpose of the RSS the main issue with the London Ontario natural history dataset is that 
the data were retrospectively adjusted to avoid EDSS scores improving from one year to the next.  In 
contrast, one-year improvements in measured EDSS scores in the RSS cohort are very frequent.  It 
therefore becomes very difficult to ensure a like-for-like comparison between the virtual placebo 
group derived from the natural history data, and the treated patients in the RSS cohort.  In the year 2 
analysis, an attempt was made to adjust the RSS data to mimic the no improvement rule in the 
natural history data, but sensitivity analysis showed that the outcomes were highly sensitive to the way 
in which this rule was applied. 
 
3.3  After reviewing a number of alternatives, SAG recommended that the scheme should use the 
British Columbia MS (BCMS) dataset
7
 as the natural history comparator.  This is not only the largest 
dataset of its kind, with a high proportion of patients followed up for 10 or more years, but also 
contains raw (unadjusted) EDSS data showing the same sort of year to year improvements as the 
RSS data. 
 
3.4  The opportunity was taken to make a number of other improvements to the Markov model used for 
the calculations, including modelling disability improvement and allowing the disability trajectory for 




3.5  Given these changes, it is not surprising that the year 4 and year 6 results which we present in this 
paper are so different from the primary analysis in the published year 2 results
6
.  However, one of the 
sensitivity analyses reported at year 2 (involving minimal use of the no improvement algorithm) gave 
very similar results to the ones we present here.  In addition, although we had not planned to repeat the 
year 2 analysis using the new dataset and model, a limited retrospective analysis suggests that had we 
done so the results for year 2 would be fully in line with those for year 4 and year 6. 
 
Appendix 4:   Relation between EDSS and utility 
 
4.1   We examined three possible sources for the relation between EDSS and utility (quality of life): 
two surveys of patients with MS
3,4
, using patient-determined measures of disability (the MS Trust 
and Heron datasets), and an unpublished paper
9
 drawing on the clinician-determined EDSS scores in 
the RSS itself (the Boggild dataset). In each case, patients were asked to completed the EQ5D 
questionnaire, an instrument which categorises the patients perceived state of health according to the 
dimensions of mobility, self-care, ability to take part in usual activities (eg work), pain/discomfort and 
anxiety/depression.  The EQ5D scores can then be converted into utility, an overall measure of 
societys perception of the patients quality of life, using standard tariffs
10
.  A utility of one represents 
perfect health; a utility of 0.5 implies that on average members of the general population would be 
regard 12 months of life in that health state as equally preferable as 6 months of life in perfect health. 
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4.2  On advice from our Scientific Advisory Group, we decided to use a synthesis of the MS Trust and 
Heron datasets for the primary analysis, primarily because they contained more data for the higher 
EDSS scores.  We also carried out a sensitivity analysis using a synthesis of all three datasets.  The 
utility values we adopted are given in the table below: 
 
Utility values used in the year 6 analysis 
 
EDSS Utility (primary analysis) Utility (secondary analysis) 
0 0.9248 0.8722 
1 or 1.5 0.7614 0.7590 
2 or 2.5 0.6741 0.6811 
3 or 3.5 0.5643 0.5731 
4 or 4.5 0.5643 0.5731 
5 or 5.5 0.4906 0.5040 
6 or 6.5 0.4453 0.4576 
7 or 7.5 0.2686 0.2825 
8 or 8.5 0.0076 0.0380 
9 or 9.5 -0.2304 -0.2246 
 
4.3  Details of the three datasets and of the methodology used for their synthesis can be found in a 





Appendix 5:  Further details on the Markov and Multi-Level Models 
 
5.1  The parameters for the two models representing disease progression for untreated patients were 
estimated using a subset of the BCMS dataset selected according to two key criteria: 
a. at some clinic visit before 31 December 1995 they would have met the 2001 criteria of 
the UKs Association of British Neurologists for eligibility for treatment with a DMT; 
b. they had at least one further EDSS measurement before the cut-off date of 31 December 
1995 (or before first treatment with a DMT if this was earlier). 
This left a total of 898 patients for analyses, followed up for a median period of 6.4 years before the 
cut-off date.  The MLM included an additional 80 patients with only one EDSS 
Markov model 
 
5.2  The Markov model defines its states in terms of the patients EDSS score rounded down to the 
nearest integer.  Thus patients at EDSS 0 are allocated to state 1, patients at EDSS 1 or 1.5 are allocated 
to state 2, and so on.  The model assumes a constant probability of making a transition from state i  to 
state j  conditional on the vector of baseline covariates x for the individual patient.  For the purposes 
described in this paper (calculation of the deviation measure and other outcomes) death from non-
MS causes was not explicitly modelled and patients in the RSS who died before the final analysis year 
were treated as lost to follow up. 
5.3   Estimation was by the method of Jackson
12
 and, after assessing a number of possible combinations 




5.4  For treated patients, it is assumed that DMTs affect only the probability of forward transitions 
(transitions to a higher EDSS state) and not the probability of backward transitions (transitions to a 
lower EDSS state).  The instantaneous hazard ratios applied to the forward transition probabilities, 
which are different for each DMT, are related to the target hazard ratios agreed between the UK 
Health Departments and the 4 companies at the outset of the scheme, but have to be adjusted for use in 
a model allowing backward as well as forward transitions.  The basis of this adjustment is described in 
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Repeated measures multi-level model 
 
5.5  We modelled the EDSS scores of individuals with MS using multilevel models
14
.  Our model had 
two levels; observations (level 1) within individuals (level 2). We used a model with a random 
intercept and two random powers of time since ABN eligibility: time and the log of time. We also 
allowed level-1 variation to change linearly with time, to take into account varying measurement error 
in EDSS scores at different levels of disability. Thus the basic model is of the form: 




where yij is the EDSS for individual i at occasion j and t ij is the time since ABN eligibility (plus one 
year) for individual i at occasion j.  
5.6  We then included the binary covariate of age at onset of MS (as in the Markov model), allowing 
this to be associated with intercept, time and log of time. We assessed the Normality of the residuals, 
and the fit of the model by comparing the actual and predicted EDSS values.  All analyses were carried 
out using Stata software
15
, and all multilevel models estimated using the runmlwin command
16
. We 
then used the coefficients from the BCMS model to predict the EDSS value for all patients in the RSS 
cohort, conditional on their first observed EDSS
17
. We assumed that the hazard ratio multiplied the 
BCMS rate of progression to give the on-treatment rate of EDSS progression. 
5.7  We used the random effects matrices from the BCMS model to estimate the natural history 
EDSS for those in the RSS cohort (at every time at which they had an observed EDSS), conditional on 
their observed baseline EDSS. The same approach was used to calculate the treated EDSS for those 
in the RSS cohort (by multiplying the progression by the hazard ratio). When calculating the observed, 
natural history and treated progression, we used the observed EDSS as the comparator, for consistency 
with the Markov analysis. We assessed the sensitivity of our analysis to this assumption by also using 
the estimated EDSS as baseline as the comparator. This did not change the deviation scores (as the 
choice of comparator cancels out in the numerator and the denominator), but led to a slightly higher 
actual progression (1.003), natural history progression (1.589) and treated progression (1.016). The 
estimated relative rate of disease progression was 63.1% (95% CI 56.6% to 63.4%).  
 
 
Appendix 6:  Descriptive analyses of possible sources of bias in RSS dataset 
 
6.1  We carried out a number of descriptive analyses of the RSS dataset in order to identify possible 
factors which might result in bias. No obvious differences were noted in the baseline characteristics 
and follow up outcomes of those patients who registered but were not eligible for the RSS analysis 
versus those that were included in the analysis, and the baseline characteristics were similar between 
those who had no EDSS data after baseline compared to those with. No apparent differences were seen 
in the outcomes from centres with the most complete available data versus those centres with the most 
missing data.   
6.2  In two instances, where this preliminary work suggested that there might be a significant source of 
bias, appropriate sensitivity analyses were added to the pre-specified list.  These related to (a) patients 
who did not start treatment within the 3 months of baseline specified in the Statistical Analysis Plan, 
who might be expected to have worse outcomes as a result of the delay in starting treatment; (b) 
patients who switched to a DMT not part of the scheme, who tend to have worse prognostic factors at 
baseline and worse outcomes than those in the primary analysis population (as expected, since these are 
generally treatments for more aggressive MS).   
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Appendix 7:   Potential bias due to differential patterns of data collection between the BCMS and 
RSS datasets 
 
7.1  We paid considerable attention to the possibility of bias resulting from different patterns of data 
collection in the RSS cohort as compared to the BCMS dataset used to estimate the parameters for the 
Markov and multi-level models. 
7.2   In the RSS cohort, we have observed a tendency for patients with worse disease progression to fail 
to attend at subsequent annual reviews, probably because there is little incentive for a patient to attend 
a review if they have already decided to discontinue DMT treatment.  This tendency was already 
noticeable in the year 2 analysis
6
 and was confirmed by the descriptive analyses carried out as part of 
this year 6 analysis.  We have attempted to quantify the potential impact of this differential loss to 
follow up through the various imputation methods described in the main paper. 
7.3   The BCMS dataset was not collected as part of a specific observational study but through routine 
clinic visits.  During the period in which the data used in this study was collected (1980-1995) effective 
disease modifying treatments were not available.  Patterns of data collection could therefore be 
different from those in the RSS. 
7.4   Web table 4 shows the results of a descriptive analysis of data from the BCMS dataset.   It 
compares baseline parameters and mean EDSS progression over the first 5 years from baseline for two 
pairs of subsets of the total cohort: 
a. patients contributing relatively frequent vs relatively infrequent data, where frequency 
was defined as the number of EDSS scores divided by the interval between first and last 
scores; 
b. patients who had a recorded EDSS score either after or within 18 months of the cut-off 
date of 31 December 1995, vs patients without such a score (who could therefore be 
regarded as lost to follow-up). 
7.5   The first comparison shows that patients with relatively frequent EDSS scores tended to have 
worse prognostic factors at baseline and worse disease progression in the first five years.  (British 
Columbia clinicians have confirmed that, in their experience, patients in the province were more likely 
to attend clinic if they had concerns over the progress of their disease.) Since the patients with faster 
disease progression are contributing more EDSS scores to the estimation process, there is at least a 
theoretical possibility that they could bias the estimates in the Markov model towards predicting higher 
rates of disease progression for untreated patients, and thus inflate the apparent treatment effect when 
compared with the actual rates of disease progression in the treated RSS cohort.  (In the MLM, this bias 
may not be operating if the data are missing at random, ie if the probability of data being missing 
depends only on parameters explicitly included in the model.) 
7.6  In contrast, the second comparison suggests that patients with relatively fast disease progression 
are more likely to be lost to follow-up, as they are in the RSS cohort, and will thus contribute less 
data at longer periods from baseline.  This would be expected to bias the estimates towards predicting 
lower rates of disease progression and would tend to offset any bias resulting from the similar 
differential loss to follow-up in the RSS dataset. 
7.7  To help quantify the possible impact of the first factor, we used the MLM to impute additional 
EDSS scores for any patients in the BCMS dataset with a gap of more than 2 years between successive 
values (this used an identical BCMS dataset as used for the continuous Markov model). This would be 
expected to increase the weighting for patients with relatively slowly progressing disease and thus to 
compensate for the expected bias.  We then re-estimated the transition probabilities for the Markov 
model using the same method as for the primary analysis. The result of this calculation was to increase 
very slightly the mean rate of disease progression predicted for the untreated RSS cohort and thus to 
increase the estimated treatment effect (deviation score of -10.6% compared to -9.9% for the primary 
analysis).   
7.8  Our tentative conclusion is that, if the differential patterns of attendance at clinics in the BCMS 
cohort compared to the RSS cohort are responsible for any bias in our estimates of the treatment effect, 
it is at most very small.    
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TABLE W1: LIST OF SUPPLEMENTARY ANALYSES UNDERTAKEN AND RATIONALE 
 
Pre-specified? Problem to be addressed Analysis undertaken 
Results at 
Sensitivity analyses 
Yes Application of "intention to treat" principles Include scores recorded after a switch to a non-scheme DMT.  In the 
counterfactual, predict disease progression with treatment as if patients stayed on 
treatment throughout period of follow-up. 
Table 3 
Yes Application of "intention to treat" principles and assessment of possible 
bias due to incomplete follow-up 
As for previous, with imputation of missing values. Web table 3 
No Possible bias due to exclusion of patients not starting treatment within 
specified 3-month window 
Include such patients in analysis set Web table 3 
No Possible bias due to censoring of EDSS scores recorded after a patient has 
switched to a non-scheme DMT 
Include such scores, including those for patients who switch to a non-scheme 
DMT before the first annual review.   
Web table 3 
Yes Possible bias due to incomplete follow-up in RSS cohort Impute missing values in the Markov framework on two extreme assumptions:  (a) 
last value carried forward, (b) linear interpolation/extrapolation using all available 
valid EDSS scores 
Table 3 
Yes Possible bias due to incomplete follow-up in RSS cohort Impute missing values in the MLM framework using the model itself.  As a 
sensitivity analysis, add 0.5 EDSS points to each imputed value 
Table 3 
Yes Possible bias due to exclusion of patients with SPMS at baseline from 
RSS analysis cohort 
Include such patients in analysis set Table 3 
Yes Test sensitivity of results to precise mapping from EDSS to utilities Use alternative set of utilities Web table 3 
Yes Main outcome measure only uses information from patient's last recorded 
EDSS - this applies an "area under the curve" approach 
Integrates actual and expected benefit for each year from baseline Web table 3 
No Assess most extreme combination of variant assumptions - Markov 
model 
Include patients with SPMS at baseline in analysis set and impute missing values 
using linear interpolation/ extrapolation 
Web table 3 
No Assess most extreme combination of variant assumptions - MLM Include patients with SPMS at baseline in analysis set and impute missing values 
using MLM 
Web table 3 
No Assess the bias due to using observed EDSS at baseline to assess 
progression, rather than estimated "true" EDSS at baseline 
Use estimated "true" EDSS at baseline (conditional on first observed EDSS) to 
calculate progression 
Appendix 5 
Other supplementary analyses 
No Assess possible implications of different patterns of availability of data in 
BCMS dataset compared to RSS dataset 
Compare baseline parameters and average rates of EDSS progression for patients 
(a) contributing relatively frequent/infrequent data, (b) not lost/lost to follow up 
(defined as contributing/not contributing any data within last 18 months before 
cut-off) 
Web table 4 
No Compare rates of disease progression in the London Ontario and British 
Columbia datasets 
Comparison of projections using a Markov model with transition matrices 
estimated from the two datasets and starting with the EDSS distribution in the RSS 
baseline population 
Web figure 1 
 
 
TABLE W2: NUMBER OF YEARS OF FOLLOW-UP DATA IN THE PER PROTOCOL ANALYSIS COHORT 
 
Patient group Number On scheme DMT 
at final year? 
Mean number of 
years on  
scheme DMT 
Data available 
for year 7 and/or 
year 8 
Total cohort  4137  3561 86.1% 4.526  2585 
Number with:  
     
  Year 6 data  2639  2263 85.8% 5.324  2003 
  Year 5 but no year 6 data  602  508 84.4% 4.322  338 
  Year 4 but no year 5 or 6 data  292  239 81.8% 3.401  94 
  Year 3 but no year 4-6 data  229  197 86.0% 2.576  64 
  Year 2 but no year 3-6 data  186  168 90.3% 1.742  42 
  Year 1 but no year 2-6 data  189  186 98.4% 0.868  44 
Mean years follow-up 5.139     
 
 








------------ Absolute treatment effect (EDSS) ------------ ----------------- Deviation scores (utility) -----------------   
Markov 
model 











Primary analysis 4,137 5.139 0.284 0.587 0.535 0.639 -10% -14% -25% -2% 
Supplementary/sensitivity analyses           
Intention to treat (ITT) analysis 4,137 5.409 0.273 0.590 0.537 0.642 (a) (a) (a) (a) 
ITT analysis with MLM imputation(b):           
  Single mean imputation 4,137 5.983 n/a 0.639 0.588 0.690 n/a (a) (a) (a) 
  Multiple imputation 4,137 5.983 n/a 0.639 0.586 0.692 n/a (a) (a) (a) 
  Single mean imputation with additional 










































(c)   
Including EDSS scores recorded after a patient has switched to a 
non-scheme DMT (including patients switching before year 1) 4,197 5.400 0.260 (c) (c) (c) -1% (c) (c) (c) 
Imputation - Markov model           
  - last value carried forward 4,209 5.992 0.378 n/a n/a n/a -32% n/a n/a n/a 
  - linear interpolation/extrapolation 4,209 5.961 0.226 n/a n/a n/a 34% n/a n/a n/a 
Imputation - multilevel model           
  - "on treatment" assumption 4,137 5.984 n/a 0.664 0.614 0.715 n/a -6% -16% 4% 
  - "off treatment" assumption:           
       single imputation 4,137 5.984 n/a 0.644 0.593 0.694 n/a -7% -17% 4% 
       multiple imputation  5.984  0.643 0.590 0.697 n/a -2% -13% 10% 
       single imputation + 0.5 EDSS points  
         for each imputed value 4,137 5.984 n/a 0.464 0.411 0.516 n/a 38% 26% 49% 
Including patients with SPMS at baseline 4,780 5.082 0.173 0.521 0.473 0.568 3% 11% 2% 20% 
Alternative utility estimates (pooled combination of 3 datasets 
including the Boggild data) 4,137 5.139 (d) (d) (d) (d) -14% -7% -18% 5% 







------------ Absolute treatment effect (EDSS) ------------ ----------------- Deviation scores (utility) -----------------   
Markov 
model 











Including patients with SPMS at baseline with imputation of 
missing values (Markov, linear extrapolation) 4,859 5.954 0.095 n/a n/a n/a 57% n/a n/a n/a 
Including patients with SPMS at baseline with imputation of 




(a) Since the ITT analysis is essentially a comparison of actual disease progression with predicted progression off treatment (rather than predicted progression on treatment),  the deviation measure cannot meaningfully be 
calculated for these variants. 
(b) In this analysis, it is assumed that patients go "off treatment" once they are lost to follow-up. 
(c) These variants were only carried out for the Markov model 
(d) As for primary analysis 




TABLE W4:  CHARACTERISTICS OF PATIENTS IN THE BCMS DATASET ACCORDING TO  
(A) THE FREQUENCY OF EDSS SCORES, (B) WHETHER LOST TO FOLLOW UP 
 
 Frequency of scores: Whether "lost to follow up": 











% female 71.7% 76.6% 75.5% 70.7% 
Age at baseline (eligibility) 37.32 37.03 36.56 38.78 
Age at onset  28.87 29.62 28.41 31.43 
MSSS score at baseline 4.21 3.61 3.74 4.35 
EDSS at baseline 2.67 2.20 2.35 2.66 
Number with year 5 data 229 144 289 84 
Mean EDSS increase  











  Frequency = number of EDSS scores divided by interval between first and last scores 












----------------- Absolute treatment effect (EDSS) ----------------- ----------------- Deviation scores (utility) ----------------- 
Markov 
model 
Multilevel model Markov 
model 
Multilevel model 




Year 4 4,110 3.532 0.268 0.514 0.466 0.561 -16% -51% -66% -37% 
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ABSTRACT
Background Because multiple sclerosis (MS) is a 
chronic disease causing disability over decades, it is 
crucial to know if the short-term effects of disease-
modifying therapies reported in randomised controlled 
trials reduce long-term disability. This 10-year prospective 
observational study of disability outcomes (Expanded 
Disability Status Scale (EDSS) and utility) was set up, 
in conjunction with a risk-sharing agreement between 
payers and producers, to investigate this issue.
Methods The outcomes of the UK treated patients were 
compared with a modelled untreated control based on 
the British Columbia MS data set to assess the long-term 
effectiveness of these treatments. Two complementary 
analysis models were used: a multilevel model (MLM) 
and a continuous Markov model.
Results 4862 patients with MS were eligible for the 
primary analysis (mean and median follow-up times 8.7 
and 10 years). EDSS worsening was reduced by 28% 
(MLM), 7% (Markov) and 24% time-adjusted Markov in 
the total cohort, and by 31% (MLM) and 14% (Markov) 
for relapsing remitting patients. The utility worsening 
was reduced by 23%–24% in the total cohort and by 
24%–31% in the RR patients depending on the model 
used. All sensitivity analyses showed a treatment effect. 
There was a 4-year (CI 2.7 to 5.3) delay to EDSS 6.0. An 
apparent waning of treatment effect with time was seen. 
Subgroup analyses suggested better treatment effects in 
those treated earlier and with lower EDSS scores.
Conclusions This study supports a beneficial effect on 
long-term disability with first-line MS disease-modifying 
treatments, which is clinically meaningful. However the 
waning effect noted requires further study.
INTRODUCTION
Multiple sclerosis (MS) is a major cause of serious 
physical disability in adults of working age. The 
majority of patients start with a relapsing remit-
ting phase (RRMS), which then becomes secondary 
progressive (SPMS) with or without superimposed 
relapses at a median disease duration of 20 years.1 
It is during this latter phase that the majority of the 
disability is manifest.
The first randomised controlled trials (RCT) of 
MS disease-modifying treatments (DMTs) were 
reported in the 1990s.25 These led to the licensing 
of three formulations of interferon beta (Betaferon/
Betaseron, Rebif and Avonex) and of glatiramer 
acetate (Copaxone) for RRMS. The licences of 
Betaferon and Rebif were subsequently extended in 
Europe to include patients with relapsing SPMS.68
All four treatments were shown, over the period 
of 23 years of the trials, to be efficacious in 
reducing relapses (by approximately 30%) and in 
reducing MRI activity, with less robust evidence on 
disability. The most important outcome, that is, the 
long-term effect of treatment on disability, could 
not be addressed within this timescale, and the 
predictive value of short-term treatment outcomes 
on longer term disability remains unproven. Only 
longer term follow-up data can provide informa-
tion on the sustainability of treatment effects and 
on delaying time to loss of independent ambulation.
Because of the uncertainty of the long-term 
benefit, the UKs National Institute for Health 
and Care Excellence (NICE) in 2002 concluded 
that it was unable to recommend the use of these 
DMTs within the UK National Health Service,9 but 
recognised that these drugs could be cost-effective 
over the longer term if early treatment effects on 
disability persisted. Consequently a novel risk-
sharing scheme (RSS) was set up between the UK 
Department of Health, the pharmaceutical compa-
nies, professional and patient groups to deliver 
these DMTs cost-effectively10 (see online supple-
mentary appendix 1 for details).
A key feature of the scheme was the monitoring 
of disability progression in a cohort of patients to 
test whether observed outcomes were in line with 
those required for cost-effectiveness. This obser-
vational study recruited over 5000 UK patients 
prescribed the interferon-βs and glatiramer acetate 
between 2002 and 2005 and followed them up over 
a 10-year period in order to measure the long-term 
effectiveness of the drugs when compared with a 
modelled natural history cohort. Two yearly anal-
yses were performed and if observed outcomes 
deviated from target by more than an agreed 
margin, the price of the drugs would be adjusted to 
restore cost-effectiveness.
At 2 years the initial Ontario natural history data 
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control group because the disability scores had been smoothed,11 
and the British Columbia MS database was selected and vali-
dated.12 13 A second independent analysis model (a multilevel 
model (MLM)) was added14 to corroborate results from the 
Markov model specified in the RSS.15
After 6 years of follow-up,13 the drugs in aggregate showed a 
40% reduction in the rate of deterioration in disability on the 
MLM in patients with relapsing remitting disease (24% on the 
Markov model); this translated into a reduction of 43% (multi-
level) or 42% (Markov) in the rate at which utility worsened, 
which was on track for the cost-effective target.10
The scientific analysis plan for this 10-year analysis16 was 
further revised in line with intention-to-treat principles, with 
additional analyses of (1) subgroups, (2) the influence of time 
on treatment effectiveness and (3) the effect of treatment on the 
time to loss of unaided ambulation. Here we report the final 
results of this study, focusing on the longer term effect of DMTs 
on disability progression.
METHODS
The detailed protocol can be found elsewhere1214 and the 
following is a summary.
Patient recruitment and follow up
Between May 2002 and July 2005, 72 sites across the UK 
recruited patients with RRMS or SPMS fulfilling the Associa-
tion of British Neurologists (ABN) 2001 criteria for treatment 
old; two relapses in the last two calendar years).17 Drug selec-
tion reflected clinical practice and was led by individual patient 
and physician choice within the licensed indications in the UK. 
Ten-year follow-up was planned with the annual EDSS18 scores, 
whether treatment was continued or not. Telephone assessments 
were permitted for EDSS values over 6.19
For this final analysis the main outcome was an intention 
to treat analysis which included all recruited patients, both 
RRMS and SPMS at baseline, and all follow-up scores including 
those from patients switching to non-scheme DMTs. However, 
subgroup analysis also focused on the RRMS at baseline patients, 
since this was the cohort for which the price adjustment scheme 
was set up.
Natural history comparator
The British Columbia MS data set is a population-based data-
base, established in 1980, with the EDSS scored by the MS 
neurologist at outpatient visits.1 Patients (n=978) were identi-
fied who, between 1980 and 1995, fulfilled similar eligibility 
criteria to the RSS cohort. The baseline for these patients was 
taken as the first clinic visit at which they fulfilled the criteria. 
Patient information was included only up to the end of 1995, 
after which DMTs were widely available in Canada.
Outcomes
For scientific purposes, our primary interest was to compare 
the rate of disability worsening (ie, disease progression) of 
patients treated with DMTs, as observed in the RSS, with that 
in an untreated modelled comparator control group (compar-
ison against control). Disease progression was modelled in the 
patients in the British Columbia data set adjusting for differences 
in prognostic factors (EDSS at baseline, age at onset) between the 
two data sets. The technical details are explained below. Disease 
progression was measured in terms of the accumulation of 
disability (as measured by EDSS) and worsening of quality of life 
(expressed as utility, derived from the EDSS scoresee online 
supplementary appendix 2), for eligible and treated patients with 
at least one EDSS score after baseline. Outcomes were expressed 
both as absolute differences between progression observed in the 
RSS treated group and the comparator control group, and the 
relative difference in progression (expressed as a percentage).
The secondary outcomes included the area under the curve 
(a cumulative measure of reduction in disability using the abso-
lute value of area under EDSStime curve calculated using the 
trapezoid rule) and the delay in the median time required for 
sustained progression to the clinically relevant milestone of 
EDSS 6.0 (needing a stick to walk 100 m), confirmed at least 6 
months with no subsequent lower scores.20
Supplementary analyses
A wide range of prespecified sensitivity analyses (online supple-
mentary table 1 and 2) were conducted to assess assumptions 
related to modelling and loss to follow-up. Prespecified subgroup 
analyses allowed us to examine treatment effect by sex, EDSS 
and disease course (RRMS/SPMS) at baseline, disease duration 
and recruitment date. (Patients recruited later in the scheme may 
be more typical of normal clinical practice than those recruited 
earlier, many of whom had been waiting for treatment and had 
more advanced disease.) We also used a variety of methods to 
explore the apparent changes in the treatment effect over time 
(online supplementary appendix 3).
Statistical design
In order to calculate the expected progression for untreated 
patients, two independent models were developed, a Markov 
model and an MLMfor further details see online supple-
mentary appendix 4. Both models used data from the natural 
history comparator data set and these were validated in previous 
studies12 14 as being reliable methods for predicting the untreated 
outcome. The essential role of the modelling is to adjust for the 
(relatively slight) differences in baseline characteristics between 
the natural history and RSS data sets.
Markov model
The Markov model uses the annual probabilities of moving 
between EDSS scores (or remaining on the same score) from 
the untreated values derived from the British Columbia data set. 
These probabilities are then applied to the baseline EDSS scores 
of the RSS cohort and to subsequent modelled EDSS states over 
10 years to give the expected EDSS progression for untreated 
patients. The difference between the expected untreated and 
observed RSS treated mean EDSS score represents the treatment 
effect.
Estimation was by the Jackson continuous time method21 using 
age at onset dichotomised at the median as a predetermined 
covariate.12 Because the assumption in the Markov model is that 
the transition probabilities from one specific EDSS score do not 
vary over time (and this assumption is unlikely to be precise), we 
used a time-varying model, with separate transition matrices 
estimated for the first 2 years after baseline and for the rest of 
the follow-up period, as a sensitivity analysis. CIs on projections 
using the Markov model are derived by bootstrapping.
Multilevel model
The MLM22 23 uses the mean trajectory for the whole popu-
lation, the variation of individual trajectories about this mean 
and the fluctuation of individual EDSS scores about the trend 
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Figure 1 Consolidated Standards of Reporting Trials diagram for all 
patients in the UK MS risk-sharing scheme. EDSS, Expanded Disability 
Status Scale; MS, multiple sclerosis; RRMS, relapsing remitting MS.
from the British Columbia data set. The model is applied to 
the baseline data for patients in the RSS data set to predict the 
EDSS progression without treatment for each individual. The 
projections are then combined across all individuals to produce 
a predicted untreated mean EDSS progression for the whole RSS 
cohort. This is then compared with the observed data in the RSS 
(the comparison against control) to estimate the absolute treat-
ment effect.
For consistency with the Markov model,12 age at onset (binary 
variable) was included as the only covariate after previous 
covariate modelling found this to be sufficient. Validation of 
the model14 24 was undertaken on the British Columbia cohort 
(internal validation) and also using a natural history data set 
from the University Hospital of Wales (external validation). 
Bootstrapping was used to derive 95% CIs.
Time to sustained EDSS 6.0
To estimate the time to sustained EDSS 6.0, a parametric 
(Weibull) model was fitted to the British Columbia Multiple 
Sclerosis (BCMS) data, with gender and baseline EDSS as covari-
ates. A similar model was fitted to the RSS data. To adjust for 
differences in baseline distributions, the strata were combined 
using as weights the proportion of patients at baseline in the RSS 
data set (see online supplementary appendix 5 for details).
Governance of the study
An independent Scientific Advisory Group consisting of Pelham 
Barton, Yoav Ben-Shlomo, Richard Gray and chaired by Richard 
Lilford developed and approved the statistical analysis plan. 
Representation from the authors, NICE, the MS Trust and the 
Department of Health attended the Scientific Advisory Group 
meetings. The representatives from each company were observers 
at the Scientific Advisory Group meetings but had no role in the 
data collection, analysis or preparation of the manuscript.
RESULTS
Patient disposition and characteristics
Out of 5602 patients registered for recruitment, 4986 were 
consented and eligible for treatment, began treatment, and had 
baseline assessments. Of these 4986, 4862 (97.5%) had at least 
one follow-up EDSS score and were included in the primary 
analysis. Of these, 17% switched to non-scheme drugs during 
follow-up, with the majority using natalizumab or fingolimod, 
and 18% discontinued treatment during the study. The Consoli-
dated Standards of Reporting Trials diagram is shown in figure 1 
(details in online supplementary table 2). The median follow-up 
was 10 years, the mean follow-up was 8.7 years and 77% of the 
primary analysis group had a minimum of 9 years of follow-up 
data. An additional 2.6% had late year 10 data collected, used in 
the sensitivity analysis.
The baseline characteristics for the analysis cohort were 
similar to those in the British Columbia data set (online supple-
mentary table 3), although RSS patients had on average slightly 
higher EDSS and age at onset and thus slightly longer disease 
duration on first assessment; however, the models adjust for 
baseline EDSS scores and age of onset.
Primary outcomes
The primary outcomes are shown in table 1. The absolute 
10-year treatment effect was a reduction of 0.61 using the MLM 
(95% CIs 0.55 to 0.66) and of 0.12 in mean EDSS using the 
Markov model (95% CIs 0.07 to 0.17). The corresponding rela-
tive reduction in progression was 28% (95% CIs 26% to 31%) 
for the MLM and 7% (95% CIs 4% to 10%) for the Markov 
model. However, using the time-varying Markov model, the 
effect size closely mirrors the MLM results (see below). In utility 
terms, the reduction in progression was 23% (95% CIs 20% to 
26%) on the MLM and 24% (95% CIs 21% to 27%) on the 
Markov model. Figure 2A,B shows how the observed disability 
progression deviates over the 10-year period from that expected 
for untreated patients (the comparator control group) for the 
MLM.
Secondary outcomes
The cumulative benefit accrued over the first 10 years of treat-
ment for the whole cohort (the area under the curve for the 
full period) was 1.3 EDSS years (95% CIs 0.9 to 1.6estimates 
available only for the Markov model). The estimated median 
time for the whole cohort to reach sustained EDSS 6.0 using 
the Weibull model was 12.5 years (95% CIs 11.8 to 13.3); this 
compares with 8.4 years (95% CIs 7.4 to 9.6) for untreated 
patients (figure 3), indicating that treatment is associated with a 
delay of 4.0 years (95% CIs 2.7 to 5.3) in reaching this relevant 
disability endpoint.
Sensitivity analyses
The results of the sensitivity analyses are shown in table 2 and 
online supplementary table 4. As expected, excluding EDSS 
scores after patients switched to alternative treatmentseffec-
tively censoring later data from patients on a worse trajectory
makes the results appear more favourable to the DMTs. Imputing 
missing values in the RSS data set makes relatively little differ-
ence to the outcomes, except in the deliberately extreme case 
(greater than a standard worse case scenario) in which we added 
0.5 EDSS points to each imputed value (on average, doubling 
the imputed progression since the last available score), where 
the magnitude of the treatment effect on EDSS was reduced by 
roughly a quarter. In contrast, a variant in which we enriched 
the British Columbia data set by imputing additional values for 
patients with relatively sparse follow-up and re-estimated the 
transition probabilities resulted in a substantially greater treat-
ment effect. Finally, using variant of the Markov model with 
time-varying transition probabilities resulted in a greater treat-
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(predicted natural history 
progression less actual)
(95% CI)
Relative rate of disease 
progression
(actual divided by predicted 
natural history) (95% CI)
(1) (2) (3)=(2–1) (4)=(1)/(2)
Rounded EDSS* Markov 1.53 (1.48 to 1.58) 1.65 (1.63 to 1.67) 0.12 (0.07 to 0.17) 93% (90% to 96%)
EDSS* MLM 1.53 (1.47 to 1.58) 2.13 (2.11 to 2.15) 0.61 (0.55 to 0.66) 72% (69% to 74%)
Utility Markov 0.122 (0.117 to 0.127) 0.161 (0.159 to 0.163) 0.039 (0.034 to 0.044) 76% (73% to 79%)
MLM 0.122 (0.117 to 0.127) 0.159 (0.156 to 0.162) 0.037 (0.031 to 0.042) 77% (74% to 80%)
*For the Markov model, half-integer EDSS states are combined with the next lower integer EDSS state. Calculations with the MLM using rounded EDSS values gave almost 
identical results to those using the full EDSS scale.
EDSS, Expanded Disability Status Scale; MLM, multilevel model; SPMS, secondaryprogressive multiple sclerosis.
Figure 2 Comparison against control results using the MLM model: disability outcomes over 10 years in RSS patients and in the untreated comparator 
control group, for the whole cohort (A) EDSS progression and (B) utility progression, and for the patients with RRMS at baseline (C) EDSS progression and 
(D) utility progression. EDSS, Expanded Disability Status Scale; MLM, multilevel model; RRMS, relapsing remitting multiple sclerosis; RSS, risk-sharing scheme.
to those from the MLM. Online supplementary appendices 6 
and 7 provide further details.
Subgroup analyses
Estimated treatment effects were rather larger for the subset of 
patients with RRMS at baseline (table 3, figure 2C,D; MLM), 
with 31% and 14% reduction in EDSS worsening and 24% and 
31% reduction in utility worsening (MLM and Markov models, 
respectively).
Other prespecified subgroup analyses using the Markov model 
(tables 4 and 5, and online supplementary table 5) suggest that 
greater treatment effects are associated with a lower EDSS score 
at baseline, patients with shorter time from disease onset, women 
rather than men, patients on treatment throughout rather than 
those who come off treatment, and patients recruited later in the 
scheme. The MLM however did not find evidence of a reduction 
in treatment effect with increasing baseline EDSS.
Changes over time
Table 6 shows how the main outcomes using the MLM model 
change when the primary analysis is repeated with years 2, 4, 6, 
8 and 10 as the end year. The results suggest that, although the 
treatment effect continues throughout the follow-up period, 
it becomes progressively smaller. We explored this through 
a number of prespecified supplementary analyses using both 
models, including the version of the Markov model with time-
variant transition probabilities. The results (online supplemen-
tary appendix 8) confirm this trend of a large initial effectin 
the first year or two after treatment initiationfollowed by a 
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Figure 3 Time to sustained EDSS 6.0 in RSS treated patients and in 
the untreated comparator control group. EDSS, Expanded Disability Status 
Scale; RSS, risk-sharing scheme.




Mean years Absolute treatment effect (EDSS) Relative treatment effect (EDSS)
Follow-up
On 
treatment Markov model MLM Markov model MLM
Primary analysis 4862 8.7 7.0 0.12 (0.07, 0.17) 0.61 (0.55, 0.66) 93% (90%, 96%) 72% (69%, 74%)
RRMS-only subgroup 4217 8.9 7.3 0.25 (0.20, 0.31) 0.68 (0.62, 0.74) 86% (83%, 89%) 69% (67%, 72%)
Supplementary/sensitivity analyses (including patients with SPMS at baseline except where noted)
Excluding EDSS scores recorded after a patient has switched to a non-scheme DMT*
Primary analysis cohort 4799 8.0 6.4 0.13 (0.08, 0.19) 0.59 (0.53, 0.64) 91% (88%, 95%) 70% (68%, 73%)
RRMS-only subgroup† 4157 8.1 6.7 0.26 (0.21, 0.32) 0.66 (0.60, 0.72) 84% (81%, 88%) 68% (65%, 71%)
Excluding EDSS scores recorded after a patient has switched to any other DMT*
Primary analysis cohort 4475 7.0 5.7 0.16 (0.11, 0.22) 0.57 (0.52, 0.62) 88% (84%, 92%) 68% (65%, 70%)
RRMS-only subgroup 3871 7.0 5.9 0.29 (0.23, 0.35) 0.64 (0.59, 0.70) 80% (76%, 84%) 65% (62%, 68%)
Imputation—Markov model, using imputed values derived from the MLM
‘on treatment’ assumption 4862 9.9 7.7 0.12 (0.07, 0.17) NA 93% (91%, 96%) NA
‘off treatment’ assumption 4862 9.9 7.0 0.10 (0.04, 0.15) NA 95% (92%, 98%) NA
Imputation—multilevel model
‘on treatment’ assumption 4862 9.9 9.9 NA 0.67 (0.62, 0.72) NA 72% (70%, 74%)
‘off treatment’ assumption
Single imputation 4862 9.9 9.9 NA 0.65 (0.59, 0.70) NA 73% (70%, 75%)
Multiple imputation 4862 9.9 9.9 NA 0.64 (0.59, 0.70) NA 73% (71%, 75%)
Single imputation +0.5 EDSS points for each 
imputed value
4862 9.9 9.9 NA 0.48 (0.43, 0.53) NA 80% (78%, 82%)
Supplement RSS data with imputed values 
derived from out-of-window year 10 scores‡
4862 8.9 7.0 0.12 (0.07, 0.18) ‡ 93% (90%, 96%) ‡
Use transition matrices from BCMS data set supplemented by imputing additional data for patients with sparse follow-up‡
Including patients with SPMS at baseline 4862 8.7 7.0 0.28 (0.23, 0.34) ‡ 84% (81%, 87%) ‡
Excluding patients with SPMS at baseline 4217 8.9 7.3 0.43 (0.37, 0.49) ‡ 78% (75%, 81%) ‡
Alternative Markov model with time-varying 
natural history transition matrices
4862 8.7 7.0 0.48 (0.42, 0.53) NA 76% (74%, 79%) NA
Year 1 baseline (see online supplementary 
appendix 8)
4360 7.9 6.2 0.07 (0.02, 0.12) 0.43 (0.38, 0.48) 95% (92%, 99%) 77% (74%, 79%)
*Patients switching before year 1 are also excluded from the analysis.
†This was the primary analysis for the interim year 6 analysis.
‡These variants were only carried out for the Markov model.
DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; MLM, multilevel model; NA, not applicable; RRMS, relapsing remitting multiplesclerosis; RSS, risk 
sharing scheme; SPMS, secondary progressive multiple sclerosis; BCMS, British Columbia Multiple Sclerosis.
the baseline (table 2 and online supplementary table 4) also 
showed a positive but smaller treatment effect.
DISCUSSION
Main findings
Our findings show a clinically significant treatment effect main-
tained at 10 years, on both EDSS and quality of life outcomes, 
with a meaningful delay to sustained loss of unaided ambulation 
of around 4 years in an already impaired cohort at treatment 
onset (median EDSS 3.5).
Our analysis also highlighted a gradual attenuation of the 
treatment effect over time, or perhaps a large initial effect 
followed by a more modest continuing effect. The treatment 
effects appeared larger for patients with RRMS, those who start 
treatment earlier in their disease course and for women. The 
evidence for the effect of baseline EDSS on the treatment effect 
is less clear.
Methodological issues
This unique study addresses an important issue related to the 
long-term impact of the first-generation DMTs, which was not 
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(predicted natural history 
progression less actual)
(95% CI)
Relative rate of disease 
progression
(actual divided by predicted 
natural history)(95% CI)
(1) (2) (3)=(2−1) (4)=(1)/(2)
Rounded EDSS* Markov 1.55 (1.49 to 1.61) 1.80 (1.78 to 1.83) 0.25 (0.19 to 0.31) 86% (83% to 89%)
EDSS* MLM 1.55 (1.49 to 1.61) 2.23 (2.21 to 2.25) 0.68 (0.62 to 0.74) 69% (67% to 72%)
Utility Markov 0.113 (0.108 to 0.119) 0.164 (0.163 to 0.166) 0.051 (0.046 to 0.056) 69% (66% to 72%)
MLM 0.113 (0.108 to 0.118) 0.150 (0.148 to 0.152) 0.037 (0.031 to 0.042) 76% (72% to 79%)
*For the Markov model, half-integer EDSS states are combined with the next lower integer EDSS state. Calculations with the MLM using rounded EDSS values gave almost 
identical results to those using the full EDSS scale.
EDSS, Expanded Disability Status Scale; MLM, multilevel model; RRMS, relapsing remitting multiple sclerosis.
novel RSS between the manufacturers and payers, we were able 
to collect high-quality long-term data on disease progression on 
a treated cohort and use historical data on untreated patients to 
construct a comparison control group.
Given the inevitable limitations of observational data, our 
study has important strengths. The RSS cohort is one of the 
largest cohorts ever used in a study of this type, with over 42 000 
patient years of data, with 9 years or more of data for nearly 80% 
of patientsa dropout rate over a decade comparable with that 
seen in recent 2-year treatment trials.25 26 Moreover these results 
reflect the real world performance of the DMTs and include 
the effects of patients discontinuing treatment, and may be more 
generalisable than estimates from highly selected short-term RCT 
populations. Our natural history comparator, from the British 
Columbia data set, is also the largest and most complete data set 
of untreated patients available for MS research.1 We used two 
completely independent modelling techniques, with comple-
mentary strengths and weaknesses: the multilevel repeated 
measures model can more easily take account of variations in the 
rate of disease progression between individual disease trajecto-
ries, whereas the Markov model predicted more accurately the 
number of patients at high EDSS levels which largely determine 
changes in mean utility (see (online supplementary appendix 
4). A third model, used for the survival analysis, confirmed the 
finding of a clinically significant treatment effect on time to loss 
of unaided ambulation.
We have implemented intention to treat principles, adapting 
the methods of our 6-year study13 to include all eligible and 
consented patients with MS prescribed these DMTs, including 
those with SPMS as well as RRMS at baseline, and data from 
patients who switched to different DMTsincluding non-scheme 
DMTsduring follow-up. We believe therefore that we have 
mitigated an important source of potential bias. Naturally, the 
possibility of bias from incomplete follow-up remains, but we 
have tested this by extensive sensitivity analyses with imputa-
tion of missing values. In addition, the patterns of follow-up 
seem broadly similar between the RSS and the British Columbia 
cohorts,13 so any residual biases are likely to offset one another 
(see online supplementary appendix 7). If anything, our results 
may be biased against a treatment effect because we used tele-
phone questionnaires in the UK cohort to capture data from 
patients with high EDSS scores who were unable to attend clinic, 
whereas there was no equivalent for the BCMS cohort. Our 
models are designed to adjust for the (relatively small) differ-
ence in baseline characteristics between the British Columbia 
and RSS data sets, but if this adjustment is imperfect this would 
be expected to bias the results against the treatment effect since 
RSS patients had on average marginally worse prognostic factors 
than British Columbia patients.
There are several other potential biases that must be consid-
ered before assuming a causal explanation for the DMTs that 
may have resulted in differences in the natural history of the two 
cohorts unrelated to treatment.
Geographical differences
Could our UK patients have a milder form of MS than the natural 
history British Columbia patients? Although British Columbia 
is more ethnically diverse, MS still predominates in Europeans 
there.27 More direct evidence demonstrated similar untreated 
trajectories by using our Canadian data set to reproduce accu-
rately 10-year outcomes in a Welsh untreated MS cohort.24
Temporal differences
Could untreated patients with MS have a slower disease progres-
sion than they used to? This concept has been supported by the 
observation that the relapse rates in the placebo arms of RCTs 
have been reducing. This is likely to be due to other reasons 
however. Now DMTs are widely available, ethical consider-
ations make it likely that patients with more active disease are 
prescribed MS drugs rather than risk being allocated to a placebo 
arm. Additionally the later trials introduced early rescue therapy 
options and stricter relapse definitions, which would also reduce 
relapse rates recorded.28 Population-based cohorts are less likely 
to be biased by selection, and there is no evidence for a better 
prognosis in recent MS cohorts from British Columbia29 nor 
Wales (Neil Robertson, personal communication).
Confounding by indication
Could treatment decisions and clinical outcomes be confounded 
by variables such as disease severity and comorbidity, as seen 
in contemporary treated and untreated comparisons? This is 
not relevant in this study because there was no treated versus 
untreated comparison from within a single cohort. The BCMS 
patients were selected using the same inclusion criteria applied 
to the UK patients. Additionally both analysis methods adjusted 
for baseline EDSS and age at entry, and adding other covari-
ates made little difference to the outcomes.12 Previous results 
from the British Columbia data20 30 demonstrated that indica-
tion bias may be important when comparing with contemporary 
untreated patients,20 because untreated patients differed, having 
a milder disease even though fulfilling the same baseline criteria 
for treatment. When the authors compared treated patients with 
historical controls as in our study, they showed a trend towards a 
treatment benefit on time to reach EDSS 6.0 (relative risk 0.77, 
CI 0.58 to 1.02), which is comparable with our results consid-
ering they had a much smaller treated cohort (n=868 vs 4986) 






































































































































Table 4 Subgroup analyses by type of MS, date of baseline assessment and baseline EDSS (both models): EDSS outcomes
Population n
















Relative rate of 
progression
Primary analysis population 4862 8.7 7.0 3.18 0.12 (0.07, 0.17) 93% (90%, 96%) 0.61 (0.55, 0.66) 72% (69%, 74%) 0.65 (0.59, 0.70) 73% (70%, 75%)
Baseline EDSS ≤3.5 2940 9.0 7.4 2.02 0.35 (0.28, 0.42) 84% (81%, 87%) 0.63 (0.56, 0.71) 74% (71%, 77%) 0.67 (0.59, 0.74) 75% (73%, 78%)
Baseline EDSS 4–5.5 1275 8.6 6.7 4.42 −0.11 (−0.21, −0.02) 110% (102%, 119%) 0.59 (0.49, 0.68) 68% (63%, 73%) 0.64 (0.54, 0.73) 69% (65%, 73%)
Baseline EDSS ≥6 647 8.0 5.5 6 −0.47 (−0.57, −0.36) 233% (202%, 265%) 0.52 (0.41, 0.62) 63% (56%, 70%) 0.59 (0.48, 0.69) 65% (59%, 71%)
RRMS at baseline 4217 8.9 7.3 2.86 0.25 (0.20, 0.31) 86% (83%, 89%) 0.68 (0.62, 0.74) 69% (67%, 72%) 0.71 (0.66, 0.78) 71% (69%, 73%)
SPMS at baseline 645 7.8 5.1 5.29 −0.76 (−0.86, −0.66) 218% (202%, 234%) 0.10 (0.00, 0.20) 93% (86%, 101%) 0.19 (0.09, 0.29) 90% (85%, 95%)
RRMS at baseline and:
Baseline EDSS ≤3.5 2882 9.0 7.5 2.00 0.39 (0.32, 0.46) 82% (79%, 86%) 0.67 (0.59, 0.74) 73% (69%, 76%) 0.70 (0.63, 0.77) 74% (71%, 77%)
Baseline EDSS 4–5.5 1093 8.7 7.0 4.40 −0.01 (−0.11, 0.10) 101% (91%, 110%) 0.68 (0.58, 0.79) 63% (58%, 68%) 0.72 (0.62, 0.83) 65% (60%, 70%)
Baseline EDSS ≥6 242 8.4 6.2 6 −0.16 (−0.35, 0.04) 143% (90%, 196%) 0.84 (0.64, 1.03) 44% (32%, 56%) 0.91 (0.72, 1.10) 47% (37%, 58%)
SPMS at baseline and:
Baseline EDSS ≤3.5 58 8.2 5.9 2.69 −1.48 (−1.87, −1.09) 181% (158%, 203%) −1.10 (−1.51, −0.70) 151% (133%, 170%) −1.05 (−1.46, −0.64) 142% (125%, 159%)
Baseline EDSS 4–5.5 182 7.8 5.1 4.55 −0.77 (−0.95, −0.59) 182% (161%, 202%) −0.01 (−0.20, 0.19) 101% (89%, 112%) 0.13 (−0.06, 0.32) 94% (85%, 102%)
Baseline EDSS ≥6 405 7.8 5.1 6 −0.65 (−0.77, −0.53) 292% (255%, 329%) 0.32 (0.21, 0.44) 76% (68%, 84%) 0.39 (0.28, 0.50) 76% (69%, 83%)
Date of baseline assessment
On or before 28 August 2003 2351 8.7 6.9 3.32 0.02 (−0.06, 0.10) 99% (94%, 103%) 0.53 (0.46, 0.61) 75% (71%, 78%) 0.58 (0.51, 0.66) 75% (72%, 79%)
After 28 August 2003 2511 8.8 7.0 3.05 0.21 (0.14, 0.29) 88% (83%, 92%) 0.67 (0.60, 0.75) 69% (66%, 72%) 0.71 (0.64, 0.78) 71% (67%, 74%)
Baseline at or before 31 August 2003 and:
Baseline EDSS ≤3.5 1352 8.9 7.5 2.07 0.27 (0.16, 0.38) 87% (82%, 92%) 0.57 (0.46, 0.68) 77% (72%, 81%) 0.61 (0.50, 0.72) 77% (73%, 82%)
Baseline EDSS 4–5.5 631 8.6 6.6 4.42 −0.21 (−0.34, −0.08) 119% (107%, 131%) 0.49 (0.36, 0.62) 73% (66%, 80%) 0.54 (0.41, 0.66) 74% (68%, 80%)
Baseline EDSS ≥6 368 7.9 5.4 6 −0.50 (−0.64, −0.36) 244% (202%, 287%) 0.48 (0.34, 0.62) 65% (56%, 74%) 0.55 (0.41, 0.69) 67% (59%, 75%)
Baseline after 31 August 2003 and
Baseline EDSS ≤3.5 1588 9.0 7.4 1.97 0.42 (0.32, 0.52) 81% (77%, 85%) 0.69 (0.59, 0.79) 72% (68%, 76%) 0.71 (0.61, 0.81) 73% (69%, 78%)
Baseline EDSS 4–5.5 644 8.5 6.8 4.43 −0.02 (−0.16, 0.11) 102% (90%, 114%) 0.68 (0.54, 0.82) 62% (55%, 69%) 0.74 (0.60, 0.87) 64% (58%, 71%)
Baseline EDSS ≥6 279 8.2 5.6 6 −0.43 (−0.58, −0.27) 219% (175%, 264%) 0.57 (0.41, 0.72) 61% (50%, 71%) 0.63 (0.48, 0.78) 63% (54%, 71%)
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; RRMS, relapsing remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.
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Table 5 Other subgroup analyses (Markov model only)
Population n












Relative rate of 
progression
Primary analysis population 4862 8.7 7.0 3.18 0.12 (0.07, 0.17) 93% (90%, 96%) 0.039 (0.034, 0.044) 76% (73%, 79%)
One-way analyses
On treatment throughout 2855 8.7 8.7 3.02 0.46 (0.39, 0.53) 73% (69%, 77%) 0.073 (0.067, 0.079) 55% (51%, 58%)
Ever off-treatment 2007 8.8 4.6 3.40 −0.36 (−0.44, −0.28) 123% (118%, 128%) −0.010 (−0.018, −0.001) 106% (101%, 111%)
By gender
Male 1224 8.6 6.8 3.19 −0.12 (−0.23, 0.00) 107% (100%, 114%) 0.013 (0.002, 0.024) 92% (85%, 99%)
Female 3638 8.8 7.0 3.17 0.20 (0.14, 0.26) 88% (84%, 92%) 0.048 (0.042, 0.053) 71% (67%, 74%)
Baseline at or before 28 
February 2003
997 8.7 7.0 3.35 0.03 (−0.09, 0.14) 98% (91%, 106%) 0.035 (0.024, 0.046) 78% (71%, 85%)
Baseline after 28 February 
2003
3865 8.8 7.0 3.13 0.14 (0.09, 0.20) 91% (88%, 95%) 0.040 (0.034, 0.045) 75% (72%, 79%)
Baseline at or before 31 
August 2003
2351 8.7 6.9 3.32 0.02 (−0.06, 0.10) 99% (94%, 103%) 0.033 (0.025, 0.040) 79% (75%, 84%)
Baseline after 31 August 
2003
2511 8.8 7.0 3.05 0.21 (0.14, 0.29) 88% (83%, 92%) 0.044 (0.037, 0.052) 73% (69%, 77%)
Disease duration at baseline
≤3 years 1251 8.8 7.3 2.46 0.45 (0.33, 0.57) 77% (71%, 83%) 0.060 (0.050, 0.070) 65% (59%, 71%)
>3 years 3611 8.7 6.9 3.43 0.00 (−0.05, 0.06) 100% (96%, 103%) 0.032 (0.026, 0.037) 80% (76%, 84%)
≤6 years 2295 8.8 7.2 2.67 0.32 (0.24, 0.40) 83% (78%, 87%) 0.051 (0.043, 0.058) 70% (65%, 74%)
>6 years 2567 8.7 6.8 3.64 −0.06 (−0.12, 0.01) 104% (99%, 108%) 0.028 (0.022, 0.035) 82% (78%, 86%)
Two-way analyses
Disease duration ≤3 years and:
Baseline EDSS ≤3.5 981 8.9 7.5 1.80 0.60 (0.47, 0.73) 73% (67%, 79%) 0.068 (0.058, 0.079) 61% (55%, 67%)
Baseline EDSS 4–5.5 199 8.4 6.7 4.41 0.00 (−0.29, 0.28) 100% (74%, 127%) 0.039 (0.009, 0.068) 74% (56%, 94%)
Baseline ≥EDSS 6 71 8.0 5.7 6 −0.35 (−0.76, 0.05) 209% (83%, 338%) 0.001 (−0.050, 0.051) 100% (65%, 135%)
Disease duration >3 years and:
Baseline EDSS ≤3.5 1959 9.0 7.4 2.12 0.23 (0.14, 0.31) 90% (85%, 94%) 0.044 (0.036, 0.051) 73% (69%, 78%)
Baseline EDSS 4–5.5 1076 8.6 6.7 4.43 −0.14 (−0.23, −0.04) 112% (104%, 121%) 0.038 (0.027, 0.048) 76% (69%, 82%)
Baseline ≥EDSS 6 576 8.0 5.4 6 −0.48 (−0.59, −0.37) 236% (204%, 268%) −0.021 (−0.038, −0.004) 114% (103%, 125%)
EDSS, Expanded Disability Status Scale.
Table 6 Variation of the treatment effect with year of analysis (MLM)
Analysis
Relative progression rate (%) at year:
2 4 6 8 10
Primary analysis cohort
EDSS basis (95% CI) 47% (41% to 52%) 58% (54% to 62%) 66% (63 to 69%) 71% (68 to 74%) 72% (69 to 74%)
Utility basis (95% CI) 36% (31% to 41%) 55% (51% to 60%) 68% (64 to 72%) 76% (73 to 80%) 77% (743 to 80%)
RRMS-only subgroup
EDSS basis (95% CI) 42% (36% to 48%) 55% (51% to 59%) 63% (60% to 66%) 69% (66% to 72%) 69% (67% to 72%)
Utility basis (95% CI) 28% (22% to 34%) 50% (45% to 55%) 62% (58% to 66%) 74% (70% to 78%) 76% (72% to 79%)
EDSS, Expanded Disability Status Scale; MLM, multilevel model; RRMS, relapsing remitting multiple sclerosis.
8.7 and 10 in our study). The use of marginal structured Cox 
modelling (which included the contemporary untreated patients) 
did not change interpretation of findings.30
Selection bias
UK patients eligible for DMTs prior to 2002 but who progressed 
rapidly so they were no longer eligible would have been excluded. 
This bias would favour a treatment effect. Working against a 
treatment effect is the exclusion of those who were previously 
eligible but were no longer active enough to be included. A bias 
against a treatment effect might have occurred due to the pres-
ence of prevalent as well as incident ABN eligible patients, which 
would have included patients with later disease being treated, 
and it is possible that DMTs may be less effective later on in the 
disease course. Indeed our results suggested a greater treatment 
effect when excluding patients recruited in the first 18 months 
(once the backlog of prevalent patients had been entered). It is 
also reassuring that disease duration at study entry was almost 
identical for both data sets (table 3).
Other methodological issues worth considering are the use 
of the EDSS as the main outcome measure and the require-
ments for the EDSS scoring. Although the EDSS is not sensi-
tive to change over the shortterm and focuses on mobility, it 
is the most widely used and accepted measure of disability in 
MS. Using this measure also allows us to convert the outcome to 
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assess whether our results are plausible by comparing the results 
with other studies. The clinicians in our study did not undergo 
formal EDSS training as is required in clinical trials, rather the 
EDSS was collected within the routine clinical setting. Sites were 
instructed to use the same clinician to perform the EDSS over 
time where possible, and it was performed mainly by neurolo-
gists with expertise in MS. This was similar to the way the British 
Columbia natural history data set EDSS measurements were 
performed and thus comparable. The interobserver variability 
in our study was previously reported31 to have a kappa value of 
0.59, 0.71 and 0.85: for full agreement, within 0.5 and within 
1.0 EDSS scores, respectively, and it is expected that the intraob-
server variability is even better.
On balance, therefore, we consider that there are sound 
reasons for believing that these results represent a true treatment 
effect. These reasons include the good agreement between our 
estimates of the absolute treatment effect at year 2 of a mean 
EDSS difference of 0.2213 and those derived from a meta-anal-
ysis of RCTs which gave a mean EDSS difference of 0.2532; the 
generally good agreement between two very different modelling 
approaches (particularly when the Markov models allows time 
to be included in the model); the adjustments included in each 
model to allow for the (relatively small) differences in baseline 
characteristics between the British Columbia and RSS data sets; 
and the use of a wide range of sensitivity analyses to test for 
possible residual sources of bias.
Implications for the treatment of MS
Assessing the longer term effectiveness of treatment is vital in 
considering the cost-effectiveness of expensive treatments for 
chronic conditions, but RCTs have not and cannot address this 
in MS where disability is acquired over many years. We have 
performed the only prospective long-term study of the treatment 
effect of MS DMTs, and have managed to recruit and retain a very 
large cohort (with higher levels than many short-term RCTs). 
Our results show that the benefits seen in the short term for these 
drugs are maintained over a 10-year period, although the treat-
ment effect appears to decrease over time and may not justify 
the prices for these drugs in some healthcare systems particularly 
where the drug costs are higher.33 This apparent waning effect 
would be consistent with the recent meta-analysis34showing an 
inverse age-dependent association with efficacy. Because age, 
disease duration and EDSS scores are all inter-related and the 
latter two were associated with the treatment effect size in our 
study, it is not clear what is the driving factor. Although newer 
treatments are now available and are often preferred because of 
greater efficacy or ease of administration, their cost-effectiveness 
has in turn been assessed by NICE using incremental compar-
ison with these first-generation drugs and more recently in direct 
head-to-head studies now that placebo studies are regarded as 
unethical. Thus the results of the MS RSS will have important 
consequences for assessing the cost-effectiveness of subsequent 
currently licensed and future drugs for MS.
Our finding that the treatment effect of these drugs is atten-
uated over time could have important implications for clinical 
practice, both for MS and perhaps for other longer term condi-
tions. It might now be ethical to conduct an RCT to determine 
whether dicontinuation of treatmentafter a given period on 
treatment, or after reaching a given level of disabilityoffers any 
disadvantage over continuing treatment. An RCT is currently 
under way to assess the effects of withdrawing treatment in older 
patients with MS who have had no relapses or new brain lesions 
for at least 5 years.35 Future trials of treatments for MS could be 
designed so that one arm receives treatment for an initial period 
and then discontinues treatment. On the basis of our findings, 
it might be more cost-effectiveand ultimately in the interests 
both of patients with MS and of patients with other conditions
to intervene earlier in the disease course, rather than to persist 
with treatment for long periods.
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Appendices to Assessing the long-term effectiveness of interferon-beta and glatiramer 
acetate in multiple sclerosis: final ten year results from the UK multiple sclerosis risk sharing 
 
 
Appendix 1:  Background to the UK MS Risk Sharing Scheme 
 
1.1   The MS disease modifying therapies (DMTs) are licensed for relapsing MS, ie for early 
stage disease, whereas the major disability is incurred in the later progressive phase.  In order 
for the DMTs to be cost-effective they must demonstrate that they significantly delay 
progression to these later stages of the disease.  
and Clinical Excellence (NICE) first looked at the DMTs in 2002 it was satisfied that there 
was robust evidence for their short-term benefits, e.g. in reducing the frequency of relapses.  
It was however unable to conclude, on the basis of the evidence then available, that the 
benefits of treatment seen in early years could safely be extrapolated over the 20 or more 
years needed to achieve cost-effectiveness1,2.   
 
1.2 The UK MS risk sharing scheme (RSS)3 has two components.  Firstly, the then current 
UK prices for the four main DMTs were reduced, where necessary, in order to achieve a cost 
effectiveness target of £36,000 per QALY, using the model of disability progression 
, a 20-year time horizon, and target 
treatment effects (relative rates of disability progression) derived from the pivotal RCTs.  
Secondly, the parties to the scheme agreed to track a prospectively observed MS cohort on 
DMTs against the trajectory required to offer cost effectiveness. The plan was to assess the 
data every two years, adjusting the price if necessary after each analysis to maintain the 20 
year cost-effectiveness target should the observed results differ from the required trajectory 
.   
 
1.3 Considering the practicalities of running such a scheme, the decision was made to follow 
the cohort for the first 10 years of the twenty year model. Over 5,500 patients were enrolled 
in 2002/2003. EDSS scores were collected pragmatically, i.e. as part of normal clinical 
practice. Although the EDSS was not assessed under trial standard protocols, it was 
performed by MS neurologists who were experienced in this scoring with the same 
neurologist being encouraged to continue scoring an individual patient throughout if possible.   
 
1.4   From 2005 to 2016 the parties to the scheme were been advised by a Scientific Advisory 
Group (SAG) chaired by Professor Richard Lilford. was to advise 
on the analysis plan for the interim and final analyses and on the interpretation of the results.  
In addition, the group advised the MS Trust (as the custodian of the data) on applications 
from other researchers to access the data on the RSS cohort. 
  
1.5 This paper focusses on the evidence generated by the scheme on the long-term 
effectiveness of the four DMTs in aggregate.  Results on the extent to which the DMTs in 
aggregate achieved the targets set at the outset of the scheme will be presented elsewhere.   
The target outcomes for individual DMTs were agreed between the companies concerned and 




Appendix 2:   Relation between EDSS and utility 
 
2.1   We examined three possible sources for the relation between EDSS and utility (quality 
of life): two surveys of patients with MS4,5, using patient-determined measures of disability 
atasets), and an unpublished paper6 drawing on the clinician-
perceived state of health according to the dimensions of mobility, self-care, ability to take 
part in usual activities (e.g. work), pain/discomfort and anxiety/depression.  The EQ5D scores 
quality of life, using standard tariffs7.  A utility of one represents perfect health; a utility of 
0.5 implies that on average members of the general population would regard 12 months of 
life in that health state as equally preferable as 6 months of life in perfect health. 
 
2.2 On advice from our Scientific Advisory Group, we decided to use a synthesis of the MS 
Trust and Heron datasets for the primary analysis, primarily because they contained more 
data for the higher EDSS scores.  The utility values we adopted are given in the table below: 
 
Utility values used for the year 10 analysis 
 
EDSS Utility  
0 0.9248 
1 or 1.5 0.7614 
2 or 2.5 0.6741 
3 or 3.5 0.5643 
4 or 4.5 0.5643 
5 or 5.5 0.4906 
6 or 6.5 0.4453 
7 or 7.5 0.2686 
8 or 8.5 0.0076 
9 or 9.5 -0.2304 
 
In our analysis of the year 6 data8,9 we also carried out a sensitivity analysis using pooled data 
from all three datasets, but the results were very similar to those of the primary analysis and 
we did not repeat this sensitivity analysis at year 10. 
2.3 Details of the three datasets and of the methodology used for their synthesis can be found 
in a report by IMS Health10. 
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Appendix 3:  Changes over time 
 
3.1 Our analysis of the year 6 data suggested that the treatment effect may reduce with time 
from baseline (start of treatment).  We therefore decided to explore this possible change over 




3.2 A multi-level model was fitted to the year 10 RSS data of identical form to that already 
fitted to the BCMS data, and the two models were used to predict disability progression from 
the same baseline distribution (the RSS baseline)a.   The resulting projections were compared 
both visually and by calculating the divergence for each year from baseline, which represents 
the cumulative treatment effect up to that point. 
 
Markov model:  time-varying hazard ratios 
 
 3.3 In the Markov framework, we used a rather different method (see Annex F of the 
statistical analysis plan11 for details).  The basic approach is to assume that the effect of 
treatment by a DMT can be modelled as a time-varying hazard ratio  specifically, a hazard 
ratio with different values for consecutive two-year periods.  The hazard ratios are varied in 
order to minimise the deviation between mean disability progression in the observed RSS 
data and in the (on treatment) counterfactual.  Two variant approaches were tried:  
i - ional 
form on the hazard ratios; and  
ii 
parametric form (eg linear, step function or negative exponential). 
 
Markov model  direct estimation of a model using RSS data 
 
3.4  Finally, we sought to estimate a Markov model using RSS data in order to examine 
which particular transitions, in which time periods, were enhanced or reduced in the RSS 
(treated) patients compared with the BCMS (untreated) patients.  Because of the large 
number of parameters and the risk of obtaining misleading results through random 
elements of the instantaneous probability matrix in the RSS model were related to those in 
the BCMS model by equations of the form 
 
 qRSSijt = q
BCMS
ijt       x       rijt     (5) 
 
where i  is the EDSS state before the transition,  j  the state after the transition, t the time from 
baseline at the start of the transition, and the hazard ratio rijt  is constrained to take one of a 
small number of possible values.  We then used a maximum likelihood method to estimate 
the most parsimonious set of the hazard ratios rijt  needed to obtain a reasonable fit to the data 
while exploring the variation of the hazard ratios with initial EDSS i  and time t.    
                                                 
a Because the functional form chosen for the model includes both time and log time terms, it is difficult to 
compare the two models simply by inspection of the coefficients to test for a time-treatment interaction.  We 





Appendix 4:  Further details on the Markov and Multi-Level Models 
 
6.1 The parameters for the two models representing disability progression for untreated 
patients were estimated using a subset of patients in the BCMS dataset12 who, at some clinic 
visit before 31 December 199
British Neurologists for eligibility for treatment with a DMT.  This gave a total of 978 
patients for potential analysis, all of whom were used to estimate the MLM.  For the Markov 
model, patients had to have had at least one further EDSS measurement before the cut-off 
date of 31 December 1995 (or before first treatment with a DMT if this was earlier). This left 
a total of 898 patients for analysis, followed up for a median period of 4.4 years before the 
cut-off date.   
Markov model 
 
4.2 The Markov model13 (half-integral 
scores are rounded down to the nearest integer).  Thus patients at EDSS 0 are allocated to 
state 1, patients at EDSS 1 or 1.5 are allocated to state 2, and so on.  The model assumes a 
constant probability of making a transition from state i  to state j  conditional on the vector of 
baseline covariates x for the individual patient.  For the purposes described in this paper death 
from non-MS causes was not explicitly modelled and patients in the RSS who died before the 
final analysis year were treated as lost to follow up.  
4.3   Estimation was by the continuous-time method of Jackson14 which does not require the 
data to be collected at regular (eg annual) intervals, and allows the transition probabilities to 
depend on baseline and other covariates.  After assessing a number of possible combinations 
of baseline covariates, a relatively simple model was chosen13 with a single baseline 
covariate, age at onset as a binary variable split about the median value in the BCMS dataset. 
Since information on MS-related death was not available from the BCMS dataset, 
probabilities for MS-  the model 
2.  -
baseline and for the rest of the follow-up period (see Appendix 7). 
4.4 The transition probabilities are then applied to the baseline EDSS scores of the RSS 
cohort and to subsequent modelled EDSS states over 10 years to give the expected EDSS 
progression for patients had they never received treatment.  The difference between the 
Confidence intervals on projections using the Markov model are derived by bootstrapping.  
Repeated measures multi-level model 
 
4.5 The repeated measures model was derived from the EDSS trajectories of individual 
patients in the British Columbia dataset.  The basic approach is to estimate a mean trajectory 
for the whole cohort, the variation of individual trajectories about this mean, and the 
fluctuation of individual EDSS scores about the trend for each individual. The model is then 
applied to the baseline data for patients in the RSS dataset to predict the EDSS progression 
which would have been expected without treatment for each individual. The projections are 
then combined across all individuals to produce a predicted mean EDSS progression for the 
whole population.   
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4.6 The model was estimated by means of the method of multilevel models15.  The EDSS 
score is regarded as a continuous variable although the observations can take only integral or 
half-integral values.  Our model16,17 had two levels; observations (level 1) within individuals 
(level 2). We used a model with a random intercept and two random powers of time since 
ABN eligibility: time and the log of time. We also allowed level-1 variation to change 
linearly with time, to take into account varying measurement error in EDSS scores at 
different levels of disability. Thus the basic model is of the form: 
  yij  0  + u0i  + e1ij + ( 1  + u1i  + e2ij ) tij  + ( 2  + u2i ) log tij , 




where yij is the EDSS for individual i at occasion j and tij is the time since ABN eligibility 
(plus one year) for individual i at occasion j,   0 to 2 are coefficients, and the e and u are 
random variables (residuals).   As with the Markov model, non-MS death is not included in 
the model. 
4.6 We then included the binary covariate of age at onset of MS (as in the Markov model), 
allowing this to be associated with intercept, time and log of time. We assessed the normality 
of the residuals, and the fit of the model by comparing the actual and predicted EDSS values.  
All analyses were carried out using Stata software18, and all multilevel models estimated 
using the runmlwin command19.  Bootstrapping was used to derive 95% confidence intervals.  
4.7 
EDSS), conditional on their observed baseline EDSS20. When calculating the observed and 
natural history progression, we used the observed baseline EDSS as the comparator, for 
consistency with the Markov analysis. We assessed the sensitivity of our analysis to this 
assumption by also using the estimated EDSS as baseline as the comparator. This led to 
slightly higher estimates of and natural history progression but does not affect the 
estimated absolute treatment effect. See the web appendices to reference 8 for details.  
 
Comparative strengths and weaknesses of the models 
 
4.8   Validation work carried out as part of our year 6 analysis has been described 
elsewhere13,16,17,. The Markov model reproduces very accurately the disability progression n 
the BCMS dataset from which it was derived, both in terms of EDSS and utility.  It also 
allocated randomly to one of two subsets, one of which was used to estimate the parameters 
for the Markov model and the other to test the predictions of the model.  However, 
subsequent work with further random splits suggested that the model is not very sensitive in 
adjusting for changes in the baseline distribution of EDSS scores, ie the model tends to 
underpredict disability progression in patients with EDSS at baseline above the median in the 
BCMS dataset, and overpredict progression in patients with EDSS below the median. 
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4.9 We believe that this problem arises from the standard Markov assumption that the 
probability of a transition from one disease state to another is independent of time from 
baseline.  In practice, most of the transitions used to estimate transition probabilities from (for 
example) EDSS 5 in the BCMS dataset occur some years after baseline;  they may not be a 
good guide to the probability of a transition for a patient who is already at EDSS 5 at 
baseline.  In principle, the use of baseline covariates (eg age at onset, generally considered a 
good predictor of speed of disability progression) should help to adjust for this difference but 
it would appear that the adjustment is insufficient.  A possible way of overcoming this 
difficulty, by estimating and using different transition probabilities for different periods after 
baseline, is described in Appendix 7 below. 
 
4.10   In contrast, multi-level models are inherently sensitive to the characteristics of 
individual patients such as baseline EDSS  in fact, in the version of the model used for this 
study there is a linear relation between the predicted EDSS for an individual patient at any 
BCMS dataset.   As a result, the MLM performed well in an external validation, predicting 
disability progression in a dataset of patients from Cardiff, Wales on the basis of a model 
estimated from BCMS data16,17. 
 
4.11 Although in this study we believe that the MLM is likely to be more robust than the 
Markov model in modelling changes in the mean EDSS of the RSS population, the Markov 
model is superior in modelling the details of the EDSS distribution.  Partly because of the 
unusual (non-linear) nature of the scale, the EDSS distribution of typical patient populations 
tends to be bi-modal, with one mode at around EDSS 2-3 and another at EDSS 4.  The 
Markov model is quite successful in reproducing this bi-modal distribution, as the chart at 
figure A1 shows.  (In the MLM, all residuals are assumed to be normally distributed so the 
predicted distribution of patients at any time is normally distributed about its predicted mean 
value.)  Since changes in mean utility for populations of MS patients are highly sensitive to 
small changes in numbers at the extreme end of the distribution (EDSS 7 and upwards) this 
suggests that the results from the Markov model may be more robust than those of the MLM 
when considering results on the utility basis. 
 
4.12  Finally, it may be worth pointing out that the survival analysis described in Appendix 5 
uses, in effect, a third independent model, which adds weight to our view that we are seeing a 




Appendix 5:  Survival analysis (delay in median time to EDSS 6) 
 
5.1   One new analysis in this year 10 analysis was to estimate the impact of treatment on the 
median time to reach the clinically significant milestone of EDSS 6 (needing a stick to walk 
100 metres).  The endpoint chosen, in line with other analyses carried out using BCMS data, 
was the first occurrence of an EDSS score of 6 or over, confirmed by at least one subsequent 
 
 
5.2   Our objective was to compare the median time required to reach this endpoint between 
the BCMS dataset (untreated patients) and the RSS dataset (treated patients), adjusting for 
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differences in the baseline distribution between the two datasets.  Ethical constraints (lack of 
consent given for transfer of BCMS individual patient data to a third party) meant that we 
could not carry out a conventional analysis of the combined data and test directly for the 
significance of a co-efficient representing the effect of treatment.  Instead we used an indirect 
method of comparison.  We fitted parametric models of identical form to the two datasets 
(see table below), after first testing (in the BCMS data) that the hazard ratios for the baseline 
covariates in the parametric model were similar to those for a non-parametric Cox 
proportional hazards model.  The model chosen was a Weibull model with gender and 
baseline EDSS (stratified as EDSS 0 to 1.5, EDSS 2 to 3.5, EDSS 4 to 5.5, and EDSS 6/6.5) 
as covariates.  Adding age at onset as a further covariate did not significantly improve the 
model.   
 
Fitted parameters for Weibull model (in log form, standard errors in brackets) 
 
Parameter BCMS dataset  
(n = 836  ) 
RSS dataset  
(n = 4,310) 
k 0.327 (0.055) 0.315 (0.023) 
Component    
  Intercept (male, EDSS 0-1.5) 3.441 (0.167) 3.477 (0.090) 
  Female 0.076 (0.109) 0.227 (0.041) 
  EDSS 2 to 3.5 -1.011 (0.146) -0.709 (0.076) 
  EDSS 4 to 5.5 -1.648 (0.180) -1.434 (0.075) 
  EDSS 6 to 6.5 -1.723 (0.240) -1.411 (0.109) 
 
Cumulative proportion reaching endpoint by year x =  1  exp( - (x k ) 
 
5.3 For each subpopulation i (each combination of gender and stratified EDSS) in the BCMS 
Pi
BCMS
 (t),  ie the proportion of patients who have 
not yet reached the endpoint at or before time t.   We then calculated the weighted average 
survival curve 
 
 PBCMS (t) =  i   wi  Pi
BCMS
 (t)     (5) 
 
where the weights wi   represent the proportion of patients in subpopulation i  in the RSS 
dataset.   This weighted average curve thus represents the survival curve we would expect for 
an untreated population with the same baseline distribution as the RSS population (ie it 
 section of the main 
paper).  The median time to EDSS for this untreated population can be readily found from 
equation (5) by seeking the time t for which the survival proportion is exactly 50%.    The 
median time to EDSS 6 for the treated patients in the RSS population is found in an 
analogous way. 
 
5.4   Calculating the confidence intervals on these estimates is not straightforward, because of 
the possibility of correlation between the sampling errors in the estimated survival 
proportions for different subpopulations.   However, using the standard outputs from the 
statistical packages used we were able to estimate for each of the models the correlation 
parameters and be
stochastic simulation (50,000 replications) to estimate the 95% confidence intervals on the 
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weighted average survival functions, and hence on the estimated median times.   To calculate 
the 95% confidence intervals on the difference in median times (the delay in reaching EDSS 
6) we relied on the fact that the BCMS and RSS datasets refer to entirely different 
populations and therefore there will be no correlation between the respective sampling errors. 
 
Appendix 6:  Further detail on the sensitivity analyses, including the results from the 
-  
 
6.1 The sensitivity analyses for this final year 10 analysis, like those we carried out at year 68, 
were intended to assess the possible impact of the most likely sources of bias, in particular 
resulting from missing values.  For the year 6 analysis, we were guided by some additional 
descriptive analyses of the RSS and BCMS data which showed where bias was most likely to 
occur (see ref 8, in particular online appendices 6 and 7; see also appendix 7 below).  A 
number of the analyses carried out at year 6 which showed only a very small impact on the 
outcomes were omitted in the year 10 analysis. 
 
6.2 The main addition at year 10 wa -
analysis described in appendix 5 above; a further motivation was that the model used for our 
primary analysis replicates very accurately changes over time in mean EDSS and mean utility 
in the BCMS dataset as a whole, but tends to underestimate disability progression in patients 
with low EDSS at baseline and overestimate disability progression in patients with high 
EDSS. We thought it would be of interest to examine the impact of using this model on our 
primary analysis, and on the main subgroup analyses, although this had not been pre-
specified in our analysis plan. 
 
6.3 In the Jackson method for estimating Markov models14 the basic unit of analysis is the 
initial and final EDSS measurements, and any relevant baseline covariates.  It is therefore 
straightforward to separate those transitions starting 0-2 years, 2-4 years, 4-
baseline, and to estimate the matrix of transition probabilities separately for each interval.  
For the BCMS dataset, the number of available transitions decreases with time from baseline 
so we pragmatically chose to focus on a model with just two time intervals, 0-2 years after 
baseline and over 2 years after baseline.  The respective transition matrices were estimated in 
exactly the same way as for the model used in our primary analysis. 
 
6.4 Validation of this time-variant model showed that it was superior to the original model in 
replicating disability progression in patients starting at individual EDSS levels, and nearly as 
good in replicating mean disability progression in the BCMS dataset as a whole.    
 
6.5  Applying the time-variant model to the primary RSS population, we found significantly 
larger estimates of treatment effects in terms both of EDSS (relative rate of disability 
progression 76% (CIs 74%,79%) vs 93% (90%,96%) for the original model) and utility 
(relative rate of utility progression 64% (CIs 61%,66%) vs 76% (73%,79%) for the original 
model). 
 
6.6 Using the time-variant model in conjunction with the sub-group analysis by initial EDSS 
also resulted in changes in the absolute estimates, though not in the qualitative conclusion 
that the treatment effect is largest for patients starting at low EDSS: 
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Baseline EDSS Relative EDSS progression: Relative utility progression: 
 Time-variant 
model 
Original model Time-variant 
model 
Original model 


























Appendix 7:   Potential bias due to differential patterns of data collection between the 
BCMS and RSS datasets 
 
7.1 We paid considerable attention to the possibility of bias resulting from different patterns 
of data collection in the RSS cohort as compared to the BCMS dataset used to estimate the 
parameters for the Markov and multi-level models. 
7.2   In the RSS cohort, we have observed a tendency for patients with worse disease 
progression to fail to attend at subsequent annual reviews, probably because there is little 
incentive for a patient to attend a review if they have already decided to discontinue DMT 
treatment.  This tendency was already noticeable in the year 2 analysis21 and was confirmed 
by the descriptive analyses carried out as part of the year 6 analysis.  We have attempted to 
quantify the potential impact of this differential loss to follow up through the various 
imputation methods described in the main paper. 
7.3   The BCMS dataset was not collected as part of a specific observational study but 
through routine clinic visits.  During the period in which the data used in this study was 
collected (1980-1995) effective disease modifying treatments were not available.  Patterns of 
data collection could therefore be different from those in the RSS. 
7.4  The Table below shows the results of a descriptive analysis of patterns of follow up  
from the BCMS dataset.   It compares baseline parameters and mean EDSS progression over 
the first 5 years from baseline for two pairs of subsets of the total cohort: 
a. patients contributing relatively frequent vs relatively infrequent data, where 
between first and last scores; 
b. patients who had a recorded EDSS score either after or within 18 months of the 











Not lost Lost 
Number  (%) 449 (50) 449 (50) 649 (72.3) 249 (27.7) 
% female 72% 77% 76% 71% 
Age at baseline (eligibility) 37.3 37.0 36.6 38.8 
Age at onset  28.9 29.6 28.4 31.4 
MSSS score at baseline 4.21 3.61 3.74 4.35 
EDSS at baseline 2.67 2.20 2.35 2.66 
Number with year 5 data 229 144 289 84 












Frequency = number of EDSS scores divided by interval between first and last scores 
Lost to follow-up = no EDSS score after or within 18 months of cut-off date (31.12.1995 
 
7.5   The first comparison shows that patients with relatively frequent EDSS scores tended to 
have worse prognostic factors at baseline and worse disease progression in the first five 
years.  (British Columbia clinicians have confirmed that, in their experience, patients in the 
province were more likely to attend clinic if they had concerns over the progress of their 
disease.) Since the patients with faster disease progression are contributing more EDSS 
scores to the estimation process, there is at least a theoretical possibility that they could bias 
the estimates in the Markov model towards predicting higher rates of disease progression for 
untreated patients, and thus inflate the apparent treatment effect when compared with the 
actual rates of disease progression in the treated RSS cohort.  (In the MLM, this bias may not 
 of data being missing 
depends only on parameters explicitly included in the model.) 
7.6  In contrast, the second comparison suggests that patients with relatively fast disease 
-
thus contribute less data at longer periods from baseline.  This would be expected to bias the 
estimates towards predicting lower rates of disease progression and would tend to offset any 
bias resulting from the similar differential loss to follow-up in the RSS dataset. 
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7.7  To help quantify the possible impact of the first factor, we used the MLM to impute 
additional EDSS scores for patients in the BCMS dataset with relatively sparse follow-up, 
which we defined as any patients with a gap of more than 2 years between successive values 
(this used an identical BCMS dataset as used for the continuous Markov model). This would 
be expected to increase the weighting for patients with relatively slowly progressing disease 
and thus to compensate for the expected bias.  We then re-estimated the transition 
probabilities for the Markov model using the same method as for the primary analysis. The 
result of this calculation, in contrast to our initial expectation, was to increase the mean rate 
of disease progression predicted for the untreated RSS cohort and thus to increase the 
estimated treatment effect (eg absolute treatment effect on the EDSS basis 0.28 (95% CIs 
0.23, 0.34) compared with 0.12 (0.07, 0.17) for the primary analysis). For further results see 
table 2 and supp table 4  please note that these results are only available for the Markov 
model.   
7.8  Our tentative conclusion is that, if the differential patterns of attendance at clinics in the 
BCMS cohort compared to the RSS cohort are responsible for any bias in our estimates of the 
treatment effect, it is at most very small.    
 
 




8.1 The results of the analysis described at appendix 3 (para 3.2) are shown in figure A2 
and summarised in the table below: 
 
Year Predicted EDSS 
progression using 
model fitted to 




model fitted to RSS 
 
Difference 
0 0 0 0 
2 0.33 (0.30, 0.36) 0.64 (0.63, 0.64) 0.30 (0.27, 0.33) 
4 0.69 (0.65, 0.72) 1.16 (1.16, 1.17) 0.48 (0.44, 0.51) 
6 1.04 (1.00, 1.08) 1.60 (1.59, 1.61) 0.56 (0.52, 0.60) 
8 1.39 (1.35, 1.44) 1.99 (1.99, 2.00) 0.60 (0.56, 0.65) 
10 1.75 (1.69, 1.80) 2.36 (2.35, 2.37) 0.62 (0.56, 0.67) 
 
There is a strong divergence of the two predictions in the first two years from baseline, 
suggestive of a strong initial treatment effect.  After that the lines continue to diverge, but at a 
progressively slower rate, and between years 8 and 10 the two lines are almost parallel, 
suggesting that by this point the treatment effect is greatly attenuatedb. 
 
Markov model:  time-varying hazard ratios 
 
8.1 
3.3) are shown in figure A3.  The general picture is of a strong treatment effect in years 0-2 
                                                 
b One should not over-interpret these results because EDSS is not intended to be an ordinal scale and changes in 
mean EDSS at different points of the scale may not be equivalent. 
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(low hazard ratio) and then a rather smaller treatment effect for the remaining years, with 
probably little consistent variation between 2-year periodsc.    
 
Markov model  direct estimation of a model using RSS data 
 
8.5 The methods described in para 3.4 of appendix 3 were used to derive a parsimonious 
model with different hazard ratios for transitions starting at different EDSS values and at 
different times from baseline. The resulting best model had the following parameters: 
 
Transition Hazard ratios for: 
 
Year 0-1 Years 1-9 
Forward transitions starting at:   
EDSS 0  1 1 
EDSS 1 to 6.5 0.67 0.59 
EDSS 7 and above 1 1 
Backward transitions starting at:   
EDSS 1 to 6.5 0.91 0.50 
EDSS 7 and above 1 1 
 
In year 1, forward transitions starting from EDSS 1-6 are retarded while backward transitions 
are hardly affected, resulting in a significant net reduction in the rate of disability 
progression.  In the following years, both forward and backward transitions appear to be 
retarded.  This could be interpreted as implying that the DMTs are reducing the variability in 
the disease process  or simply that what we have been interpreting as changes in the 
om 
concealed relapses, whose frequency is reduced as a result of the DMTs.  There is still a 
reduction in the net rate of disability progression in years 2 onwards, because forward 
transitions are more frequent than backward transitions, but this net benefit from treatment is 
smaller than in year 1. 
 
8.6 Repeating the analysis with the time-variant model described in appendix 6 (ie with 
different transition matrices for year 0 and for year 1 and following years) the estimated 
parameters were: 
 
                                                 
c At face value, the non-parametric estimates imply that the treatment effect for years 9-10 is stronger than in the 
three previous 2-year periods.  Fitting a quadratic function to describe the hazard ratios from year 3 onwards 
gave a parameter for quadratic term, representing the downwards curvature seen in figure A2, which was just 
significant at a 95% threshold (p =0.047).  However, it seems likely that this is a spurious result.  Firstly, we 
cannot imagine any plausible biological mechanism to explain why the treatment effect should diminish and 




Transition Hazard ratios for: 
 
Year 0-1 Years 1-9 
Forward transitions starting at:   
EDSS 0  1 1 
EDSS 1 to 6.5 0.71 0.77 
EDSS 7 and above 1 1 
Backward transitions starting at:   
EDSS 1 to 6.5 1.72 0.83 
EDSS 7 and above 1 1 
 
The average log likelihood was - 0.991 compared with  0.996 for the simple model, ie using 
a different transition matrix for year 1 marginally improves the fit to the data.  In this 
analysis, treatment with a DMT increases the probability of a backward transition (disease 
improvement) in the first year after initiation of treatment. Otherwise the interpretation of 




8.7  All three sets of results are consistent with the hypothesis that there is a strong initial 
treatment effect, followed by a period in which patient disability in treated patients increases, 
but at a rather slower rate than for untreated patients.  To examine this further, we carried out 
a further unplanned sensitivity analysis comparing actual and expected disability progression 
(para 29) this showed a smaller treatment effect than the primary analysis after adjusting for 
the shorter period of follow-up, especially on the EDSS basis (for instance the relative EDSS 
progression on the MLM is 77% (CIs 74%, 79%) with a year 1 baseline compared to 72% 
(69%, 74%) for the primary analysis).  There is however still a substantial treatment effect on 
all measures after year 1  see table 2 and supp table 4 for the details.  This observation is, 
incidentally, further evidence that the observed treatment effect which we report on this paper 
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Figure A2:  Variation of treatment effect with time - projected EDSS progression 
applying the multilevel model first to the RSS cohort and then to the untreated 
comparator control group  
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Figure A3:  Variation of implied hazard ratios with time using the Markov model, for 
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Abstract.
Background: Within Parkinson’s there is a spectrum of clinical features at presentation which may represent sub-types of the
disease. However there is no widely accepted consensus of how best to group patients.
Objective: Use a data-driven approach to unravel any heterogeneity in the Parkinson’s phenotype in a well-characterised,
population-based incidence cohort.
Methods: 769 consecutive patients, with mean disease duration of 1.3 years, were assessed using a broad range of motor,
cognitive and non-motor metrics. Multiple imputation was carried out using the chained equations approach to deal with missing
data. We used an exploratory and then a confirmatory factor analysis to determine suitable domains to include within our cluster
analysis. K-means cluster analysis of the factor scores and all the variables not loading into a factor was used to determine
phenotypic subgroups.
Results: Our factor analysis found three important factors that were characterised by: psychological well-being features; non-
tremor motor features, such as posture and rigidity; and cognitive features. Our subsequent five cluster model identified groups
characterised by (1) mild motor and non-motor disease (25.4%), (2) poor posture and cognition (23.3%), (3) severe tremor
(20.8%), (4) poor psychological well-being, RBD and sleep (18.9%), and (5) severe motor and non-motor disease with poor
psychological well-being (11.7%).
Conclusion: Our approach identified several Parkinson’s phenotypic sub-groups driven by largely dopaminergic-resistant fea-
tures (RBD, impaired cognition and posture, poor psychological well-being) that, in addition to dopaminergic-responsive motor
features may be important for studying the aetiology, progression, and medication response of early Parkinson’s.
Keywords: Parkinson’s disease, Cohort studies, cluster analysis, factor analysis
INTRODUCTION
Parkinson’s disease (PD) is a common neurode-
generative condition encompassing both motor and
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rology, Level 3, West Wing, John Radcliffe Hospital, Headley Way,
Headington, Oxford OX3 9DU, UK. Tel.: +44 01865 234337; Fax:
+44 01865 234837; E-mail: michele.hu@ndcn.ox.ac.uk.
non-motor symptoms. Even within pathologically
defined patient cohorts, there remains a spectrum of
clinical features, treatment response and prognosis [1].
These differences in clinical phenotype may represent
different PD subtypes, but there is no widely accepted
consensus on the criteria for such groups. Clinically
accurate sub-typingmay result in improved delineation
of aetiological mechanisms, better prognostic coun-
selling, and improved targeting of disease modifying
therapies.
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Attempts to sub-classify PD include “top-down”
approaches which depend on an a priori assumption,
such as the division of subjects bymotor phenotype and
age of onset [2, 3]. Unfortunately, this approach relies
on accurate clinical observation to recognise patterns
from all available variables, which is difficult given
the breadth of clinical features. Recently, attempts at
subtyping have employed data-driven, “bottom-up”
approaches, allowing unexpected patterns or discrim-
inating features to be determined [4]. Outcomes of the
group characteristics depend heavily on the breadth
and depth of the variables inputted into the models.
In this study, we have used an approach with key
methodological refinements including: 1) restriction to
incident patients, to avoid the confounding effects of
disease duration, with a far broader range of motor
and non-motor assessments than most previously pub-
lished studies 2) using factor analysis methods to
reduce the large number of motor/non-motor variables
into a smaller number of clinically important domains
describing patient variability 3) using k-means cluster
analysis with the inclusion of additional clinical fea-
tures that may have not been already captured by the
factor analysis.
MATERIALS AND METHODS
Patient selection with inclusion/exclusion criteria
PDpatients diagnosedwithin the past 3.5 years were
prospectively recruited as part of the Oxford Parkin-
son’s Disease Centre (OPDC) cohort study from 11
hospitals across the Thames Valley covering a pop-
ulation of approximately 2.1 million (PD-Discovery,
website: http://opdc.medsci.ox.ac.uk). Full details of
this cohort are described elsewhere, [5] with partic-
ipants being recruited between September 2010 and
September 2014.
Patients were eligible for study inclusion if they
met the UK Parkinson’s Disease Society Brain Bank
(UKPDBB) criteria for the diagnosis of idiopathic PD,
as judged by a neurologist, with no atypical features to
suggest an alternative diagnosis following systematic
clinic assessment derived from theNIHPD-DOCstudy
questionnaire (http://grants.nih.gov/grants/guide/rfa-
files/RFA-NS-11-001.html). Patients with secondary
parkinsonism due to head trauma or medication
use, or features of atypical parkinsonism syndromes,
such as multiple system atrophy, progressive supra
nuclear palsy, corticobasal degeneration, dementia
with Lewy bodies, or with significant documented
postural BP drop on standardised measurement or
significant urinary symptoms were excluded. Each
patient was assigned a percentage probability that they
metUKPDBBcriteria for PD diagnosis by the research
neurologist following the study visit. Date of symp-
tom onset was recorded as the date the patient or
their carer first became aware of motoric symptoms
in relation to their PD, even if occurring on a mild or
intermittent basis without initial obvious progression;
for example hand tremor, reduced manual dexterity
or arm swing. Date of diagnosis was recorded as the
date the patient was first given a diagnosis of PD
by their hospital specialist (neurologist or geratolo-
gist), with the subsequent delay frommotoric symptom
onset to diagnosis, and delay from date of diagnosis to
first (baseline) research clinic visit calculated. Disease
duration from motoric symptom onset to date of first
(baseline) research clinic visit was also calculated.
Patient evaluation
A full description of the tests and assessments used
to assess the Discovery cohort has been published
[5, 6]. Assessments were done by the patient com-
pleting self-evaluating questionnaires at home and a
clinic consultation conducted by a trained neurologist
and a nurse. Where patients were taking dopaminer-
gic medications, the assessment was carried out in
the clinically-defined on-state. Medication use was
recorded allowing the calculation of the levodopa
equivalent daily dose (LEDD) [7]. Patient response
to antiparkinson therapy was assessed using the
physician-rated Clinical Global Impression of Change
Scale (CGI-C) [8]. Included in the cluster analysis
were: theMovement Disorders Society (MDS) revised
Unified Parkinson’s Disease Rating Scale (UPDRS
part I and part III); ‘Sniffin’ Sticks 16-item odour iden-
tification test; Big Five Inventory – extraversion scale;
Epworth Sleepiness Scale; REMSleep Behaviour Dis-
order Screening Questionnaire; Leeds Anxiety and
Depression Scale (LADS); Becks Depression Inven-
tory (BDI); Questionnaire for Impulsive-Compulsive
Disorders in Parkinson’s Disease; Honolulu Asia
Aging Study Constipation Questionnaire; Montreal
Cognitive Assessment; Phonemic and Semantic ver-
bal fluency; Purdue Peg-board Test; the timed Get Up
and Go test; Flamingo test; Orthostatic blood pres-
sure measurement. We explicitly did not include age
at onset as this is a demographic variable rather than
a feature of PD. Age at onset could influence the phe-
nomenologyofPD through twomechanisms: (a) itmay
confound phenotypic variability due to age-related
comorbidity so older patients will have worse motor
M. Lawton et al. / Parkinson’s Phenotype 271
function unrelated to their PD and/or (b) it may be a
proxy marker for different pathophysiological mech-
anisms which in turn alter the presenting features of
PD. Adjusting for age would be helpful for the former
but harmful for the latter as it would reduce the like-
lihood of identifying different sub-groups. Given the
exploratory nature of the analysis, we therefore chose
to see how any sub-types related to age in our analyses.
Standard protocol approvals, registrations, and
patient consents
The study was undertaken with the understanding
and written informed consent of each subject, with the
approval of the local NHS ethics committee, and in
compliance with national legislation and the Declara-
tion of Helsinki.
Analysis dataset
Analysis was restricted to patients who were diag-
nosed within the previous 3.5 years and had a
high probability of idiopathic PD (≥90% clinician-
determined) following careful, structured neurological
assessment.Where available,we used the latest follow-
up visit to determine the likelihood of PD (n= 538,
58.2% seen after 18 and n= 170, 18.4% seen after 36
months).
Dealing with missing data
Where questionnaire data were partially completed
we used the mean score if 80% or more questions
were answered within a questionnaire. We then car-
ried outmultiple imputation using the chained equation
approach to create 10 imputed datasets.
Determining variables to include within the
cluster analysis
Our first step was to carry out an exploratory factor
analysis (EFA) within each imputed dataset. We deter-
mined the number of important factors, only retaining
those with an eigenvalue >1. A promax (oblique)
rotation was used and only variables with a loading
modulus of ≥0.4 were deemed sufficiently important
to carry over to the second step.
The second step involved a confirmatory factor anal-
ysis (CFA) using the multiply imputed data given the
results from the EFA and examining the following
goodness of fit statistics: Comparative Fit Index (CFI),
Tucker-Lewis Index (TLI) and the Root Mean Square
Error of Approximation (RMSEA). A model was con-
sidered to fit the datawell if CFIwas≥0.90, TLI≥0.90
and RMSEA ≤0.06 [9]. We estimated factor scores
for each individual from our CFA within each imputed
dataset. At this stage we also considered other clini-
cally important variables for the cluster analysis that
were not found to load in any of our factors. Factor
scores and other clinically important variables were
combined using Rubin’s rules [10] to construct a single
dataset for carrying out the cluster analysis.
Cluster analysis
We then examined if any variables which did not
load on the factor analysis had value in identifying sub-
groups by standardising them, so that they had equal
weighting within the k-means cluster analysis and test-
ing their inclusion in the cluster analysis. Ordered
categorical and binary variables were weighted using
the rules set out by Hennig et al. [11]. To determine the
optimumnumber of clusterswecarriedout hierarchical
clustering using the Ward algorithm [12] calculating
the Calinski/Harabasz pseudo-F index [13] and the
Duda/Hart pseudo-T-squared [14]. A higher value of
Calinski/Harabasz pseudo-F index and a smaller value
of the Duda/Hart pseudo-T squared indicate more dis-
tinct clustering. We considered models with between
2 to 5 clusters.
We then carried out k-means cluster analysis
using the optimumnumber of clusters determined from
the hierarchical analysis. To ensure convergence to
the global maximum, we fitted the model using 500
random starts, and estimated the Calinski/Harabasz
pseudo-F index stopping rule [13] to determine the
optimal solution.
To test the utility of the sub-group classification, we
examined the associations between the clusters with
variables not included within the factor/cluster analy-
sis, such as age at onset, time since diagnosis, and time
since symptom onset, response to medication using
the CGI-C, LEDD and the number of untreated indi-
viduals. We also examined the association between
cluster membership and classification of PD patients
into tremor dominant or postural instability/gait diffi-
culty (PIGD), popularised by Jankovic [2] and updated
by Stebbins et al. [15] for the MDS UPDRS.
To further test the reliability of the cluster solu-
tions we applied a cross-validation approach where the
data was randomly split into halves five times and the
k-means cluster analysis repeated separately on each
half. The number of individuals classified into the cor-
rect clusterwas then determined.Hair et al. suggest that
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Fig. 1. Flow chart of patient entry into study.
a very stable cluster solutionwould lead to >90%being
correctly classified, a stable cluster solution 80–90%
being correctly classified and a somewhat stable cluster
solution 75–80% being correctly classified [12].
Computing
STATA version 13 was used to carry out the mul-
tiple imputation, Exploratory Factor Analysis (EFA)
and the k-means cluster analysis. The Confirmatory
Factor Analysis (CFA) and estimation of factor scores
was carried out within Mplus.
RESULTS
At the time of this analysis, OPDC had recruited
924 patients (see Fig. 1) but we excluded 154 sub-
jects either because of disease duration (41), they had
a prior PD probability of <90% clinically (112), or
because of a concomitant neurological disorder lead-
ing to significant disability in addition to PD, such
that assessment of motor function was invalid (1). One
individual was subsequently found to be a duplicate
and was dropped from the cluster analysis. This left
769 subjects (age of onset 64.8 years) for the analysis.
The baseline characteristics are presented in Table 1.
12.7% of patients were untreated and the mean MDS-
UPDRS part III was 26.3. The variables included in
our factor analysis had between 0.3%–7.8% missing
values.
Exploratory factor analysis (EFA)
We included 34 variables measuring motor and non-
motor domains within our EFA. MDS-UPDRS part III
was split into four domains (rigidity, bradykinesia, pos-
tural, and tremor) to enable better discrimination. We
also included the part III question related to speech.
Laterality of symptoms was derived from the differ-
ence in responses between corresponding questions
related to the right- and left-side from theMDSUPDRS
part III (see Supplementary Table 1 for more detail on
how each variable was derived).
Within each imputed datasetwe found four factors to
have an eigenvalue greater than 1. The first factor was
a mixture of variables measuring non-motor features
mostly related to psychological well-being: LADS,
BDI, QUIP, BFI neuroticism and apathy, fatigue and
pain domains from MDS-UPDRS. The second factor
captured motor features either from the MDS UPDRS
(rigidity, bradykinesia, postural, speech) or quantified
motor performance (‘Get up and Go’ test, the flamingo
test and Purdue pegboard test). The third factor
Table 1
Basic baseline descriptives of patients
Variable Observed N Mean (sd; range) or n (%)
Female 769 261 (33.9%)
Ethnicity (non-white) 764 11 (1.4%)
Age onset (years) 765 64.77 (9.74; 28.17–87.45)
Disease duration from onset (years) 765 2.92 (1.86; 0.16–13.90)
Disease duration from diagnosis (years) 765 1.32 (0.96; 0.01–3.50)
Delay from first motoric symptom onset to diagnosis (years) 762 1.61 (1.64; 0–13.5)
MDS-UPDRS part Ia 759 8.62 (5.16; 0–33)
MDS-UPDRS part IIa 763 8.67 (6.13; 0–35)
MDS-UPDRS part IIIa 768 26.33 (11.00; 5–77)
MDS-UPDRS part IVa 767 0.26 (0.97; 0–11)
MDS-UPDRS total (parts I+II+III+IV)a 758 43.87 (17.85; 7–123)
MOCA (adjusted for education years)a 764 24.98 (3.36; 13–30)
Untreated 766 97 (12.7%)
Levodopa equivalent daily dose (mg) 762 284.38 (212.83; 0–1267.5)
Hoehn and Yahr: median (IQRb); mean (range) 768 2 (2-2); 1.84 (1–3)
aChanged denominator where 80% or more of questions were answered. bInter-quartile range. Motor assessments (UPDRS and Hoehn and
Yahr) were rated in the clinically-defined ‘on medication’ state for treated PD patients.
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Table 2
Confirmatory factor analysis standardised factor loadings of vari-
ables selected from exploratory factor analysis















Purdue peg board −0.662










CFI =Comparative Fit Index, TLI =Tucker-Lewis Index, and
RMSEA=Root Mean Square Error of Approximation. CFI, TLI
and RMSEA are all measures of model fit.
captured cognition (MOCA,MMSEandphenomic and
semantic fluency). A fourth factor captured constipa-
tion (from the UPDRS part I constipation question
andHonoluluAsiaAging Study constipation question-
naire).
Confirmatory factor analysis (CFA)
Our EFA found very consistent results between the
imputed datasets. For the CFA we could not estimate
a constipation factor since a factor with only two vari-
ables is not identifiable. Our CFA of the remaining
three factors fell slightly short of our pre-defined good-
ness of fit criteria with a CFI of 0.79, TLI of 0.88, and a
RMSEA of 0.082. It is likely that our poor goodness of
fit is due to the large number of variables in the first two
factors [16] and our sample size [12]. However since
we are only interested in calculating factor scores and
not testing the validity of our structural model we kept
the CFA as defined.We named factor 1, “psychological
well-being”, factor 2, “non-tremor motor” and factor
3, “cognitive” (Table 2). Within each factor, variable
loadings varied from 0.35 to 0.85, 0.43 to 0.76, and
0.59 to 0.78 respectively.
The factor analysis did not capture a number of clin-
ical features probably since they were not significantly
correlated with any of the other variables in the anal-
ysis. Hence we decided to include any variable in our
cluster analysis that was not loading into one of our
factors. We did however exclude the other four BFI
variables (since no other previous cluster analysis has
looked at these personality traits) and the UPDRS con-
stipation variable (since the other constipation variable
was measuring the same trait) for the sake of parsi-
mony.
Hierarchical and K-means cluster analysis
Supplementary Table 2 shows the statistics used to
determine the optimum number of clusters from the
hierarchical cluster analysis fitted using theWard algo-
rithm. Different conclusions on the optimum number
of clusters would be drawn from different statistics.
The Calinski/Harabasz pseudo-F index favoured a two
cluster solution, and the Duda/Hart pseudo-T-squared
a five cluster solution. This highlights the need for
substantial researcher judgement on determining the
optimum number of clusters and also the exploratory
nature of cluster analysis. Because the two cluster
solution appeared to discriminate patients mainly on
disease severity with a poor and good group (Sup-
plementary Figure 1), we chose to go forward with
the exploratory five cluster solution as more help-
ful in describing the clinical heterogeneity between
patients. Figure 2 shows the means values of each of
the standardised variables within each cluster, all vari-
ables were coded such that positive indicates worse
and negative better than average score. For the later-
ality variable positive is more bilateral than average
and negative more unilateral than average. The groups
were ordered in terms of size with the largest as the
first. Table 3 shows the association between the clus-
ters and ten variables not included within the factor
analysis. There was moderate evidence of a difference
in the mean duration of disease between clusters how-
ever in absolute terms the difference was negligible
and hence we are confident these clusters are not an
artefact of disease duration.
Patients in group 1 (25.4%) showed a milder form
of PD and they also had a lower than average age
at onset, a higher proportion of females, more drug
naïve individuals and a lower LEDD. The second
group (23.3%) comprised of individuals with worse
than average non-tremor motor symptoms, cognitive
features, smell, postural hypotension and with bilat-
eral disease. They also had a higher than average age
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Fig. 2. Within cluster means of the standardised variables for the 5 cluster solution. Positive is worse than average and negative better than
average. For laterality positive is more bilateral than average and negative more unilateral than average.
Table 3
Association of clusters with variables not included within the cluster analysis, along with a p-value derived from a hypothesis test that the
variable is equally distributed (i.e. same mean or same proportion) amongst the five clusters. Note that these variables were derived from the
complete case and there was some missingness associated with these variables
Variable (Hypothesis test statistic; p-value) Total Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
(N= 769) (N= 195, (N= 179, (N= 160, (N= 145, (N= 90,
25.4%) 23.3%) 20.8%) 18.9%) 11.7%)
Femalea (12.1; p= 0.0166) 261 (33.9%) 82 (42.1%) 45 (25.1%) 56 (35.0%) 49 (33.8%) 29 (32.2%)
Disease duration from onsetb (2.5; p= 0.0423) 2.9 (1.9) 2.7 (1.6) 2.8 (1.7) 3.0 (1.9) 3.1 (2.0) 3.3 (2.2)
Disease duration from diagnosisb (3.7; p= 0.0052) 1.3 (1.0) 1.1 (0.9) 1.4 (1.0) 1.3 (1.0) 1.5 (1.0) 1.4 (0.9)
Age onsetb (30.0; p< 0.0001) 64.8 (9.7) 61.8 (8.7) 70.4 (7.7) 64.2 (9.7) 61.0 (9.3) 67.1 (10.8)
Age onset <50a (18.6; p= 0.0009) 60 (7.8%) 20 (10.3%) 3 (1.7%) 16 (10.0%) 18 (12.5%) 3 (3.4%)
UPDRS motor phenotypea (104; p< 0.0001)
Tremor dominant 407 (53.8%) 118 (61.5%) 65 (37.1%) 132 (83.5%) 58 (40.6%) 34 (38.6%)
Indeterminate 95 (12.6%) 22 (11.5%) 24 (13.7%) 12 (7.6%) 25 (17.5%) 12 (13.6%)
Postural instability gait difficulty 254 (33.6%) 52 (27.1%) 86 (49.1%) 14 (8.9%) 60 (42.0%) 42 (47.7%)
[Clinician global impression of change (CGI-C)]a
(35.4; p= 0.0004)
Much or very much improved 354 (48.7%) 83 (46.1%) 96 (55.5%) 59 (39.6%) 77 (55.8%) 39 (44.8%)
Minimally improved 188 (25.9%) 49 (27.2%) 42 (24.3%) 34 (22.8%) 34 (24.6%) 29 (33.3%)
No change to much worse 124 (17.1%) 25 (13.9%) 29 (16.8%) 34 (22.8%) 19 (13.8%) 17 (19.5%)
No medication tried 61 (8.4%) 23 (12.8%) 6 (3.5%) 22 (14.8%) 8 (5.8%) 2 (2.3%)
Drug naı́vea (21.7; p= 0.0002) 97 (12.7%) 37 (19.1%) 14 (7.8%) 29 (18.2%) 11 (7.6%) 6 (6.7%)
LEDD totalb (11.3; p< 0.0001) 284.4 (212.8) 229.1 (191.8) 314.8 (186.5) 236.4 (214.8) 357.5 (251.1) 310.2 (185.7)
LEDD total on medicationbc (6.0; p= 0.0001) 328.8 (194.3) 287.5 (171.3) 341.7 (168.9) 295.9 (200.2) 387.1 (238.2) 336.7 (168.6)
aChi-squared test. bAnova. cThe LEDD restricted to those who are taking dopaminergic medication.
M. Lawton et al. / Parkinson’s Phenotype 275
at onset and a lower proportion of females. Within
this cluster over 49% were classified as PIGD, which
was larger than the average proportion (34%). This
cluster had higher than average LEDD and a higher
proportion who responded well to therapy. The third
group (20.8%) had patients with worse than average
tremor scores but whowere better than average inmost
of the other domains and with very unilateral disease.
These individuals had similar average age at onset to
the overall population and 84% of this cluster was
classified as tremor dominant compared to 54% in the
entire study population. This cluster had larger propor-
tion of untreated individuals than the study population
(18% versus 13%), and a lower than average LEDD.
This cluster also had a lower proportionwho responded
well to PD therapy. The fourth group (18.9%) were
marked by poor psychological well-being, RBD, and
sleep problems. They also seemed to have better motor
function, cognitive and postural hypotension than aver-
age with a lower than average age at onset, responded
well to medication and were also on a higher than
average LEDD. The fifth and smallest group (11.7%)
were worse than average on almost all of the domains
(except smell), showing a more severe form of PD.
This group showed very severe psychological well-
being which could be a secondary response to their
fast progression or part of the clinical endophenotype.
Within this cluster about 48%were classified as PIGD,
very few individuals were untreated and they had a
higher than average LEDD. The equivalent analysis
for the two cluster solution is shown in Supplemen-
tary Table 3 for comparison. Supplementary Figure 2
shows the association between the UPDRS phenotype
and the 5 cluster solution. It is interesting that although
the third cluster is almost completely tremor dominant
this cluster only includes about 32% of all the tremor
dominant individuals. This highlights the differences
in these approaches, that tremor dominant individu-
als have relatively more tremor problems compared to
PIGD problems but do not necessarily have worse than
average tremor.
Please note that the binary variable, hallucinations,
and the categorical variables, urinary and constipation,
have been scaled in a way so that they have equal
weighting in the k-means cluster analysis when com-
pared to the more continuous variables. However this
does not mean that the distance of the within cluster
means from the population average for these three vari-
ables can be interpreted in the same way as the other
variables. Instead they should be considered relative to
the other clusters. For instance the severity of urinary
symptoms in the fifth cluster is worse that the sever-
ity in the fourth cluster. However we cannot be certain
whether the severity of urinary symptoms in the fifth
cluster is any less than the severity of sleepiness prob-
lems in the fifth cluster even though the within cluster
mean of sleepiness is further from the population aver-
age.
Supplementary Table 4 shows the stability of the five
cluster solution using our cross-validation approach.
On average 73.8% of individuals were correctly clas-
sifiedwhich is close to the borders of a somewhat stable
solution according to the Hair et al. criteria. The sta-
bility across the five split datasets was not consistent
ranging from stable (83.7% correctly classified) to an
unstable solution (64.5% correctly classified) so with-
out an external validation it is difficult to determine the
stability of our five cluster model. However the stabil-
ity of the two cluster solution in the cross-validation
is much better with on average 95.9% of individuals
being correctly classified (Supplementary Table 5), a
very stable solution which was consistent across the
five split datasets. The apparent stability of the 2 clus-
ter solution compared to the 5 cluster solution is not
particularly surprising since there are 1 compared to
4 ways of incorrectly classifying an individual in the
two and five cluster solutions respectively.
DISCUSSION
Our analyses suggest that there may be five sub-
groups of patients with recently diagnosed PD: 1) mild
motor and non-motor disease, 2) poor posture, gait,
cognition, smell and postural hypotension, 3) severe
tremor, 4) poor psychological well-being, RBD and
sleep, and 5) severe motor, non-motor and cognitive
disease, with poor psychological well-being. Our ini-
tial approach used a bottom-up data-driven approach
to group together individuals with similar symptoms
with little a priori assumptions. However, one limi-
tation of using a purely data-driven approach is that
the choice of variables and their breadth will partially
determine what factors are identified i.e. a badly mea-
sured domain, even though clinically important, will
appear statistically less informative than another for
which several scales have been included. We therefore
felt it important to supplement the factor analysis with
a second stage approach where we added nine other
domains that had not emerged from the factor analysis.
This combined approach has advantages over simply
using a priori assumptions about the importance of
UPDRS tremor and non-tremor sub-items in defining
such phenotypes [2].
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Depending on which statistical approach we chose,
we could have decided that the two cluster solutionwas
more appropriate. However this solution only seemed
to group people essentially as good or bad across a
range of disease severity measures (motor, non-motor,
psychological well-being and cognition- see Supple-
mentary Figure 1). The five cluster solution allowed for
disease severity measures to be preferentially affected,
for example group3) abovewho score poorly on tremor
motor measures with relative sparing of non-tremor
motor, cognitive and psychological well-being mea-
sures. This may be a more valid representation of the
PD disease spectrum encountered in routine clinical
practice. Interestingly, the five cluster solution might
be more clinically relevant as the two cluster solution
found no evidence of an association with drug respon-
siveness, (p= 0.13, see Supplementary Table 3) whilst
the five cluster solution did find strong evidence of
an association between cluster grouping and levodopa
response (p= 0.0004).
One caveat for this study is that levodopa respon-
sivenesswas assessed using the clinician-ratedClinical
Global Impression of Change Scale (CGI-C). This ret-
rospective questionnaire involves the clinician asking
the patient (and carer) about their overall impression
of motor response to previously trialled dopaminer-
gic medications. The CGI-C therefore, is likely to
be a less accurate measure of true levodopa response
when compared to formal levodopa challenge test-
ing for example. While we have performed this in a
patient subgroup, unfortunately overall numbers are
small due to practical purposes, and insufficient to
extend to the more general cluster model being pre-
sented here. Caveats aside, it is interesting to note
that cluster 2 (which resembles PIGD with impaired
postural and cognitive function) has a good CGI-C
medication response similar to cluster 4, despite these
subjects being older. One of the difficulties in inter-
preting these results is that this group also have the
fewest number of drug naïve patients, possibly because
their parkinsonian motor features are more severe and
disabling than those with tremor-dominant disease.
Hence this may be biasing the proportions in the CGI-
C results if we assume that drug naı̈ve would show
excellent response had they been treated. In addi-
tion this may also reflect a “ceiling effect” whereby
milder tremor-dominant patients despite showing drug
responsiveness can only improve to a more moderate
degree than those with more severe disease. Lastly,
cluster 2 has a higher LEDD so may have had the
opportunity to demonstrate a bigger drug response
compared to other clusters. The higher LEDDmay also
reflect the more severe motoric symptoms (bradyki-
nesia, rigidity, and gait imbalance) experienced by
this group, which are likely to be stronger deter-
minants of disability than tremor symptoms, hence
driving up the increased overall treatment doses.
Future work will focus on comparing the accuracy
of GCI-C versus formal levodopa challenge in assess-
ing medication response and predicting progression in
early PD.
At least two phenotypes defined in the current study,
namely 4) poor psychological well-being, RBD and
sleep and 5) severe motor, non-motor and cognitive
disease with poor psychological well-being, would
have been missed using conventional “top-down” PD
classification models. These findings are novel and
potentially of high clinical relevance, as they underline
the importance of early non-motor symptoms such as
RBD, anxiety, depression, apathy, pain and fatigue in
underpinning the disease heterogeneity seen in early
PD. To date, few studies using data-driven techniques
have assessed the baseline importance of non-motor
symptoms in such a large well-characterised inci-
dent PD cohort. This is particularly relevant given
the increasingly acknowledged importance of non-
motor symptoms over and above motor symptoms in
determining patient-related quality of life and subse-
quent decline [17]. Symptoms such as RBD, which
can manifest prior to the onset of motoric symptoms,
are characterised pathologically by involvement of the
locus coeruleus, subcoeruleus, pedunculopontine and
serotonergic raphe nuclei [18].
The co-existence in group 5 of significantly worse
scores in both motor and non-motor domains high-
lights the importance of the latter, and in particular
psychological well-being which may or may not be
secondary to a worse clinical evolution. This group
had poor scores across both subjective and objective
evaluations of motor, cognitive and other non-motor
domains, thus excluding the possibility that they sim-
ply reflect a poor perception of personal well-being,
which is a common occurrence in mood disorders such
as anxiety and depression. Although every effort was
made to exclude atypical Parkinsonism fromour analy-
sis, it is of course possible that a proportion of subjects
in group 5 do not have PD but rather an atypical parkin-
sonian disorder such as multiple system atrophy or
progressive supranuclear palsy. As we follow-up our
subjects over the next 10 years, wewill be able to deter-
mine if atypical features emerge in this subgroup and
ultimately post-mortem pathological diagnosis should
help clarify if they have a more rapidly progressive
form of PD or atypical Parkinsonism.
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Patients in group 4 scored particularly poorly on
RBDmeasures, however function on motor and cogni-
tive testing was good compared to other groups. This,
together with the fact that RBD is a prodromal fea-
ture, which may have a 15-year latency before the
emergence of motor symptoms [19] might suggest that
RBD is a risk but not a prognostic marker for sub-
sequent PD. Previous longitudinal studies have also
shown that concomitant RBD was not associated with
greater worsening of motor disability scores, cognition
or depression, in patients with PD [20–22].
It is uncertain whether the phenotypic features of
group 2, who are on averagemuch older, merely reflect
age-related co-morbidities such as poor posture, cog-
nition, smell, postural hypotension, or are a distinct
aetiological sub-group.
A recent study using principle component analysis
[23] in a prevalent PD cohort found that a compos-
ite score of predominantly nondopaminergic (PND)
features which are largely insensitive to dopaminergic
medication (postural instability, gait difficulty, cog-
nitive impairment, depressive symptoms, psychotic
symptoms, excessive daytime somnolence and auto-
nomic dysfunction) might provide a more accurate
evaluation of disease severity and progression in PD.
Our results support this finding and raise the important
issue of how best to select patients for future disease-
modifying or neuroprotective trials in PD.
If only certain sub-groups respond to a neuropro-
tective agent, existing trials are more likely to result
in a false negative result and future trials will need
far larger sample sizes to group according to baseline
phenotype with concomitant cost implications. It is
unclear as to whether the 12% of PD patients assigned
to group 5, who appear severe across a range of motor
and non-motor measures, should be selected as being
the most likely to benefit from future disease modify-
ing interventions, or might be least likely to benefit
due to more advanced pathophysiology. Phenotypic
differences seen across PD might therefore be a major
contributing factor to the current lack of a convincing
neuroprotective agent for this disease, despite multiple
drug trials in this field.
Our results are consistent with several studies apply-
ing cluster methodology in PD [24–33] that found a
milder disease group with a young age at onset, [25,
26, 28–33] a group with severe gait dysfunction and
cognitive impairment [24, 27] and a tremor dominant
group [28, 29, 31]. Most studies have found a rapid
disease progression group with an older age at onset
[25–32]. The relationship between cognitive function
and impairments in gait, posture and non-tremormotor
features in PD has been well documented in previ-
ous studies [34]. It seems that our finding of a group
which has poor RBD, psychological well-being and
sleepiness has not been found in previous studies, pos-
sibly because information about these features have not
always been collected.
Although we argue against including age at onset in
the cluster analysis we explored using it in our factor
and cluster analysis as some of the previous studies
have done [25, 27–29, 31, 32]. Including age at onset
in the factor analysis wouldmean it loading on the non-
tremormotor factor veryweakly and hencewould have
made little difference to our estimated factor scores. If
it was included at the cluster analysis stage we would
have qualitatively found five groups of similar phe-
nomenology.
These sub-groups have been derived from baseline
visits, hence are not confounded by disease dura-
tion. Future evaluation will determine whether patients
retain their initial clinical phenotype or whether
changing from one clinical phenotype to another is
an important marker of subsequent progression. We
are currently undertaking an independent replication
in collaboration with a second UK cohort (Track-
ing Parkinson’s Disease) which used a very similar
methodology (90% of variables are the same).
We cannot yet draw firm conclusions as to the
prognostic value of these clusters, but with further
follow-up we will determine whether this classifi-
cation is of greater value than existing approaches
which discriminate patients based on simpler base-
line measures. We will also test whether these clusters
have biological or clinical utility by comparing data
on genotypes, biomarkers, including neuroimaging as
well as responsiveness to drug therapy, and the onset
of clinically-meaningful end points, such as motor
fluctuations, dyskinesias, dementia, dependency or
institutionalisation and long-term mortality.
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[13] Caliński T, &Harabasz J (1974) A dendritemethod for cluster
analysis. Commun Stat Theory Methods, 3, 1-27.
[14] DudaRO,Hart PE,&StorkDG (2001)Pattern Classification,
Wiley, New York.
[15] Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK,
& Tilley BC (2013) How to identify tremor dominant and
postural instability/gait difficulty groups with the movement
disorder society unified Parkinson’s disease rating scale:
Comparison with the unified Parkinson’s disease rating scale.
Mov Disord, 28, 668-670.
[16] Kenny DA, & McCoach DB (2003) Effect of the number of
variables on measures of fit in structural equation modeling.
Struct Equ Modeling, 10, 333-351.
[17] Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, &
Chaudhuri K (2011) The impact of non-motor symptoms on
health-related quality of life of patients with Parkinson’s dis-
ease. Mov Disord, 26, 399-406.
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Supplementary Tables 
Supplementary Table 1. Detailed description of the variables included in the analysis 
and  
how they were derived and analysed. 
List of variables named 
 
Explanation 
UPDRS_apathy Categorical from UPDRS part I (question 1.5) 
UPDRS_hallucinations Binary from UPDRS part I (question 1.2) 
UPDRS_speech Categorical UPDRS part III question 3.1 
UPDRS_rigidity Continuous rigidity questions from UPDRS part III 
(mean score 3.3) 
UPDRS_bradykinesia Continuous bradykinesia questions from UPDRS part III 
(mean score 3.2,  3.4, 3.5, 3.6, 3.7, 3.8, 3.14) 
UPDRS_postural Continuous postural questions from UPDRS part III 
(mean score 3.9, 3.10, 3.11, 3.12, 3.13) 
UPDRS_tremor Continuous tremor questions from UPDRS part III (mean 
score 3.15, 3.16, 3.17, 3.18) 
UPDRS_laterality Continuous. Absolute value of right-left questions from 
UPDRS part III  
UPDRS_fatigue Categorical from UPDRS part I (question 1.13) 
UPDRS_pain Categorical from UPDRS part I (question 1.9) 
UPDRS_constipation Categorical from UPDRS part I (question 1.11) 
UPDRS_urinary Categorical from UPDRS part I (question 1.10) 
Sniffin Continuous 
MOCA Continuous  adjusted for education years 
MMSE Continuous 
Phenomic fluency Continuous  age adjusted 
Semantic fluency Continuous  age adjusted 
Purdue total Continuous  Sum from the pegboard test using left hand, 
right hand and both hands 





Binary - Dichotomised into top quintile (average time) 
Flamingo Binary (dichotomised into bottom quintile) 
BFI_extraversion Continuous Big Five inventory total 
BFI_agreeableness Continuous Big Five inventory total 
BFI_conscientiousness Continuous Big Five inventory total 
BFI_neuroticism Continuous Big Five inventory total 
BFI_openess Continuous Big Five inventory total 
ESS Continuous Epworth sleepiness scale total 
RBD Continuous  
Honolulu Constipation Categorical- presence of constipation 
Leeds_anxiety Continuous 
Leeds_depression Continuous 
BDI Continuous  Becks Depression Inventory 
QUIP_all Binary  presence of any one of the QUIP scores 
Systolic BP postural drop Continuous - (Mean of lying SBPs)  standing SBP 
 
 
Supplementary Table 2. Statistics to determine the number of clusters from the Ward 
hierarchical clustering.  A higher value of Calinski/Harabasz pseudo-F index indicates 
more distinct clustering and a smaller value of the Duda/Hart pseudo-T squared indicates 
more distinct clustering.  Bold indicates most distinct cluster. 




2 98.37 37.46 
3 73.48 41.49 
4 63.46 37.54 
5 57.07 25.17 
 
Supplementary Table 3.  Association of clusters with variables not included within the 
cluster analysis, along with a p-value derived from a hypothesis test that the variable is 
equally distributed (i.e. same mean or same proportion) amongst the two clusters.  Note 
that these variables were derived from the complete case and there was some missingness 




























(8.5; p=0.0037) 1.3 (1.0) 1.2 (0.9) 1.4 (1.0) 
Age onsetb  
(85.4; 
p<0.0001) 64.8 (9.7) 62.1 (9.0) 68.3 (9.5) 
Age onset <50 a  
(14.2; 
p=0.0002) 60 (7.8%) 
48 
(11.0%) 12 (3.6%) 
UPDRS phenotype a 
(47.7; p<0.0001) 























Clinicians global impression of change   a 
(5.7; p=0.1269) 

























tried 61 (8.4%) 
43 
(10.6%) 18 (5.6%) 





(15.7%) 29 (8.7%) 





















cThe LEDD restricted to those who are taking dopaminergic medication  
Supplementary Table 4. Stability of the five cluster solution using our cross-validation 
approach 
Split dataset Number assigned to the same cluster (%) 
1 644 (83.7%) 
2 556 (72.3%) 
3 510 (66.3%) 
4 496 (64.5%) 
5 631 (82.1%) 
Average 567.4 (73.8%) 
 
 
Supplementary Table 5. Stability of the two cluster solution using our cross-validation 
approach 
Split dataset Number assigned to the same cluster (%) 
1 742 (96.5%) 
2 713 (92.7%) 
3 758 (98.6%) 
4 754 (98.0%) 
5 744 (96.7%) 




Web Figure 1.  Within cluster means of the standardised variables for the 2 cluster solution.  Positive is worse than average. For laterality 

























cluster 1 cluster 2
cluster 3 cluster 4
cluster 5
Equating scores of the University of Pennsylvania Smell Identification
Test and Sniffin' Sticks test in patients with Parkinson's disease
Michael Lawton a, *, Michele T.M. Hu b, c, Fahd Baig b, c, Claudio Ruffmann b, c,
Eilidh Barron d, Diane M.A. Swallow d, Naveed Malek d, Katherine A. Grosset d, Nin Bajaj e,
Roger A. Barker f, Nigel Williams g, David J. Burn h, Thomas Foltynie i, Huw R. Morris j,
Nicholas W. Wood k, Margaret T. May a, Donald G. Grosset d, Yoav Ben-Shlomo a
a School of Social and Community Medicine, University of Bristol, United Kingdom
b Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, University of Oxford, United Kingdom
c Oxford Parkinson's Disease Centre, University of Oxford, United Kingdom
d Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom
e Department of Neurology, Queen's Medical Centre, Nottingham, United Kingdom
f Clinical Neurosciences, John van Geest Centre for Brain Repair, Cambridge, United Kingdom
g Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, United Kingdom
h Institute of Neuroscience, University of Newcastle, United Kingdom
i Sobell Department of Motor Neuroscience, UCL Institute of Neurology, United Kingdom
j Department of Clinical Neuroscience, UCL Institute of Neurology, United Kingdom
k Department of Molecular Neuroscience, UCL Institute of Neurology, United Kingdom
a r t i c l e i n f o
Article history:
Received 13 April 2016
Received in revised form
8 September 2016








a b s t r a c t
Background: Impaired olfaction is an important feature in Parkinson's disease (PD) and other neuro-
logical diseases. A variety of smell identification tests exist such as “Sniffin’ Sticks” and the University of
Pennsylvania Smell Identification Test (UPSIT). An important part of research is being able to replicate
findings or combining studies in a meta-analysis. This is difficult if olfaction has been measured using
different metrics. We present conversion methods between the: UPSIT, Sniffin’ 16, and Brief-SIT (B-SIT);
and Sniffin’ 12 and Sniffin’ 16 odour identification tests.
Methods: We used two incident cohorts of patients with PD who were tested with either the Sniffin’ 16
(n ¼ 1131) or UPSIT (n ¼ 980) and a validation dataset of 128 individuals who took both tests. We used
the equipercentile and Item Response Theory (IRT) methods to equate the olfaction scales.
Results: The equipercentile conversion suggested some bias between UPSIT and Sniffin’ 16 tests across
the two groups. The IRT method shows very good characteristics between the true and converted Sniffin’
16 (delta mean ¼ 0.14, median ¼ 0) based on UPSIT. The equipercentile conversion between the Sniffin’
12 and 16 item worked well (delta mean ¼ 0.01, median ¼ 0). The UPSIT to B-SIT conversion showed
evidence of bias but amongst PD cases worked well (mean delta ¼ "0.08, median ¼ 0).
Conclusion: We have demonstrated that one can convert UPSIT to B-SIT or Sniffin’ 16, and Sniffin’ 12 to 16
scores in a valid way. This can facilitate direct comparison between tests aiding future collaborative
analyses and evidence synthesis.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Impaired olfaction is an important non-motor feature of
Parkinson's disease (PD). It is thought to be an early pre-clinical
sign of PD [1] and can be used to help in the diagnosis of PD
before the development of definite motor features [2,3]. Olfactory
impairment may also be an early marker of other neurological
diseases such as Alzheimer's disease [4], multiple sclerosis [5],
idiopathic rapid eye movement sleep behaviour disorder [6],
Huntington's disease [7], multiple system atrophy [8], progressive
supranuclear palsy [9] and parkinsonism dementia complex seen in
* Corresponding author. Office G.04, Canynge Hall, 39 Whatley Road, Bristol, BS8
2PS, United Kingdom.
E-mail address: Michael.Lawton@bristol.ac.uk (M. Lawton).
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Guam [10]. Differences in olfactory dysfunction between neuro-
logical diseases may be helpful in the differential diagnosis [11] of
parkinsonian disorders [12]. Detailed reviews of olfactory
dysfunction in neurological disorders have been previously pub-
lished [11,13].
Many research studies collect data on olfaction and an impor-
tant aspect of high quality research is the ability to replicate find-
ings from studies or undertaking systematic reviews with or
without a meta-analysis to synthesise evidence and examine for
heterogeneity. This is more difficult if olfaction has been measured
using a different metric within the different studies leading to
potentially artefactual differences. The ability to estimate scores on
one test from scores on another test helps reduce this problem.
Olfaction is often measured using smell identification tests such as
Sniffin’ Sticks [14] or the University of Pennsylvania Smell Identi-
fication Test (UPSIT) [15].
Both the Sniffin’ [16] and UPSIT [17] tests have published
normative data centiles stratified by age and gender allowing us to
determine the olfactory changes that are likely to be caused by
disease in addition to that due to the natural aging process. This is
particularly important in PD which predominantly affect the older
population. Whilst the published normative data for Sniffin’ strat-
ified age as 5e15; 16e35; 36e55; and >55, the UPSIT stratified
using five year age bands up to 85 and above. The stratification
method employed by UPSIT is arguably more sensible given that
olfactory impairment rises dramatically between 65 and 80 years
[18].
We aimed to create conversion tables from an UPSIT score to a
standard Sniffin’ 16 item odour identification score, between the
Sniffin’ 12 and 16 item odour identification versions and between
the UPSIT and Brief Smell Identification test (B-SIT) using two large
cohorts of individuals with PD to help researchers pool data in
future collaborative studies. An additional useful by-product of our
conversion is that we can convert the published age/gender strat-
ified centiles for the UPSIT to equivalent Sniffin’ scores.
2. Methods
2.1. Study populations
Data were available from two incidence cohorts of patients with
PD. The Oxford Parkinson's Disease Centre Discovery cohort con-
sists of individuals from 11 hospitals across the Thames Valley.
Patients were recruited between study onset in September 2010 up
to May 2015. Full details of this study are described in detail else-
where [19]. Patients were eligible for study inclusion if theymet the
UK PD Brain Bank Criteria according to a neurologist with a special
interest in PD. We included any individuals diagnosed within the
last three and a half years and who were given a probability of
PD# 90% as rated by a clinician based on their clinical opinion. This
was to try to eliminate the inclusion of similar conditions that have
been incorrectly diagnosed as PD. All individuals in this study had
their olfaction measured using the standard Sniffin’ test.
Tracking Parkinson's is a large incidence cohort of patients with
PD recruited from around the UK. Patients were recruited between
February 2012 andMay 2014 if they were diagnosed within the last
3.5 years and met Queen Square Brain Bank criteria. Full details of
this study are described elsewhere [20]. Again we only included
individuals who were given a probability of PD # 90% as rated by a
clinician. In this cohort, olfaction was initially measured using the
UPSIT. However during the course of the study a difficulty arose in
obtaining the UPSIT kits and the studywas forced to switch to using
the Sniffin’ test instead. This means we have two groups of in-
dividuals within the same cohort completing different tests.
We also have a third dataset of subjects “Testing of olfaction in
Parkinson's and controls” (TOPC) who undertook both tests (Sniffin’
and UPSIT) concurrently so we could validate our conversion al-
gorithms. This comprised of 128 subjects (61 PD and 67 controls)
who were recruited as a convenience sample from the regional,
West of Scotland, Movement Disorder Clinic. The order on which
individuals took the two tests was randomised thusminimising any
order effects, such as patients scoring worse on the second test due
to fatigue.
All three studies had ethical approval and were undertakenwith
the understanding and written consent of each subject and in
compliance with the declaration of Helsinki.
2.2. Olfaction tests
The UPSIT test has 40 items, where each item has one correct
answer and three incorrect answers or “distractors”. The test is a
forced choice paradigm, that is, if an individual is unsure of an
answer they are forced to guess a response hence a score of 25% on
average would reflect random guessing. An UPSIT result is scored
out of 40 where a higher score indicates better olfaction. There is
also a reduced 12 item version [21] of the UPSIT called the Brief-
Smell Identification Test (B-SIT), previously called the Cross-
cultural Smell Identification Test (CC-SIT).
The standard Sniffin’ test has 16 odour identification items,
where each item has one correct answer and three incorrect an-
swers or “distractors”. Again the test is a forced choice paradigm. A
Sniffin’ result is scored out of 16 where a higher score indicates
better olfaction. There is also a Sniffin’ 12 itemversion [22] which is
a subset of the 16 item version.
2.3. Statistical analysis
The first and simplest method of equating one scale to another is
equipercentile equating with log-linear smoothing which matches
scores on the two tests using their percentile ranks after first
smoothing the distribution. This method requires that the two
groups are equivalent in olfaction usually through design creating
randomly equivalent groups or by carrying out both tests on the
same population. In our case it would mean assuming the groups
taking the Sniffin’ and UPSIT tests are equivalent with regards to
olfaction.
Our second method used Item Response Theory (IRT) which
models individual's responses on the item level by fitting a series of
latent variable models for each item. The power of the IRT approach
is that we calibrated our model between groups with potentially
different olfaction by using items that are common to both tests.
We assumed that the two groups are linearly related by their
olfaction and calculated a calibration slope and intercept between
the two groups. After calibration we built the distribution of scores
and then equated using equipercentile methods.
Both the equipercentile and IRT methods are described in detail
by Kolen and Brennan [23] whilst the details of how we used the
IRT method and the computing programs we used are discussed
further in the Web appendix.
We used both methods to convert between the UPSIT and
Sniffin’ 16 item test. Since the Sniffin’ 12 items is a subset of the
Sniffin’ 16 item and the B-SIT is a subset of the UPSIT they were
carried out on the same population. Hence we only used the
equipercentile method for the UPSIT to B-SIT and Sniffin’ 12 to 16
item conversions. We used our validation dataset to test how well
the conversions performed by comparing the concordance corre-
lation coefficient [24] (a measure of agreement between two
continuous variables) between true and equivalent results as well
as the characteristics of the difference (or delta) between the true
and equivalent.
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We also converted the centile position stratified by age and
gender from the UPSIT normative data charts to an equivalent
Sniffin’ score to providemore detailed normative comparative data.
We used at or below the 15th centile as a cut-point for determining
whether an individual has impaired olfaction corrected for age and
gender as we have done in previous research [25]. There are some
inconsistent and random fluctuations in the centiles (probably due
to sample size issues) hence we used LOWESS techniques to
smooth the cut-points before applying our conversion.
3. Results
3.1. Demographic and clinical data for Tracking Parkinson's and
Oxford Discovery cohorts
Table 1 compares the data we have from the Tracking Parkin-
son's with 980 individuals who took the UPSIT test and 294 who
took the Sniffin’ test at the baseline visit. These two sub-groups of
the Tracking Parkinson's cohort have a similar proportion of fe-
males, age when the testing took place, motor severity (measured
by the Movement Disorder Society Unified PD Rating Scale or MDS-
UPDRS part 3), disease severity (measured by Hoehn and Yahr
stage) and cognitive impairment (measured by the education
adjusted Montreal Cognitive Assessment or MoCA). However the
UPSIT sub-group had slightly longer disease duration. This is not
surprising given that the UPSIT sub-group would have been
recruited first in the study, which would include both incident and
some prevalent cases (up to 3.5 years), however the cases that are
recruited later on in the centres would consist of mainly incident
cases since the prevalent pool of cases would have already been
recruited.
In the Oxford Discovery cohort we have 837 individuals who
took the Sniffin’ 16-item odour identification test at the baseline
visit. When compared to the group who took the UPSIT test from
the Tracking Parkinson's cohort they had slightly shorter disease
duration, a similar proportion of females and similar age at testing.
They also had worse motor severity, disease severity and more
cognitive impairment. Comparing the Tracking Parkinson's Sniffin’
subset and Oxford Discovery groups they show similar gender, age
and cognitive impairment but Oxford Discovery has worse motor
and disease severity and longer disease duration from diagnosis. Of
paramount importance is that there is no evidence (p ¼ 0.12) of a
difference in Sniffin’ scores between the Tracking Parkinson's
subset and Oxford Discovery groups. We therefore pooled the
Sniffin’ data from the two cohorts for our UPSIT to Sniffin’ 16
conversion. Web table 1 shows the demographic data from the
TOPC validation study and Web Fig. 2 shows the distribution of
UPSIT and Sniffin’ 16 scores stratified by patient type. The corre-
lation between the UPSIT and Sniffin’ 16 scores was 0.81 in this
sample.
3.2. UPSIT to Sniffin’ 16 conversion
Table 2 shows the conversions from the UPSIT to a Sniffin’ 16
equivalent using the two methods. In general, most UPSIT scores
were grouped into 2 point values equivalent to 1 Sniffin’ point but
this could be as wide as 5 points for the (0e4) group using the IRT
method. Table 3 presents the characteristics of these different
conversions when tested on the TOPC validation data in which we
compared an UPSIT predicted Sniffin’ 16 to a true Sniffin’ 16 score.
The concordance correlation coefficient between the true and
equivalent Sniffin’ is very good and similar using both the equi-
percentile (0.79) and IRT methods (0.80). The difference between
equipercentile predicted and true Sniffin’ was acceptable although
there was some evidence of under-prediction bias (positive mean
delta). The individual IRT parameter estimates (a, b, c) for the UPSIT
data and the combined Sniffin’ data can be found in Web Tables 2
and 3 When using the IRT method we found that the calibration
slope was 1.093 and the calibration intercept was 0.180. This is
equivalent to saying that the individuals taking the UPSIT test had
marginally better olfaction and also a slightly larger spread of
olfaction when compared to the Sniffin’ group. However mean
olfaction that is 0.180 higher is small considering the groups are
scaled to a mean of 0 and sd of 1. The validation of the IRT method
Table 1
Demographic and clinical data for Tracking Parkinson's and Discovery cohorts (restricted to recently diagnosed and probability of PD # 90% at latest visit).
Variable Tracking Parkinson's UPSIT
data (N ¼ 980): Mean (sd;
range) or n(%)
Tracking Parkinson's Sniffin’



















1.38 (0.9; 0e3.5) 1.14 (0.9; 0e3.1) <0.001a 1.28 (1.0, 0e3.5) 0.02a 0.02a
Female 347 (35.4%) 101 (34.4%) 0.76c 299 (35.7%) 0.89c 0.70c
Age at test 67.5 (9.1; 31.8e91.1) 67.6 (9.0; 38.1e88.3) 0.93a 67.3 (9.5; 32.2e90.5) 0.58a 0.62a




0e1 508 (52.5%) 143 (49.8%) 193 (23.1%)
2 417 (43.1%) 132 (46.0%) 581(69.4%)
3þ 43 (4.4%) 12 (4.2%) 63 (7.5%)
MoCA adjusted 25.4 (3.3; 10e30) 25.4 (3.2; 10e30) 0.93b 25.0 (3.3; 13e30) 0.02b 0.07b
UPSIT score 19.6 (6.7; 3e37) NA NA NA NA
Sniffin’ 16 score NA 7.5 (2.8; 0e15) NA 7.2 (2.9; 1e15) NA 0.12a
BSIT score 5.7 (2.2; 0e12) NA NA NA NA
Sniffin’ 12 score NA 6.0 (2.4; 0e12) NA 5.7 (2.5; 0e12) NA 0.18a
UPDRS¼Movement Disorder Society unified Parkinson's disease rating scale, MoCA¼Montreal cognitive assessment, UPSIT¼ University of Pennsylvania Smell Identification




d In Tracking Parkinson's 1.5 changed to 1 and 2.5 changed to 2 for comparability between cohorts.
e One individual with both UPSIT and Sniffin’ in Tracking Parkinson's was excluded from the test of differences between the two groups.
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on the TOPC data resulted in a delta that has a mean very close to
zero and a median of zero showing that this conversion appears to
have little evidence of bias. Web Fig. 3 shows graphically the degree
of agreement between the true Sniffin’ and the UPSIT equivalent
Sniffin’ using the two methods.
Comparison of these calibration estimates to the conversions
carried out using the equipercentile method showed some agree-
ment. Assuming these calibration estimates are correct implies that
the olfaction was slightly different in the two populations and
hence the assumptions for the equipercentile method do not hold.
Considering these calibration estimates, individuals taking the
UPSIT test seem to have slightly better olfaction when compared to
the Sniffin’. In agreement with this the equipercentile method
showed evidence of the difference in olfaction in the observed bias.
Table 4 shows the cut-points corresponding to the 15th centile
of olfaction score stratified by age and gender from the UPSIT
normative data. The table also shows the smoothed cut-points
using LOWESS techniques and the equivalent Sniffin’ score when
applying our conversion chart from the IRT method in Table 2. This
allows researchers to define a binary hyposmic group (Yes/No)
based on poor olfaction (%15th centile) for each gender and
different age groups which can be used in analyses testing pre-
dictors of hyposmia.
3.3. Sniffin’ 12 to Sniffin’ 16 conversion
In the conversion from Sniffin’ 12 to 16 we are no longer bound
by assuming the groups to be equal because they are identical. This
means that we can use data from each visit in the Discovery cohort
rather than only using the baseline data. The number of individuals
eligible for analysis were 837, 564, and 275 from visits 1, 2, and 3
respectively from the Discovery cohort along with the 294 from the
Tracking Parkinson's cohort. The 1970 observations of combined
Sniffin’ 16 data has amean of 7.0 and s.d. of 2.8 whilst the combined
Sniffin’ 12 data has a mean of 5.6 and s.d. of 2.4. Web table 4 shows
the conversion scores from Sniffin’ 12 to a Sniffin’ 16 equivalent and
Table 3 shows the validation of this conversion using the TOPC data.
With these two tests being so similar it is not surprising that the
concordance between true and equivalent Sniffin’ 16 was very high,
0.97, that the average delta between the two was so close to zero
and the standard deviation of the delta was also low at 0.96. Web
Fig. 4 shows graphically the degree of agreement using the true
Sniffin’ 16 and the Sniffin’ 12 equivalent Sniffin’ 16. It could be
argued that the percentiles used in the equipercentile method
should not include an individual more than once, re-running this
method using only the baseline data from the Discovery cohort
gave an identical conversion.
3.4. UPSIT to B-SIT conversion
Web table 5 shows the conversion scores from UPSIT to B-SIT
and Table 3 shows the validation of this conversion. The concor-
dance coefficient is relatively high, 0.82, however when looking at
the delta there is some evidence of over-prediction bias (negative
average delta) in our conversion, mean ¼ "0.63 and median ¼ "1.
However if we stratify the delta by PD cases (mean delta ¼ "0.08
and median ¼ 0) and controls (mean delta ¼ "1.13 and
median ¼ "1) there is only evidence of bias for the controls. Web
Fig. 5 shows graphically the degree of agreement using the true
B-SIT and the UPSIT equivalent B-SIT.
4. Discussion
We used two methods to equate scores on the UPSIT test to
scores on the Sniffin’ 16 smell identification test, scores on the
Sniffin’ 12 item to Sniffin’ 16 item smell identification tests and also
scores on the UPSIT and B-SIT tests.
It has been shown that the differences in olfaction between PD
patients and controls is not related to any particular odour type
[26]. This suggests that although our conversions have been created
using only PD patients they could potentially be used for controls
and/or other diseases where olfactory dysfunction is not related to
particular odour types.
A previous paper reported that the correlation between the
Sniffin’ and UPSIT scores was 0.85 [14] which is similar to 0.81, the
value we found in our TOPC data. Another reported that the test-
retest correlation of the UPSIT was 0.9 [27] and was 0.86 in the
Sniffin’ [28]. These results are of a similar magnitude with our
correlation between true and UPSIT equivalent Sniffin’ 16 of 0.8.
Both variability in test-retest performance and inadequate
Table 2
Conversion table for different methods between the raw UPSIT scores and the
equivalent Sniffin’ 16 score.
Raw UPSIT score Equivalent Sniffin’ 16 score



















Validation of the different conversions in the Testing of olfaction in Parkinson's and controls (TOPC) validation dataset.
Analysis Concordance between true score and
converted equivalent score
Difference between true score and converted
equivalent score mean (sd; range)
Difference between true score and converted
equivalent score median (IQR)
Equipercentile method e
converting UPSIT to Sniffin’ 16
0.79 0.66 (2.38; "7 to 7) 1 ("1 to 2)
IRT method e converting UPSIT to
Sniffin’ 16
0.80 0.14 (2.42; "7 to 7) 0 ("1 to 2)
Equipercentile method e
converting Sniffin’ 12 to Sniffin’
16
0.97 0.01 (0.96; "2 to 2) 0 ("1 to 1)
Equipercentile method e
converting UPSIT to BSIT
0.82 "0.63 (1.44; "4 to 2) "1 ("2 to 0)
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conversion may have contributed to the differences between the
true and converted scores, though our results are consistent with
the test-retest correlations.
There were a number of limitations to our work. The validation
dataset we used was small and does not cover the entire range of
scores for the two olfaction tests. Also if we had designed our two
incidence cohorts with these conversions in mind it would have
been better to randomise patients to receive either the UPSIT or the
Sniffin’ test. There are also clear differences between the Tracking
and Discovery groups, especially in cognition which is related to
olfaction, which could be the reason why the equipercentile
method on the UPSIT to Sniffin conversion showed some evidence
of bias and made it necessary to use the IRT method. Another
consideration is that the UPSIT normative data was derived using a
US version. The cohorts that we studied used a newer UK version
adapted due to cultural differences as some smells in the US version
were unfamiliar in the UK population. Despite this, the UK and US
versions are still very similar, sharing 33 items with some changes
to distractors.
Our UPSIT to B-SIT conversion had high concordance but some
evidence of bias. However this disappeared when only considering
the PD cases from the TOPC data. None of our other conversions
showed evidence of difference in the delta when stratified by PD or
Control. This could be because (a) this conversion is not valid; (b)
the conversion is valid and the differential observation between PD
cases and controls was a chance finding; or (c) our conversion is
only valid for PD patients contradicting our belief that differences
in olfaction between PD patients and controls is not related to any
particular odour type.
The choice of what olfaction test to use in a study will be
determined by several factors (i) time available and burden on
participants (ii) cost of administering tests (iii) sample size. Another
issue to consider is that shorter tests may be less sensitive (e.g. 40-
item UPSIT versus 16 item Sniffin’) thereby reducing the ability to
differentiate between groups. However statistical power is also
related to sample size and measuring the UPSIT on a large sample
would take considerably more time than a quicker test like the B-
SIT. In some circumstances one may be happy to trade-off sensi-
tivity against increased sample size. Longer tests are also less likely
to be affected by random measurement error and will therefore
have greater reliability. The association between reliability and test
length is most famously highlighted by the Spearman-Brown pre-
diction formula [29] and has beenmodelled before in olfaction [27].
In olfactory tests this is emphasised by the fact that the test-retest
correlation was 0.9 in the UPSIT and 0.71 in the B-SIT [27].
We created a valid and reliable conversion of UPSIT scores to
Sniffin’ scores and from Sniffin’ 12 item to 16 item. Also we have
arguably created a valid and reliable conversion fromUPSIT to B-SIT
scores for PD patients. These conversions will be used to merge
olfaction data from the Oxford Discovery and Tracking Parkinson's
cohorts to investigate the influence of baseline olfaction and
hyposmia in predicting future cognitive and motor decline in these
longitudinal cohorts of early PD. We believe that these conversion
charts will facilitate more replication of research findings and
greater data sharing across many neurological diseases and studies
that measure olfaction using these tests.
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Table 4
Age and gender stratified 15th centile from UPSIT normative data included smoothed results and the equivalent Sniffin’ results.
Age group Males Females
%15th centile UPSIT Smootheda %15th centile UPSIT Equivalent Sniffin’ %15th centile UPSIT Smootheda % 15th centile UPSIT Equivalent Sniffin’
15e19 33 33 14 35 35 14
20e24 33 33 14 35 34 14
25e29 34 33 14 34 34 14
30e34 33 32 13 34 34 14
35e39 33 32 13 34 33 14
40e44 32 31 13 34 33 14
45e49 33 30 12 34 32 13
50e54 29 29 12 32 31 13
55e59 26 27 11 32 30 12
60e64 28 24 10 31 27 11
65e69 22 22 9 26 25 10
70e74 19 19 8 22 22 9
75e79 18 16 6 16 18 7
80e84 12 13 5 15 15 6
>¼85 10 9 3 15 13 5
NB. For males 60e64 where the 15th centile is both a score of 28 and 29 we chose 28 which was more in keeping with the surrounding values.
a Smoothed using lowess techniques and a bandwidth of 0.7.
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Equating University of Pennsylvania Smell Identification Test scores and Sniffin  
Scores in Patients with  
 





To carry out the Item Response Theory method (IRT) we fitted a series of latent variable 
models for each item where olfaction is the latent variable. We modelled the probability of 
correctly answering an item on a test given the latent olfaction variable and a three parameter 
IRT model.  These parameters are often described as the discrimination, difficulty and lower 
asymptote parameters.  An example of an IRT model can be seen in web figure 1.  Here  is 
the latent olfaction variable; c is the lower asymptote parameter, or equivalently the 
probability of correctly answering the question even with very poor olfaction or by chance; b 
is the difficulty parameter or level of olfaction at which the probability is exactly half-way 
between 1 and the lower asymptote; a is the discrimination parameter or proportional to the 
slope where = b. Within a group we scale the olfaction variable to have a mean of zero and 
standard deviation of 1.   
 
After creating the IRT model we calibrated the two sets of models using the fact that the 
estimated parameters should be identical in the common items if the olfaction of the two 
groups is also identical.  In this study we assumed that items were common if they have the 
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same answer.  For instance the correct answer for item 11 on the  and item 20 on the 
UPSIT is apple. Using this definition there are 13 common items between the  and 
UPSIT.  There are a number of methods that can be used to calibrate the items on two tests, 
in our case we used the Stocking-Lord characteristic curve method.  Once we have fitted our 
models and calibrated the parameters between the two tests, then we can equate the overall 
scores on the two tests using either the true or observed score equating methods, in our case 
we used the observed score equating method. We decided to use the observed score method 
because theoretically its properties are easier to justify and it does not require extrapolation at 
the very low scores where the true score method is undefined. 
 
The equipercentile equating was carried out using the equate library [1] in R 3.0.1.  The IRT 
model fitting was carried out in BILOG-MG [2], the calibration using STUIRT [3] and the 





We used the observed score equating method as part of our IRT equating.  However the other 
IRT equating method, true score equating, would have given slightly different conversions 
especially at the upper and lower ends of the scales.  However when validating the true score 
equating on the TOPC data we found very similar results with a small bias between true and 
converted  results (results not shown - available on request).  Also of note is that as 
well as combining the  data for the UPSIT to  conversion we also tried each 
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method using the  data from each cohort separately (results not included).  This led to 
nearly identical results and for brevity we only included the combined analysis. 
 
 
There are some limitations to this work in our application of the IRT method.  Firstly there 
was evidence of a lack of fit in some questions but BILOG warns that the item fit statistic 
might be unreliable when the number of items is less than 20.   This is exactly what we 
observed with a greater lack of fit in the  test compared to the UPSIT.  Secondly we 
had some slight convergence issues for the  test which is likely to be due to the 
smaller number of items.  Thirdly we made the tenuous assumption that the items on the 
 
functions in a test (which would affect estimates of the three IRT parameters) is likely to be 
related to not only the correct answer but also the three distractors which were not always the 
same across the two tests.  Fourthly the different calibration methods in IRT gave different 
estimates for the calibration slope and intercept which is likely due to the problems around 
validation of our conversion showed good characteristics. 
 
On a practical perspective, the equipercentile method was very simple to carry out within R.  
In contrast the time taken to learn and carry out IRT equating was considerably longer given 
the need to use multiple programs and the difficulty of exporting data in different formats 
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controls (TOPC) validation dataset 
Variable Controls (N=67) 
mean (sd; range) or n (%) 
PD (N=61) 
mean (sd; range) or n (%) 
Female 36 (53.7%) 24 (39.3%) 
Age at test 61.0 (13.2; 18.0  81.8) 66.8 (8.9; 46.5-81.6) 
UPSIT 28.0 (6.9; 6-39) 16.7 (6.0; 7  38) 
 11.6 (2.8; 5-16) 6.6 (3.3; 2-15) 
BSIT 7.3 (2.2; 3- 11) 4.7 (2.1; 1-11) 
 9.3 (2.4; 4-12) 5.3 (2.6; 2-11) 
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Web table 2. IRT parameter estimates for three-parameter logistic IRT model using UPSIT 
data of 980 individuals.   The chi-square item fit p-value is a test between observed and 












item fit  
p-value 
1 0.249 1.004 1.795 0.161 0.966 
2 0.440 0.648 1.610 0.305 0.627 
3 0.589 1.004 0.063 0.205 0.186 
4 0.408 0.767 1.191 0.226 0.959 
5 0.438 0.634 0.781 0.154 0.484 
6 (mint) 0.543 1.113 0.394 0.253 0.528 
7 (banana) 0.496 1.087 1.290 0.384 0.981 
8 (clove) 0.522 1.291 0.683 0.316 0.901 
9 (leather) 0.681 0.851 -0.291 0.246 0.217 
10  0.442 1.169 1.075 0.290 0.967 
11 0.758 0.835 -0.829 0.188 0.036 
12 0.210 1.296 1.616 0.119 0.614 
13 0.792 1.040 -0.895 0.203 0.008 
14 (coffee) 0.558 0.500 0.278 0.198 0.689 
15 (cinnamon) 0.430 1.146 1.534 0.342 0.694 
16  0.383 0.906 1.007 0.176 0.672 
17 0.545 0.918 0.248 0.196 0.599 
18 0.476 0.945 0.965 0.293 0.571 
19 0.632 0.757 -0.263 0.158 0.204 
20 (apple) 0.533 0.790 1.115 0.376 0.993 
21  0.664 0.580 -0.376 0.207 0.234 
22 (turpentine) 0.233 0.935 2.447 0.191 0.655 
23 0.612 0.811 -0.061 0.200 0.091 
24 (liquorice) 0.331 1.404 1.214 0.197 0.831 
25 0.195 0.861 3.124 0.175 0.961 
26 (pineapple) 0.495 0.738 0.763 0.250 0.49 
27 0.333 0.623 2.492 0.260 0.956 
28 (orange) 0.532 0.859 0.502 0.252 0.478 
29  0.519 0.816 0.627 0.263 0.992 
30 0.445 0.880 0.888 0.228 0.652 
31 0.388 0.611 1.470 0.214 0.71 
32 0.382 0.981 1.563 0.279 0.764 
33 0.730 1.135 -0.447 0.266 0.07 
34 0.559 1.115 0.675 0.356 0.998 
35 0.750 1.118 -0.637 0.216 0.033 
36 (lemon) 0.291 0.803 2.477 0.241 0.218 
37  0.403 0.487 3.013 0.337 0.953 
38 0.536 0.956 0.250 0.183 0.222 
39 (rose) 0.460 0.850 0.790 0.222 0.691 
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Web Table 3.  IRT parameter estimates for three-parameter IRT model using combined visit 
-square item fit p-value is a test between observed and predicted 














1 (orange) 0.714 0.747 -0.525 0.186 <0.001 
2 (leather) 0.452 0.823 1.229 0.320 0.269 
3 (cinnamon) 0.350 0.596 1.868 0.262 0.317 
4 (mint) 0.677 0.790 -0.176 0.236 <0.001 
5 (banana) 0.446 0.795 0.754 0.208 0.003 
6 (lemon) 0.354 0.664 1.781 0.175 0.08 
7 (liquorice) 0.469 1.666 0.924 0.218 0.04 
8 (turpentine) 0.347 0.557 3.823 0.315 0.834 
9  0.585 0.584 0.526 0.321 0.01 
10 (coffee)  0.490 0.867 0.968 0.186 0.07 
11 (apple) 0.190 1.098 2.861 0.154 0.427 
12 (clove) 0.442 0.662 0.870 0.231 0.043 
13 (pineapple) 0.364 0.562 1.283 0.171 0.031 
14 (rose) 0.561 0.375 0.804 0.252 0.055 
15  0.381 2.257 0.970 0.185 0.213 
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0 - 4 0 
5 - 7 1 
8 - 10 2 
11 - 12 3 
13 - 15 4 
16 - 18 5 
19 - 21 6 
22 - 24 7 
25 - 28 8 
29 - 31 9 
32 - 35 10 
36 - 38 11 
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Web Figure 1.  Example of a three parameter logistic IRT model.  The dashed lines are added 
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Web Figure 2.  
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Web Figure 3.  
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Web Figure 4.   
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Web Figure 5.  Agreement of true B-SIT and UPSIT equivalent B-SIT in the Testing of 
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ABSTRACT
Objectives To use a data-driven approach to determine 
the existence and natural history of subtypes of 
Parkinson’s disease (PD) using two large independent 
cohorts of patients newly diagnosed with this condition.
Methods 1601 and 944 patients with idiopathic 
PD, from Tracking Parkinson’s and Discovery cohorts, 
respectively, were evaluated in motor, cognitive and 
non-motor domains at the baseline assessment. Patients 
were recently diagnosed at entry (within 3.5 years of 
diagnosis) and were followed up every 18 months. We 
used a factor analysis followed by a k-means cluster 
analysis, while prognosis was measured using random 
slope and intercept models.
Results We identified four clusters: (1) fast motor 
progression with symmetrical motor disease, poor 
olfaction, cognition and postural hypotension; (2) mild 
motor and non-motor disease with intermediate motor 
progression; (3) severe motor disease, poor psychological 
well-being and poor sleep with an intermediate motor 
progression; (4) slow motor progression with tremor-
dominant, unilateral disease. Clusters were moderately to 
substantially stable across the two cohorts (kappa 0.58). 
Cluster 1 had the fastest motor progression in Tracking 
Parkinson’s at 3.2 (95% CI 2.8 to 3.6) UPDRS III points 
per year while cluster 4 had the slowest at 0.6 (0.1–1.1). 
In Tracking Parkinson’s, cluster 2 had the largest response 
to levodopa 36.3% and cluster 4 the lowest 28.8%.
Conclusions We have found four novel clusters that 
replicated well across two independent early PD cohorts 
and were associated with levodopa response and motor 
progression rates. This has potential implications for 
better understanding disease pathophysiology and the 
relevance of patient stratification in future clinical trials.
INTRODUCTION
Parkinsons disease (PD) is a progressive neurode-
generative disorder characterised by a wide range 
of motor and non-motor features, for which there 
is no known cure. However, therapeutic strategies 
might soon be available with prolonged benefits that 
could affect the underlying pathogenesis, and hence 
delay or ultimately prevent the inexorable course 
of this disease. To date, none of the 16 drugs eval-
uated for PD disease modification have succeeded 
in phase III trials, with a further eight compounds 
currently in the discovery pipeline.1 PD is an 
inherently complex disorder with known hetero-
geneity in terms of clinical presentation as well as 
rate of progression and risk of disease complica-
tions. The basis for this is only now starting to be 
understood, in terms of the role of genetic factors, 
for example, glucocerebrosidase gene mutations. 
The implications for future clinical trial designif 
patient heterogeneity is ignored at baseline study 
selection, leading to potential confounds and misin-
terpretation of subsequent progression/complica-
tion ratesare highly significant.
Few naturalistic cohort studies in PD have been 
undertaken using large numbers of representative, 
community-ascertained patients, unselected on the 
basis of age or family history, and prospectively 
followed early from diagnosis. Such cohorts would 
more faithfully recapitulate disease evolution in 
the true-to-life populations encountered in clin-
ical practice, where disease progression reflects 
both pathophysiology and any treatment effects, as 
reported in the CamPaIGN study.2
Data-driven approaches to delineate subtypes 
using cohorts of incident PD as well as cross-sec-
tional studies37 have hypothesised that there are 
different PD subtypes. Better defining these subtypes 
will be important for understanding the aetiology 
of the disease, discovering biomarkers related to 
prognosis and for stratified medicine, including the 
discovery and response to new medications.8 In this 
study, we sought to better explore this aspect of PD 
using two large independent cohorts of newly diag-
nosed PD and in particular the number of distinct 
disease subtypes, their levodopa responsiveness and 
rate of motor and cognitive decline. This extends 
our previous work in this area using only one of 
the two cohorts (Discovery), without assessing 
levodopa responsiveness or the subsequent rate of 
motor and cognitive decline.9
MATERIALS AND METHODS
Patient populations
Tracking Parkinsons is a prospective cohort of 
recently diagnosed patients with PD who were 
recruited from around the UK between February 
2012 and May 2014. Full details of this cohort 
and full inclusion/exclusion criteria have been 
published elsewhere.10 The Oxford Parkinsons 
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Table 1  Demographic and clinical characteristics at baseline for the patients in the two studies
Variable
Tracking Parkinson’s cohort (n=1601) 
mean (SD) or n (%)
Discovery cohort (n=944) mean (SD) 
or n (%) P-value difference between cohorts
Female 554 (34.6%) 334 (35.4%) 0.69*
Ethnicity (non-white) 28 (1.8%) 20 (2.1%) 0.51*
Age diagnosis (years) 65.9 (9.3) 65.9 (9.6) 0.92†
Disease duration from diagnosis (years) 1.3 (0.9) 1.2 (0.9) 0.03†
MDS-UPDRS part I‡ 9.1 (5.2) 8.8 (5.1) 0.09†
MDS-UPDRS part II‡ 9.5 (6.2) 8.7 (6.0) <0.001†
MDS-UPDRS part III‡ 22.3 (11.9) 26.4 (10.8) <0.001†
MDS-UPDRS part IV‡ 0.7 (1.7) 0.3 (1.1) <0.001†
MDS-UPDRS total (all four parts)‡ 41.8 (18.7) 44.2 (17.5) 0.002†
MoCA (adjusted for education years)‡ 25.4 (3.4) 25.0 (3.3) 0.012†
Untreated 149 (9.3%) 119 (12.6%) 0.01*
LEDD (mg) 293 (205) 282 (212) 0.20†
LEDD (those on medication) (mg) 324 (190) 327 (194) 0.77†
Hoehn and Yahr§ median (IQR) 1 (1–2) 2 (2–2) <0.001*
Motor assessments (UPDRS and Hoehn and Yahr) were rated in the clinically defined ‘on medication’ state for treated patients with PD.
*χ2 test.
†T-test.
‡Changed denominator where 80% or more of questions were answered.
§In Tracking Parkinson’s cohort, Hoehn and Yahr 1.5 and 2.5 were changed to 1 and 2, respectively, for comparison with Oxford Parkinson’s Disease Centre Discovery cohort.
LEDD, levodopa equivalent daily dose; MDS, Movement Disorders Society; MoCA, Montreal Cognitive Assessment; UPDRS, Unified Parkinson’s Disease Rating Scale.
referred to as Discovery) is also a prospective cohort of 
recently diagnosed patients with PD who were recruited from 
11 hospitals in the Thames Valley region between September 
2010 and January 2016. Full details of the Discovery cohort 
and full inclusion/exclusion criteria have also been published 
elsewhere.11 In both studies, patients were defined as recently 
diagnosed if recruited within 3.5 years of diagnosis. In order 
to exclude patients with similar conditions that may have been 
incorrectly diagnosed as PD, we only included individuals in 
by a research neurologist/movement disorder specialist at 
their latest visit. Patients have been (and are continuing to be) 
followed up every 18 months. Both studies were funded by 
Parkinsons UK.
Patient evaluation
Assessments of patients were via self-completed questionnaires 
and from outpatient clinics using standardised and validated 
scales both at baseline and follow-up. Variables used in this 
analysis were those adopted in our original cluster analysis 
paper9 and which were also included in the Tracking Parkin-
sons cohort, and these included the Movement Disorders 
Society (MDS) revised Unified Parkinsons Disease Rating 
Scale (UPDRS), where part III was measured in the on state; 
Big Five Inventory; Epworth Sleepiness Scale; REM Sleep 
Behaviour Disorder Screening Questionnaire; Hospital Anxiety 
and Depression Scale; Questionnaire for Impulsive-Compulsive 
Disorders in Parkinsons Disease; Honolulu Asia Aging Study 
Constipation Questionnaire; Montreal Cognitive Assessment 
(MoCA) adjusted for education years; Semantic verbal fluency 
(animals); Orthostatic blood pressure measurement; and 
Sniffin 16 odour identification scores. The levodopa equivalent 
daily dose (LEDD) was calculated from medication use ques-
tionnaires using established formulae.12 In addition, a levodopa 
challenge was carried out giving us a quantitative measure of 
response to medication (see online supplementary e-appendix 
for more details on methods).
Statistical analysis
more questions were answered in any given test. Additionally, 
missing baseline data were imputed using the chained equations 
approach separately in the two cohorts. Factor analysis was used 
as a variable reduction technique on all the baseline phenotypic 
variables (details in online supplementary e-appendix). We then 
derived the clusters by using a k-means analysis of the factor 
scores and other baseline phenotypic variables not loading into 
one of the factors. Variables were standardised separately within 
each cohort to ensure that each variable had the same weighting 
within the k-means analysis. Further details are described in our 
previous publication.9
A discriminant analysis model was then fitted to the Tracking 
Parkinsons clusters and used to predict clusters within the 
Discovery cohort. These predicted clusters were compared with 
the k-means clusters in the Discovery cohort to determine the 
stability of our approach. We used the kappa statistic to compute 
the extent of agreement and adopted accepted guidelines13 to 
determine the strength of this agreement.
We then carried out a between-cluster comparison of a range 
of clinical and demographic variables, which had not been used 
in the estimation of the clusters using analysis of variance and χ2 
tests. We modelled important disease-related variables (UPDRS 
III and MoCA scores) longitudinally using multilevel random 
slope and intercept models to estimate disease progression by 
cluster. A sensitivity analysis using pattern-mixture models was 
carried out to determine whether patients lost to follow-up may 
potentially have biased our disease progression estimates.14
RESULTS
We analysed data on 1601 patients in Tracking Parkinsons 
and 944 in Discovery (online web supplementary figure 1). 
years (see table 1). The disease duration from diagnosis was on 
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Table 2  Confirmatory factor analysis within the Tracking Parkinson’s 
cohort showing standardised factor loadings of variables selected from 








MDS-UPDRS I apathy 0.512
MDS-UPDRS I fatigue 0.599





MDS-UPDRS III speech 0.420
MDS-UPDRS III rigidity subscore 0.535
MDS-UPDRS III bradykinesia subscore 0.769




CFI, TLI and RMSEA are all measures of model fit.
BFI, Big five inventory; QUIP, Questionnaire for Impulsive-Compulsive Disorders in 
Parkinson's disease.
CFI, Comparative Fit Index; HADS, Hospital Anxiety and Depression Scale; MDS, 
Movement Disorders Society; RMSEA, root mean square error of approximation; TLI, 
Tucker-Lewis Index; UPDRS, Unified Parkinson’s Disease Rating Scale.
Figure 1  Important salient clinical features of the four clusters across the two cohorts where the percentages within each cluster are from the Tracking 
Parkinson’s cohort.
Discovery cohort had more severe motor disease as measured by 
the UPDRS III and disease severity as measured by the Hoehn 
and Yahr or the sum score of UPDRS parts IIV (p<0.001), and 
slightly worse average cognition as measured by the MoCA. 
However, the Tracking Parkinsons cohort had worse motor 
aspects of experiences of daily living (UPDRS II) and motor 
complications (UPDRS IV) and had fewer untreated patients.
Cluster analysis
In our factor analysis, we found two factors: a psycholog-
ical well-being and a non-tremor motor factor (table 2), as we 
reported previously.9 This shows that within our baseline pheno-
typic variables, we had multiple variables related to psycholog-
ical well-being and to non-tremor motor function that were 
highly correlated. Using the statistics in web supplementary table 
1 helped us decide that four clusters gave us an optimal solution. 
Figure 1 highlights the important features of the clusters and 
figure 2 shows the average of each of the standardised variables 
within each cluster for the Tracking Parkinsons and Discovery 
cohorts. The groups were arbitrarily ordered in terms of size 
for Tracking Parkinsons, but for the Discovery cohort they 
were ordered by similarity to the Tracking Parkinsons clusters. 
In general, the cluster patterns between the cohorts were fairly 
similar but with some differences (see below). Details of the clus-
ters are available in  web supplementary table 2, which shows all 
the scores from the different tests included in the cluster analysis 
and categorised scores using standard cut-points from the litera-
ture for easier clinical interpretation. More details of the factor 
and the cluster analysis can be found in the online supplemen-
tary e-appendix.
The following describes the clusters observed in Tracking 
Parkinsons (unless otherwise stated). The fast motor progres-
sion (1) cluster had less advanced motor features and psycho-
logical well-being but worse than average non-motor features 
such as blood pressure postural drop, olfaction and cognition 
with more symmetrical motor disease. However, within the 
Discovery cohort, the non-tremor motor was worse, rather 
than better than average, for this cluster. The mild motor 
and non-motor disease (2) cluster showed a milder form of 
the disease being better in most domains and was similar in 
the Discovery cohort analysis. The severe motor disease, poor 
psychological well-being and poor sleep (3) cluster was similar 
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Figure 2  Within cluster means of the standardised variables for the four k-means cluster solution in both cohorts along with the 95% CI for the mean. 
Positive (above the dotted line) is worse than average and negative better than average. For laterality, positive is more bilateral than average and negative 
more unilateral than average. Note that hallucinations, constipation and urinary are categorical variables and were standardised using a slightly different 
method (see online supplementary appendix 1). In Tracking Parkinson’s, cluster 1 n=493 patients, cluster 2 n=459, cluster 3 n=336 and cluster 4 n=313, 
while in Discovery, cluster 1 n=218, cluster 2 n=319, cluster 3 n=196 and cluster 4 n=211. BP, blood pressure; RBD, rapid eye movement sleep behaviour 
disorder.
especially in non-tremor motor features particularly brady-
kinesia and postural scores, worse psychological well-being 
and poor sleep and excessive daytime somnolence. The slow 
motor progression (4) cluster had severe tremor with unilat-
eral disease and was similar in Discovery except for the fact 
that the non-tremor motor features were better than average 
in Discovery and worse than average in Tracking Parkinsons.
Web supplementary table 3 shows the agreement between 
the k-means clusters in Discovery and those predicted by the 
Tracking Parkinsons discriminant model. This reveals an overall 
0.61) indicating moderate to substantial agreement.13 The major 
inconsistency comes in the mild motor and non-motor disease (2) 
be in the fast motor progression (1) cluster.
Clinical and demographic correlates of the clusters
The focus for the rest of this paper is on the clusters predicted 
from the larger Tracking Parkinsons model and applied to 
the Discovery cohort because future patients would be clas-
sified from their baseline measurements into predicted clus-
ters. We found a modest difference in disease duration since 
diagnosis (maximum average difference 3.5 months) between 
the clusters in both cohorts (table 3) but did not regard this 
as being clinically important in terms of explaining differ-
ences in phenotype. There was evidence of differences in 
gender, age at diagnosis, motor phenotype, Hoehn and Yahr 
stage, and medication use at baseline across the four clusters 
in both cohorts (p<0.001 in all variables) (see table 3). The 
mild motor and non-motor disease (2) cluster had the highest 
proportion of women and youngest age at diagnosis, while the 
fast motor progression (1) cluster had the highest age at diag-
nosis. The severe motor disease, poor psychological well-being 
and poor sleep (3) cluster had the highest proportion with the 
postural instability gait difficulty (PIGD) phenotype while the 
slow motor progression (4) cluster had the highest proportion 
of tremor-dominant disease at baseline. The LEDD at base-
line was highest in the severe motor disease, poor psycholog-
ical well-being and poor sleep (3) cluster, which also had the 
smallest proportion of untreated patients.
Within the Tracking Parkinsons cohort, the L-dopa challenge 
had their 24-month visit. In the Discovery cohort, only 273 
challenge indicating a lack of power and potential selection 
bias in this data set. The mean percentage decrease in UPDRS 
III comparing pre with post challenge was greater in Tracking 
was highest in the mild motor and non-motor disease (2) cluster 
and slightly lower than average in the slow motor progression 
(4) cluster within both cohorts. There was strong evidence of a 
difference in response to L-dopa across the clusters in Tracking 
Parkinsons (p=0.002), but not so strong in the smaller sample 







































































































































Table 3  Association of clusters with variables not used in the cluster analysis, along with a p value derived from a hypothesis test that the variable is equally distributed (ie, same mean or same 
proportion) among the four clusters
Variable
Tracking Parkinson’s clusters Discovery—clusters predicted from Tracking Parkinson’s model



















Women* <0.001 554 (34.6%) 144 (29.2%) 204 (44.4%) 98 (29.2%) 108 (34.5%) <0.001 334 (35.4%) 92 (30.0%) 87 (52.1%) 58 (26.0%) 97 (39.3%)
Disease duration from 
diagnosis† <0.001 1.3 (0.9) 1.3 (0.9) 1.2 (0.9) 1.5 (0.9) 1.4 (0.9) 0.002 1.2 (0.9) 1.2 (0.9) 1.1 (0.9) 1.4 (0.9) 1.2 (0.9)
Age diagnosis† <0.001 65.9 (9.3) 68.1 (8.1) 62.6 (9.3) 66.5 (9.8) 66.7 (9.2) <0.001 65.9 (9.6) 67.6 (8.8) 62.7 (9.4) 67.0 (9.5) 65.1 (10.2)
Age diagnosis <50* <0.001 98 (6.1%) 16 (3.2%) 51 (11.1%) 19 (5.7%) 12 (3.8%) <0.001 60 (6.4%) 8 (2.6%) 18 (10.8%) 12 (5.4%) 22 (8.9%)
UPDRS motor phenotype*‡
  Tremor dominant <0.001 741 (48.0%) 194 (40.8%) 241 (54.9%) 92 (28.3%) 214 (70.6%) <0.001 510 (54.7%) 129 (43.0%) 98 (59.0%) 90 (40.7%) 193 (78.5%)
  Indeterminate 196 (12.7%) 61 (12.8%) 54 (12.3%) 41 (12.6%) 40 (13.2%) 115 (12.3%) 44 (14.7%) 22 (13.3%) 28 (12.7%) 21 (8.5%)
  Postural instability gait 
difficulty 606 (39.3%) 221 (46.4%) 144 (32.8%) 192 (59.1%) 49 (16.2%) 308 (33.0%) 127 (42.3%) 46 (27.7%) 103 (46.6%) 32 (13.0%)
Hoehn and Yahr stage*
  0–1.5 <0.001 808 (51.4%) 259 (53.6%) 298 (66.2%) 110 (33.4%) 141 (45.5%) <0.001 216 (23.0%) 76 (24.9%) 60 (35.9%) 21 (9.5%) 59 (24.0%)
  2–2.5 685 (43.6%) 211 (43.7%) 147 (32.7%) 181 (55.0%) 146 (47.1%) 660 (70.2%) 208 (68.2%) 103 (61.7%) 178 (80.2%) 171 (69.5%)
  3 79 (5.0%) 13 (2.7%) 5 (1.1%) 38 (11.6%) 23 (7.4%) 64 (6.8%) 21 (6.9%) 4 (2.4%) 23 (10.4%) 16 (6.5%)
Untreated* <0.001 149 (9.3%) 33 (6.7%) 69 (15.0%) 12 (3.6%) 35 (11.2%) 0.001 119 (12.6%) 35 (11.4%) 28 (16.8%) 14 (6.3%) 42 (17.0%)
LEDD total† <0.001
293
(205) 304 (195) 245 (202) 361 (204) 272 (203) <0.001 282 (212) 292 (196) 242 (206) 345 (225) 241 (209)
LEDD total on medication†§ <0.001
324
(190) 327 (183) 289 (188) 375 (195) 309 (188) <0.001 327 (194) 333 (173) 293 (191) 368 (213) 297 (193)
Levodopa challenge†
  Percentage change 0.002 32.1 (22.8) 30.6 (23.0) 36.3 (24.0) 31.9 (21.7) 28.8 (20.9) 0.06 23.6 (15.2) 22.1 (15.5) 29.4 (16.7) 23.4 (16.0) 22.5 (12.3)
*χ2 test.
†Analysis of variance.
‡Changed denominator where 80% or more of questions were answered.
§The LEDD restricted to those who are taking dopaminergic medication.
Cluster 1 is fast motor progression; cluster 2 is mild motor and non-motor disease; cluster 3 is severe motor disease, poor psychological well-being and poor sleep; cluster 4 is slow motor progression.
LEDD, levodopa equivalent daily dose; UPDRS, Unified Parkinson’s Disease Rating Scale.
 on 27 July 2018 by guest. Protected by copyright. http://jnnp.bmj.com/ J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2018-318337 on 25 July 2018. Downloaded from 
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Table 4  Comparison of per-year progression rates within the two cohorts using the two approaches: multilevel random slope and intercept 
models (MLMs) versus pattern-mixture models (PMMs)
Cluster









1 3.16 (2.76 to 3.55) 3.08 (2.70 to 3.45) 2.76 (2.30 to 3.22) 2.66 (2.20 to 3.13)
MDS-UPDRS III 2 2.56 (2.18 to 2.95) 2.62 (2.23 to 3.01) 2.25 (1.63 to 2.86) 2.29 (1.72 to 2.87)
3 2.48 (1.99 to 2.97) 2.66 (2.02 to 3.31) 1.81 (1.26 to 2.37) 1.79 (1.13 to 2.46)
4 0.61 (0.11 to 1.11) 0.65 (0.09 to 1.21) 1.61 (1.08 to 2.15) 1.67 (1.04 to 2.30)
P values <0.001 <0.001 0.007 0.04
1 −0.16 (−0.26 to −0.06) −0.20 (−0.32 to −0.09) −0.19 (−0.30 to −0.07) −0.21 (−0.33 to −0.09)
MoCA adjusted 2 −0.02 (−0.12 to 0.08) −0.04 (−0.12 to 0.04) −0.10 (−0.25 to 0.05) −0.09 (−0.24 to 0.05)
3 −0.22 (−0.34 to −0.09) −0.31 (−0.50 to −0.13) −0.27 (−0.41 to −0.14) −0.34 (−0.53 to −0.14)
4 −0.04 (−0.17 to 0.08) −0.10 (−0.29 to 0.08) −0.17 (−0.30 to −0.04) −0.20 (−0.34 to −0.06)
P values 0.04 0.017 0.41 0.26
1 1.63 (1.46 to 1.81) 1.61 (1.44 to 1.78) 1.43 (1.22 to 1.64) 1.44 (1.21 to 1.67)
MDS-UPDRS II 2 1.25 (1.08 to 1.42) 1.32 (1.13 to 1.51) 1.01 (0.73 to 1.28) 0.94 (0.68 to 1.19)
3 1.51 (1.29 to 1.74) 1.68 (1.33 to 2.02) 1.25 (1.01 to 1.49) 1.41 (1.08 to 1.74)
4 1.14 (0.92 to 1.37) 1.32 (1.02 to 1.62) 1.25 (0.99 to 1.51) 1.34 (1.04 to 1.63)
P values 0.001 0.06 0.13 0.02
Cluster 1 is fast motor progression; cluster 2 is mild motor and non-motor disease; cluster 3 is severe motor disease, poor psychological well-being and poor sleep; cluster 4 is 
slow motor progression.
MDS, Movement Disorders Society; MoCA, Montreal Cognitive Assessment; UPDRS, Unified Parkinson’s Disease Rating Scale.
Comparison of prognosis by clusters between Tracking 
Parkinson’s and Discovery
-
ment visits, respectively, with a median follow-up time of 3.0 
54-month and 72-month assessment visits, respectively, with a 
median follow-up time of 3.0 years (IQR 1.54.4). All of the 
progression rates by cluster and cohort are shown in table 4. 
There was evidence of a significant difference in progression 
rates for the UPDRS III across clusters in Tracking Parkinsons 
(p<0.001) and in Discovery (p=0.007). The same pattern of 
was seen in both cohorts. The fast motor progression (1) cluster 
had the fastest progression: 3.2 UPDRS III points per year in 
Tracking Parkinsons and 2.8 points per year in Discovery, while 
the slow motor progression (4) cluster had the slowest motor 
progression, although the estimate for progression in the slow 
motor progression (4) cluster was markedly slower in Tracking 
Parkinsons (0.6 UPDRS III points per year) than Discovery (1.6 
CIs (see figure 3). Repeating the analysis using the UPDRS part 
II score (web supplementary figure 2), we found the same clus-
ters in Tracking Parkinsons with the fastest and slowest progres-
sion; however, in the Discovery cohort, we found no evidence of 
difference in progression rates.
Cognitive decline, as measured by the MoCA, was fastest in 
the severe motor disease, poor psychological well-being and poor 
sleep (3) cluster in both cohorts (figure 4), but overall there was 
no significant difference in cognitive progression rates across 
clusters (Tracking Parkinsons p=0.04; Discovery p=0.41).
Repeating our analyses using pattern-mixture models showed 
little difference in progression rate estimates (table 4), providing 
evidence that withdrawal has not biased our estimates. Adjusting 
the slope and intercept for baseline LEDD in our UPDRS III 
models, an attempt to see the effect that treatment had on 
progression rates, we found very similar rates (results not 
included).
No significant differences in motor UPDRS III progression 
were found between conventional tremor, PIGD and mixed 
clusters (web supplementary figure 3), although in Tracking 
(p<0.001), there was some evidence to suggest that those in the 
PIGD cluster have faster cognitive decline (web supplementary 
figure 4).
DISCUSSION 
Our analyses identified four phenotypic subgroups among 
patients recently diagnosed with PD: (1) fast motor progression 
with symmetrical motor disease, poor olfaction, cognition and 
postural hypotension; (2) mild motor and non-motor disease 
with intermediate motor progression; (3) severe motor disease 
(prominent bradykinesia/postural impairment), poor psycho-
logical well-being (mood, apathy, pain, fatigue) and poor sleep 
with intermediate motor progression; (4) slow motor progression 
with tremor-dominant, unilateral disease. The kappa statistic 
showed that the clusters calculated within the Discovery cohort 
were relatively stable compared with those predicted using the 
Tracking Parkinsons cohort model even though some baseline 
characteristics differed significantly between the cohorts.
Our analysis has taken into account the five points recom-
mended for studies using cluster analysis.6 (1) Our sample 
of patients with PD were all recently diagnosed and hence 
had more similar disease duration than other cross-sectional 
studies. (2) We used two sample populations of patients who 
have been well phenotyped across a wide a range of important 
domains. (3) We have taken into account the limitations of 
k-means by (a) using hierarchical clustering prior to the anal-
ysis to determine the number of clusters, (b) standardising all 
the variables so they have equal weighting and (c) using 500 
random starts to prevent the selection of local optima. (4) We 
have looked at independent associations between our clusters 
with clinically meaningful variables such as response to L-dopa 
challenge and disease progression. (5) We have validated our 




















































































































7Lawton M, et al. J Neurol Neurosurg Psychiatry 2018;0:1–9. doi:10.1136/jnnp-2018-318337
Movement disorders
Figure 3  Longitudinal follow-up in MDS-UPDRS part III by cohort. Difference between clusters progression rates p<0.001 in Tracking Parkinson’s and 
p=0.007 in Discovery. Changed denominator where 80% or more of questions were answered. Observed data were split into yearly bins (0–1, 1–2, 2–3, 
3–4 and 4–5 years) and the means plotted. MDS, Movement Disorders Society; UPDRS, Unified Parkinson’s Disease Rating Scale.
Our previous paper reported five clusters in the Discovery 
cohort. The clusters in our new analysis are qualitatively similar 
although two of the original clusters (a) poor psychological 
well-being, rapid eye movement sleep behaviour disorder and 
sleep, and (b) severe motor and non-motor disease with poor 
psychological well-being have now merged into a single cluster 
(cluster 3). Our clusters are consistent with other similar studies 
in PD, which generally find a group with milder symptoms and 
a younger age at onset3 5 1522 (our second cluster). Three studies 
also found a tremor-dominant group17 18 20 (our fourth cluster) 
and most studies find a group with more severe symptoms or 
rapid disease progression3 4 1522 (our first and third clusters). 
Importantly, we have now demonstrated different rates of 
motor progression across our baseline-defined clusters, with a 
mean annual deterioration in UPDRS III scores varying signifi-
cantly from 0.6 to 3.2 points (in Tracking Parkinsons) between 
those with slowest and fastest progression. Interestingly, we also 
found, in keeping with another study3, that poor cognition and 
postural hypotension predicted faster motor progression.
What is the clinical relevance of these findings?
Stratification, or defining different subcategories, is key to better 
understanding disease mechanisms and kinetics in PD, predicting 
disease course and ultimately delivering personalised manage-
ment strategies. The emerging focus of PD trial design is on early 
motor disease, including novel immunomodulatory therapies 
that require intensive and invasive monitoring. Traditionally, 
little account has been taken of disease heterogeneity in early 
PD when selecting patients for randomised, placebo-controlled 
studies. However, our results show that baseline phenotype is 
associated with variable rates of subsequent motor progression, 
although confounded by potential medication response effects. 
The mean difference in UPDRS motor scores between the fastest 
and slowest motor progression subtypes in Tracking Parkinsons 
was 2.6 points, equivalent to the primary hierarchical endpoint 
of several studies, including the ADAGIO study.23 Recruit-
ment without taking into account heterogeneity and potential 
sources of recruitment bias may lead to less efficient designs, 
though there are various trade-offs between the cost of selecting 
patient subgroups, the sample size required for demonstrating 
a reduction in disease progression and increasing the length of 
follow-up.
Strengths and limitations
This study has used two of the largest PD incidence cohorts 
worldwide. In addition, the methods were designed collab-
oratively with similar variables being collected using almost 
identical inclusion criteria, though the source of recruitment 
differed. While this may impact on the frequency of the subtypes 
of PD, it should not influence the consistency of the clusters 
or the within-cluster progression rates. It is possible that some 
patients will turn out to have other parkinsonian disorders, such 
as multiple system atrophy, despite only including those with a 
the fast progression cluster. We had little missing data and we 
used imputation methods to reduce any bias. The association 
we found with levodopa response (which was analysed as rela-
tive change) may simply reflect the fact that the second cluster 
has milder disease, and since our estimates of motor function is 
carried out in the on state, we would expect those with mild 
motor disease to be those who respond well to the medication. 
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Figure 4  Longitudinal follow-up in Montreal Cognitive Assessment (MoCA) by cohort. Difference between cluster progression rates p=0.04 in Tracking 
Parkinson’s and p=0.41 in Discovery. Changed denominator where 80% or more of questions were answered. Observed data were split into yearly bins 
(0–1, 1–2, 2–3, 3–4 and 4–5 years) and the means plotted.
challenge although the vast majority of those missing this data in 
the Tracking Parkinsons cohort is due to them either not taking 
levodopa as part of their normal medication regime or not 
reaching the 24-month time point. Levodopa response is also 
composed of both short-duration and long-duration responses.24 
Our levodopa challenge only measures the short-term response 
and our pre-dose scores are largely determined by the long-dura-
tion response. Also, the long-duration response is typically much 
larger than the short-duration response.
We used non-statistical criteria to help judge the best 
number of clusters, as the optimal number of clusters can differ 
depending on which statistic is the primary focus. Each cohort 
has its strengths and weaknesses. Tracking Parkinsons is larger 
with more centres from a wider area of the UK population. The 
Discovery cohort used fewer clinicians to assess participants and 
had lower inter-rater variability. Discovery had more disabling 
disease and slightly worse cognitive function at baseline. Each 
cohort may have a slightly different mix of patients, but this will 
also occur in patients recruited for different clinical trials.
The major limitation in this analysis is that most of our data are 
restricted to the first 3 years of follow-up due to the studies being 
ongoing and patients not yet reaching 4.5 years of follow-up. We 
suspect this has reduced our power to detect differences between 
the clusters. The associations we saw between clusters and 
progression rates could be due to non-linearity of growth rates; 
however, non-linearity cannot be tested until the vast majority of 
patients have four or more observations.
We took a pragmatic perspective where disease progres-
sion estimates reflected both pathophysiology and treat-
ment effects. An alternative approach is measurement of the 
untreated (underlying) progression of subtypes, which reduces 
potential confounding effects of dopaminergic therapy in modi-
fying disease progression, and has been applied elsewhere.25 26 
Accordingly the generalisability of our method may be limited if 
different treatment regimes were used in other clinical settings.
Neuropathological characterisation of the patient clusters at 
post mortem would help to address the question of the distri-
bution and loads of α-synuclein, tau, vascular and amyloid 
pathology in driving both baseline clinical phenotype and subse-
quent motor and cognitive progression throughout the disease 
evolution of PD.27 It is intriguing to speculate whether patients 
in cluster 1, who have the fastest motor progression, prominent 
baseline non-motor symptoms, more symmetrical disease and 
a poor levodopa response, are defined by prominent cerebro-
vascular or amyloid pathologies. Clear delineation of patient 
subtypes is likely to introduce other potential therapeutic targets 
and lifestyle interventions to the clinical trials arena that look 
beyond pure α-synuclein-driven pathology. To date, a total of 
345 subjects with PD (195 Tracking Parkinsons, 150 Discovery 
cohort) have signed up to the nationally funded Parkinsons UK 
Brain Donation programme, with six brains now available for 
neuropathological characterisation to begin to address these 
issues.
CONCLUSION
We have found four clusters that replicate across two large inde-
pendent cohorts of newly diagnosed patients with PD and which 
are associated with different responses to levodopa and motor 
progression rates. Future work should examine the reasons for 
these differences, and with longer follow-up and using growth 
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groups with different progression rates and how this relates to 
their baseline characteristics. This will also allow us to determine 
the robustness and clinical use of stratifying patients early in the 
disease course with better defined endpoints.
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The Tracking Parkinsons cohort began measuring olfaction using the University of 
Pennsylvania Smell Identification Test (UPSIT) before changing to the Sniffin sticks 16 item 
odour identification test when there became a difficulty in obtaining the UPSIT kits.  The 
Discovery cohort only measured olfaction using the Sniffin sticks 16 item odour 
identification test.  We used IRT methods to convert the UPSIT scores to equivalent Sniffin 
16 scores1.  We also used equipercentile methods to convert Leeds Anxiety and Depression 
scale into the more commonly used Hospital Anxiety and Depression scale. 
 
We consider the L-dopa challenge as a percentage change by dividing the difference in pre 
and post dose total MDS-UPDRS III score measurements by the pre dose measure.  A 
pragmatic levodopa challenge test was performed only in consenting patients who were 
already taking levodopa medication by the time of their 18 month (Discovery) or 24 month 
(Tracking Parkinsons) visit. Patients were asked to omit their usual levodopa dose 
approximately 12 hours before the morning challenge test. Patients who were also taking 
levodopa agonist medication, MAO-B or COMT inhibitors were also asked to omit these 12 
hours before the challenge test (or 24 hours before if taking once daily dopamine agonist 
formulations). During the levodopa challenge, the patient was given their usual dose of oral 
levodopa with peripheral dopa-decarboxylase inhibitor, rather than a supramaximal standard 
dose of levodopa, and the MDS-UPDRS III performed at baseline and 1 hour later to assess 








Since k-means cluster analysis is not a statistical model per-say (it does not measure the 
uncertainty in any model estimates as it is just an algorithm) so it is not possible to use 
Rubins rules to collate the 10 imputed datasets into one model.  So for simplicity we used 
the data from our 10 multiply imputed datasets to create one single dataset (after carrying out 
the confirmatory factor analysis which is a statistical model) by taking the average for each 
variable across all 10 datasets.  Also note that the amount of missing data we had was small 
and unlikely to bias our results in anyway.  After taking into account those individuals who 
answered between 80-100% of a questionnaire in Tracking Parkinsons we had between 
0.9%-5.3% missing baseline data (although the BFI and Sniffin scores had ~10% missing 
data because they were collected at six months post baseline and were hence affected by 
drop-out) whilst in Discovery we had between 0.4% - 4.8% missing data.  
 
Our factor analysis consisted of first an exploratory factor analysis in the Discovery cohort 
followed by a confirmatory factor analysis (CFA) in the Tracking Parkinsons cohort. In the 
CFA we examined the following goodness of fit statistics:  Comparative Fit Index (CFI), 
Tucker-Lewis Index (TLI) and the Root Mean Square Error of Approximation (RMSEA). A 
model was considered to fit the data well if CFI was ! 0.90, TLI ! 0.90 and RMSEA " 0.08  
The same algorithm that produced the factor scores in Tracking Parkinsons was used in 
Discovery to ensure comparability between these variables across the cohorts. 
 
Pattern-mixture models were estimated using a Structural Equation Modelling approach 




time-points.  The variances and covariance of the latent (random) intercept and slope were 
constrained to be equal across the clusters.  Our pattern-mixture model was defined such that 
all patients withdrawing were considered the same, i.e withdrawing after visit 2 was 
considered to have the same effect on the intercept and slope as withdrawing after baseline. 
The numbers withdrawn in Tracking Parkinsons was 302/1601 (18.9%) and within 







Exploratory factor analysis (EFA) 
In Discovery using the eigenvalue criteria we found 2 factors in each of the ten imputed 
datasets.  The two factors identified were identical to the psychological well-being and non-
tremor motor factors from the original paper EFA 2 (ignoring unavailable variables not in 
both datasets, that is the Purdue tests, the Get Up and Go Test and the flamingo test) except 
that the non-tremor motor factor also included the MoCA and semantic fluency variables.   
 
Confirmatory factor analysis (CFA) 
The CFA in the Tracking Parkinsons cohort using the variables from the EFA only met one 
of our pre-defined goodness of fit criteria with a CFI of 0.83, TLI of 0.87, and a RMSEA of 
0.078. Although the cognitive and motor variables in the second factor might be highly 
correlated we thought that clinically it did not make sense to include them within the same 
factor.  Dropping the two cognitive variables from this factor improved the goodness of fit 
with a CFI of 0.91, TLI of 0.93, and a RMSEA of 0.063. Therefore we excluded the cognitive 
variables from this factor with main manuscript Table 2 displaying the results from the 
resulting CFA. We named factor 1 psychological well-being and factor 2 non-tremor 
motor matching our original paper.  The factor loadings varied from 0.31  0.86 and 0.42  
0.77 in the two factors respectively. At this stage we excluded the other four BFI variables 
not loading into a factor and the UPDRS constipation variable for the sake of parsimony, 
which is the same approach used in our original paper. We also excluded the semantic 






Cluster Analysis  choosing number of clusters 
Web table 1 shows the statistics we used to determine the optimum number of clusters which 
pointed to the two and five cluster solutions in both Tracking Parkinsons and Discovery.   So 
we used criteria other than these fit statistics to decide which was the optimum number of 
clusters. 
 
We considered, initially, the agreement between our k-means clusters in the Discovery cohort 
and the clusters predicted from our Tracking Parkinsons discriminant model.  The two 
cluster solution had excellent overall agreement (91.5%) and a kappa statistic consistent with 
almost perfect agreement (0.83) however because this only stratified individuals into a 
good and bad group this was not regarded as clinically that informative. The five cluster 
solution had the same overall agreement (67.9%) as the four cluster solution and a higher 
kappa statistic 0.60 compared to 0.58.  However these kappa statistics are almost equivalent 
and both close to the borders of what would be considered moderate to substantial 
agreement.  We chose the four cluster solution because it is more parsimonious than the five 
cluster. 
 
 Comparison of prognosis by clusters between Tracking Parkinsons and Discovery 
 
We looked at what would happen if we relaxed the assumptions in our pattern-mixture model 
such that variances of the outcomes are equal across time-points or clusters and the 




following models for UPDRS III and compared commonly used goodness of fit statistics like 
AIC, BIC as well as likelihood ratio tests. 
1. Variances and covariance of random effects are different for the four clusters 
2. Variances of the outcomes are different at each time-point 
3. Combining assumptions for models 1 and 2 above. 
4. As model 3 but variances of the outcomes are also different within each cluster 
Using the goodness of fit statistics in Tracking PD we would select model 3 over our standard 
PMM model.  However within all models the largest difference in mean progression rate  
(compared to standard PMM model) in any cluster was 0.22 UPDRS III points per year so 
almost identical to our default model.  Using the same model (which was also favoured by AIC 
and likelihood ratio tests) in Discovery the largest difference in mean progression rate in any 
cluster was 0.12 UPDRS III points per year and the difference between clusters p-value 
increased from 0.04 to 0.10.  However if we used the BIC to select a model in Discovery we 
would have selected the default model.  Hence we are confident that the assumptions we made 
in our model has not made any impact on our progression rate estimates.  We will further 





Web Table 1. Statistics to determine the number of clusters from the Ward hierarchical clustering.  A higher value of Calinski/Harabasz pseudo-
F index indicates more distinct clustering and a smaller value of the Duda/Hart pseudo-T squared indicates more distinct clustering.  Bold 
indicates most distinct cluster. 
 
 Tracking Parkinsons cohort Discovery cohort 








2 163.4 75.3 96.2 32.3 
3 116.1 73.2 69.6 39.6 
4 99.8 42.4 58.9 26.0 







Web Table 2.  Scores from each test within the four k-means clusters from both cohorts at baseline using the imputed data.  Where standard cut-
points exist in literature categorised scores are given as well as their total test scores.  For standalone questions from the MDS-UPDRS scales the 
questions were dichotomised at 1 or above. 
  Discovery clusters 
Variable Total 
N=1601 
Cluster 1  
N=493 








Cluster 1  
N=218 






UPDRS speecha 782 











UPDRS rigidity 3.7 (2.9) 3.1 (2.7) 2.6 (2.2) 4.8 (3.2) 5.1 (2.9) 5.3 (2.7) 6.0 (2.9) 4.4 (2.3) 6.2 (2.8) 5.2 (2.5) 
UPDRS 
bradykinesia 10.8 (7.0) 8.9 (5.8) 7.0 (4.9) 15.0 (7.3) 15.0 (6.5) 13.0 (6.5) 15.0 (6.1) 9.9 (5.2) 16.3 (6.9) 12.6 (5.9) 
UPDRS 
Postural 2.6 (2.3) 2.2 (1.8) 1.6 (1.6) 3.8 (2.7) 3.2 (2.4) 2.6 (2.2) 3.1 (2.1) 1.7 (1.6) 3.8 (2.8) 2.1 (1.7) 
UPDRS tremor 4.6 (3.8) 3.1 (2.9) 3.5 (2.7) 4.5 (3.5) 8.9 (3.8) 5.0 (3.8) 3.8 (3.4) 3.1 (2.5) 5.9 (3.8) 8.3 (3.2) 
Percentage 
UPRDS III due 



























UPDRS apathya 499 











UPDRS fatiguea 1242 











UPDRS paina 894 











BFI neuroticism 23.3 (6.4) 22.1 (5.8) 22.1 (6.5) 26.4 (6.3) 23.7 (6.3) 22.3 (6.5) 20.9 (6.6) 21.6 (5.9) 26.4 (6.0) 20.9 (6.3) 




(27.6%) 66 (13.4%) 76 (16.6%) 215 (64.0%) 85 (27.2%) 
197 




(55.6%) 17 (8.1%) 
HADS 








(19.4%) 37 (7.5%) 29 (6.3%) 194 (57.7%) 50 (16.0%) 
168 




(52.0%) 17 (8.1%) 
QUIP 350 









































MoCA 25.4 (3.4) 24.7 (3.3) 27.1 (2.3) 24.0 (4.0) 25.4 (3.1) 25.0 (3.3) 23.3 (3.3) 26.5 (2.4) 24.0 (3.5) 25.4 (3.2) 
MoCAf- Normal 1211 











MoCAf- MCI 183 









































(14.7%) 23 (7.2%) 
44 
(22.4%) 6 (2.8%) 
Systolic 




(12.1) 6.1 (14.5) 3.2 (12.4) 
Constipationh 529 











UPDRS urinarya 942 











aDichotomised individual UPDRS questions at 1 or more 
bDichotomised Laterality at a difference of four or more between left side and right side 
cDichotomised HADS at 8 or more 
dDichotomised RBD at 5 or more 




fCategorised MoCA -23 = MCI, or 24+ = Normal 
g  





Web Table 3. Agreement of patients in Discovery classified in each cluster: Kmeans on Discovery vs predicted clusters from Tracking Parkinsons 
discriminant analysis model 
 Predicted 1 Predicted 2 Predicted 3 Predicted 4 
Kmeans 1 160 0 44 14 
Kmeans 2 110 154 22 33 
Kmeans 3 6 3 157 30 
Kmeans 4 31 10 0 170 
Overall agreement 67.9% 






WEB FIGURE LEGENDS 
 
Web figure 1. Flow chart for entry into this analysis 
 
 
Web Figure 2.  Longitudinal follow up in MDS-UPDRS part II by cohort Difference between clusters progression rates p=0.001 in Tracking 
Parkinsons and p=0.13 in Discovery. Changed denominator where 80% or more of questions were answered Observed data was split into yearly 




Web Figure 3.  Longitudinal follow up in MDS-UPDRS part III by cohort looking at conventional clusters (TD, PIGD, mixed). Difference 
between clusters progression rate p=0.21 in Tracking Parkinsons and p=0.95 in Discovery. Changed denominator where 80% or more of 




Web Figure 4.  Longitudinal follow up in MoCA by cohort looking at conventional clusters (TD, PIGD, mixed). Difference between clusters 
progression rate p<0.001 in Tracking Parkinsons and p=0.33 in Discovery. Changed denominator where 80% or more of questions were 
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Web figure 1. Flow chart for entry into this analysis 
  
 
Web Figure 2.  Longitudinal follow up in MDS-UPDRS part II by cohort Difference between clusters progression rates p=0.001 in Tracking 
Parkinson’s and p=0.13 in Discovery. Changed denominator where 80% or more of questions were answered Observed data was split into yearly 
bins (0-1,1-2,2-3,3-4 and 4-5 years) and the means plotted. 
 
Web Figure 3.  Longitudinal follow up in MDS-UPDRS part III by cohort looking at conventional clusters (TD, PIGD, mixed). Difference 
between clusters progression rate p=0.21 in Tracking Parkinson’s and p=0.95 in Discovery. Changed denominator where 80% or more of 
questions were answered. Observed data was split into yearly bins (0-1,1-2,2-3,3-4 and 4-5 years) and the means plotted. 
 
Web Figure 4.  Longitudinal follow up in MoCA by cohort looking at conventional clusters (TD, PIGD, mixed). Difference between clusters 
progression rate p<0.001 in Tracking Parkinson’s and p=0.33 in Discovery. Changed denominator where 80% or more of questions were 
answered. Observed data was split into yearly bins (0-1,1-2,2-3,3-4 and 4-5 years) and the means plotted. 
